Preoperative risk stratification based on PDE4D7 expression and preoperative clinical variables

Through the combination of PDE4D7 gene expression profile and CAPRA score, an improved preoperative risk assessment method for prostate cancer is provided, solving the problem of insufficient risk classification in the prior art, and improving the accuracy and personalization of treatment decisions.

CN111742061BActive Publication Date: 2024-11-19KONINKLIJKE PHILIPS NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201880089754.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-12-21
Filing Date
2018-12-19
Publication Date
2024-11-19
Estimated Expiration
2038-12-19

AI Technical Summary

Technical Problem

The existing preoperative risk classification methods for prostate cancer fail to effectively describe the degree of disease or invasiveness of all patients, resulting in insufficient treatment decisions, especially in the very low and low risk groups, with significant risk of recurrence and biochemical in the medium-risk population. The risk of progress is low but the heterogeneity is high, making it difficult to make accurate treatment recommendations.

Method used

By determining the gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in prostate cancer subjects, combining preoperative clinical variables, expression-based risk scores were calculated, and combined with CAPRA scores, improved preoperative prognosis risk scores were developed. to guide more accurate treatment decisions.

Benefits of technology

This method can more accurately assess the preoperative risk of prostate cancer patients, help doctors reduce unnecessary treatment burden in extremely low and low-risk groups, and improve treatment effectiveness in the intermediate-risk group, ensuring the identification of invasive pathological characteristics and management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN111742061B_ABST
    Figure CN111742061B_ABST
Patent Text Reader

Abstract

The present invention relates to a method for preoperative risk stratification of prostate cancer subjects, comprising determining a gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining an expression-based risk score for the subject based on the gene expression profile, and determining a preoperative prognostic risk score for the subject based on the expression-based risk score and preoperative clinical variables of the subject. This can improve the stratification of subjects in the preoperative setting, thereby leading to better first-line treatment decisions. For example, for certain subgroups of prostate cancer patients, a preoperative prognostic risk score can provide better advice on whether to choose active surveillance or active intervention (e.g., radical prostatectomy).
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to a method for preoperative risk stratification of prostate cancer subjects. Furthermore, the present invention relates to a diagnostic kit, to the use of the kit in a method for preoperative risk stratification of prostate cancer subjects, to the use of a phosphodiesterase 4D variant 7 (PDE4D7) gene expression profile in preoperative risk stratification of prostate cancer subjects, and to corresponding computer program products. Background of the Invention

[0003] Cancer is a type of disease in which a group of cells show uncontrolled growth, invasion and sometimes metastasis. These three malignant properties of cancer distinguish it from benign tumors, which are self-limiting and do not invade or metastasize. Prostate cancer (PCa) is the most common non-skin malignancy in men. Its manifestation is a heterogeneous disease with various potentials that gradually progress to fatal forms of the disease. Of the estimated 417,000 new cases per year in Europe, approximately 92,000 will die from the disease (see Ferlay J. et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet], Lyon, France, International Agency for Research on Cancer, 2013).

[0004] Clinically, various preoperative risk classification schemes have been developed based on longitudinal biological patient outcomes (see Rodrigues G. et al., “Pre-treatment risk stratification of prostate cancer patients: A critical review”, Canadian Urological Association Journal, Vol. 6, No. 2, pages 121-127, 2012). Although various national and international guidelines recommend active surveillance (AS) for men with very low and low-risk prostate cancer (see Mohler J. et al., "NCCN clinical practice guidelines in oncology: Prostate cancer, Version 1.2016", Journal of the National Comprehensive Cancer Network, Vol. 14, No. 1, pages 19-30, 2016), there is a significant subgroup of this patient population with a 10%-25% risk of cancer recurrence after first-line treatment (see, e.g., Hernandez DJ et al., "Contemporary evaluation of the D'amico risk classification of prostate cancer", Journal of Urology, Vol. 70, No. 5, pages 931-935, 2007). These patients suffer from the burden of subsequent treatment, often triggered by biochemical recurrence. Likewise, within the intermediate-risk population, there is a subgroup with a low risk of biochemical progression (see, eg, Jung JW et al., “Stratification of patients with intermediate-risk prostate cancer”, BJU International, Vol. 115, No. 6, pages 907-912, 2015).However, this group is heterogeneous and includes patients with different outcomes, including those with aggressive pathological features (see Abern MR et al., “Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: Possible implications for active surveillance from the SEARCH database”, The Prostate, Vol. 73, No. 4, pages 409-417, 2013).

[0005] Clinical risk descriptors do not effectively describe the extent of disease or its aggressiveness in all patients. Therefore, better patient stratification is needed to optimize first-line treatment decisions. SUMMARY OF THE INVENTION

[0007] One object of the present invention is to provide a method for preoperative risk stratification of prostate cancer subjects, which can enable better primary treatment decisions. Another object of the present invention is to provide a diagnostic kit, use of the kit in a method for preoperative risk stratification of prostate cancer subjects, use of phosphodiesterase 4D variant 7 (PDE4D7) gene expression profiling in preoperative risk stratification of prostate cancer subjects, and corresponding computer program products.

[0008] In a first aspect of the present invention, a method for preoperative risk stratification of a prostate cancer subject is provided, comprising:

[0009] determining a gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject,

[0010] determining an expression-based risk score for the subject based on the gene expression profile, and

[0011] A preoperative prognostic risk score is determined for the subject based on the expression-based risk score and preoperative clinical variables of the subject.

[0012] The cAMP signaling pathway is known to play an important role in the development and progression of prostate cancer (see Merkle D. and Hoffmann R., "Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: Cross-talk with the androgen receptor", Cellular Signaling, Vol. 23, No. 3, pages 507-515, 2011). Although the adenylate cyclase family is responsible for the synthesis of cAMP, cyclic nucleotide phosphodiesterases (PDEs) appear to represent the only cellular mechanism for its destruction. PDEs provide both signal termination and, more importantly, compartmentalization of cAMP signaling within the cellular 3D matrix. This is achieved by spatially discrete disruption of cAMP by subpopulations of different PDE isoforms sequestered by localized ankyrins / signalosomes (see, e.g., Conti M. and Beavo J., "Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling", Annual Review of Biochemistry, Vol. 76, pages 481-511, 2007). Thus, changes in the expression and / or activity of different PDE isoforms can alter downstream signaling pathways during disease development and progression, providing potential targets for new biomarkers and targeted therapeutic interventions. Indeed, altered expression of members of the PDE4 family that degrade cAMP appears to be associated with many different diseases, including stroke, acrodysplasia, schizophrenia, and COPD. In recent years, it has been shown that downregulation of a specific PDE4 isoform (PDE4D7) may have an impact on prostate cancer (see, e.g., R. et al., "Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression", British Journal of Cancer, Vol. 113, No. 10, pages 1502-1511, 2015). The PDE4D7 isoform is the so-called long isoform because it contains both the UCR1 and UCR2 regulatory domains. UCR1 is present in the long, rather than the short, PDE4 isoform and can be regulated by various protein kinases (including PKA and MK2), and also determines the functional consequences of phosphorylation of the ERK catalytic unit. Functionally, it provides a portion of the cellular desensitization system for cAMP and enables cross-talk between signal transduction pathways, for example, leading to activation of ERK and AMPK.

[0013] By determining a risk score based on expression of a prostate cancer subject based on the gene expression profile of PDE4D7, other molecular information representing the biology of the disease is obtained. The prognostic ability of PDE4D7 can be used for preoperative patient risk assessment by determining a preoperative prognostic risk score that is not only based on the preoperative clinical variables of the subject, but also based on an expression-based risk score. This can allow for improved stratification of subjects in a preoperative setting, which can lead to better first-line treatment decisions. For example, for certain subgroups of prostate cancer patients, a preoperative prognostic risk score can allow for better recommendations regarding whether to select active surveillance or active intervention (e.g., radical prostatectomy).

[0014] The term "phosphodiesterase 4D7" or "PDE4D7" refers to the splice variant 7 of the human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D7 gene, for example, as defined in the NCBI Reference Sequence: NM_001165899.1, and in particular to the nucleotide sequence shown in SEQ ID NO: 19, which corresponds to the sequence of the NCBI Reference Sequence for the PDE4D7 transcript indicated above, and also to the corresponding amino acid sequence shown in, for example, SEQ ID NO: 20, which corresponds to the protein sequence encoding the PDE4D7 polypeptide as defined in the NCBI Protein Accession Reference Sequence NP_001159371.1. The term "phosphodiesterase 4D7" or "PDE4D7" also refers to an amplicon that can be generated by the primer pair PDE4D7_forward (SEQ ID NO: 21) and PDE4D7_reverse (SEQ ID NO: 22) and detected by the probe SEQ ID NO: 23.

[0015] The PDE4D7 polypeptide can also be detected using the primer pair PDE4D7-2_forward (SEQ ID NO: 24) and PDE4D7_reverse (SEQ ID NO: 25), and can be detected by the probe SEQ ID NO: 26.

[0016] The term "PDE4D7" also encompasses nucleotide sequences having a high degree of homology to PDE4D7, such as a nucleic acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 19, or an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20, or a nucleic acid sequence that encodes an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20, or a nucleic acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 20. An amino acid sequence encoded by a nucleic acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence shown in NO:19.

[0017] The term "biological sample" or "sample obtained from a subject" refers to any biological material obtained from a subject, such as a prostate cancer patient, by a suitable method known to those skilled in the art. The biological sample used can be collected in a clinically acceptable manner, such as in a manner that preserves nucleic acids (particularly RNA) or proteins.

[0018] The biological sample can include body tissues and / or body fluids, such as, but not limited to, blood, sweat, and urine. In addition, the biological sample can contain a cell extract derived from an epithelial cell or a cell population comprising an epithelial cell, such as a cancerous epithelial cell or an epithelial cell derived from a suspected cancerous tissue. The biological sample can include a cell population derived from glandular tissue, such as a sample that can be derived from the prostate of a male subject. In addition, if necessary, cells can be purified from the body tissues and body fluids obtained and then used as a biological sample. In some embodiments, the sample can be a tissue sample, a urine sample, a urine sediment sample, a blood sample, a saliva sample, a semen sample, a sample comprising circulating tumor cells, an extracellular vesicle, a sample comprising exosomes secreted by the prostate, or a cell line or cancer cell line.

[0019] In a particular embodiment, a biopsy or resection sample may be obtained and / or used. Such a sample may include cells or cell lysates.

[0020] It is also conceivable that the contents of the biological sample may be subjected to an enrichment step. For example, the sample may be contacted with a ligand that is specific to the cell membrane or organelle of a cell type, such as a prostate cell, for example, functionalized with magnetic particles. The material concentrated by the magnetic particles may then be used in detection and analysis steps as described above or below.

[0021] Furthermore, cells such as tumor cells can be enriched by filtering fluid or liquid samples such as blood, urine, etc. As mentioned above, this filtration method can also be combined with an enrichment step based on ligand-specific interactions.

[0022] The term "prostate cancer" refers to a cancer of the prostate gland in the male reproductive system that occurs when prostate cells mutate and begin to multiply uncontrollably. Typically, prostate cancer is associated with elevated levels of prostate-specific antigen (PSA). In one embodiment of the invention, the term "prostate cancer" relates to a cancer that shows a PSA level greater than 4.0. In another embodiment, the term relates to a cancer that shows a PSA level greater than 2.0. The term "PSA level" refers to the concentration of PSA in the blood (ng / ml).

[0023] The term "non-progressive prostate cancer status" refers to an individual whose sample does not show parameter values ​​indicative of "biochemical recurrence" and / or "clinical recurrence".

[0024] The term "progressive prostate cancer status" refers to a sample from an individual showing parameter values ​​indicative of "biochemical recurrence" and / or "clinical recurrence".

[0025] The term "biochemical recurrence" generally refers to a biological value of recurrence where PSA is elevated, indicating the presence of prostate cancer cells in the sample. However, other markers can also be used that can be used to detect the presence or suspicion of the presence of cancer.

[0026] The term "clinical recurrence" refers to the presence of clinical signs indicating the presence of tumor cells, such as signs measured using in vivo imaging.

[0027] As used herein, the term "prognosis of prostate cancer" refers to, for example, a prediction of the course of disease or outcome of a diagnosed or detected prostate cancer, over a period of time, during treatment, or after treatment. The term also refers to determining the chance of disease survival or recovery, and predicting the expected survival time of a subject. Specifically, prognosis can involve determining the likelihood that a subject will survive within a future period of time (e.g., 6 months, 1 year, 2 years, 3 years, 5 years, 10 years, or any other time period).

[0028] Preferred preoperative clinical variables include one or more of the following: (i) age of the subject; (ii) prostate-specific antigen (PSA) level; (iii) primary and secondary biopsy Gleason scores; (iv) clinical stage; and (v) percentage of tumor biopsies that are positive.

[0029] The treatment decision of primary localized prostate cancer depends on the combination of future disease progression risk and life expectancy to a great extent.National Comprehensive Cancer Network (NCCN) has defined five risk categories (seeing MohlerJ.et al.) according to preoperative clinical variables.For each risk group from extremely low, low, medium (divided into favorable and unfavorable medium), high and extremely high risk, several interventions are provided in the prostate cancer guideline of current implementation to select.Previously, the more advanced instrument of clinical risk prediction was presented in the form of mathematical model, it was merged into single scoring by clinical variable value (seeing Lughezani G.et al., " Predictive and prognostic models in radical prostatectomy candidates:Acritical analysis of the literature " .European Urology, Vol.58,No.5,pages 687-700,2010). One of the most widely validated clinical risk algorithms for preoperative decision support is the preoperative CAPRA score (see Cooperberg MR, "The UCSF Cancer of the Prostate Risk Assessment (CAPRA) Score: Astraightforward and reliable pre-operative predictor of disease recurrence after radical prostatectomy", Journal of Urology, Vol. 173, No. 6, pages 1938-1942, 2005). This score is a combination of clinically available information, i.e., patient age, preoperative PSA, biopsy Gleason score, percentage of tumor-positive biopsies, and clinical stage. This score was originally published in 2005 and has since been validated in several studies (see Brajtbord J Set al., "The CAPRA score at 10 years: Contemporary perspectives and analysis of supporting studies", European Urology, Vol. 71, No. 5, pages 705-709, 2017). By combining the molecular information provided by expression-based risk scores with information from this extensively validated set of preoperative clinical variables, a preoperative prognostic risk score with improved prognostic power can be obtained.

[0030] It is also preferred that the method further comprises:

[0031] Determine the subject's Preoperative Cancer of the Prostate Risk Assessment (CAPRA) score,

[0032] Among them, the preoperative prognostic risk score was determined by combining the expression-based risk score and the preoperative CAPRA score.

[0033] As mentioned above, the preoperative CAPRA score is one of the most widely validated clinical risk algorithms for preoperative decision support in prostate cancer. It provides a categorical score between 1 and 10, which is divided into three categories: low risk (preoperative CAPRA score of 0-2), moderate risk (preoperative CAPRA score of 3-5) and high risk (preoperative CAPRA score of 6-10). Given its current level of validation as a prognostic algorithm in prostate cancer and its easy-to-interpret single score output, the preoperative CAPRA score can be advantageously combined with an expression-based risk score to form a preoperative prognostic risk score, which can be easily determined in clinical practice and can further improve preoperative prognosis compared to using the preoperative CAPRA algorithm alone.

[0034] It is further preferred to combine the expression-based risk score and the preoperative CAPRA score with a regression function derived from a population of prostate cancer subjects.

[0035] Regression analysis can help people understand how the typical value of the dependent variable (or "standard variable") will change when any one of the independent variables changes while the other independent variables remain fixed. This relationship between the dependent and independent variables is captured in the regression function, which can be used to predict the dependent variable given the value of the independent variable. The dependent variable can be, for example, a binary variable, such as biochemical recurrence within 5 years after surgery. In this case, the regression is a logarithmic regression based on the logarithmic function of the independent variable, which here includes or consists of an expression-based risk score and a preoperative CAPRA score. With the help of the regression function, the prediction of, for example, the risk of biochemical recurrence after 5 years can be improved.

[0036] Additionally, the preoperative prognostic risk score is preferably determined as a subject's modified Preoperative Cancer of the Prostate Risk Assessment (CAPRA) score, wherein the primary and secondary biopsy Gleason scores are replaced with an expression-based risk score.

[0037] On the one hand, the biopsy Gleason score has a significant impact on the preoperative CAPRA score. However, at the same time, the inventors found that Gleason scores vary greatly between pathologists. By replacing the biopsy Gleason score information within the preoperative CAPRA score with the molecular information provided by the expression-based risk score, a modified preoperative CAPRA score can be obtained that is more reliable and less susceptible to variations in the assessments provided by different pathologists.

[0038] It is further preferred that the expression-based risk score is a value within a predetermined range, wherein a number of points within the range of 0-3 are added to the modified preoperative CAPRA score according to the value.

[0039] The preoperative CAPRA score takes into account the initial and second biopsy Gleason scores as follows: If both the initial and second biopsy Gleason scores are in the range of 1-3, no points are added to the modified preoperative CAPRA score. Alternatively, if the initial biopsy Gleason score is in the range of 1-3 and the second biopsy Gleason score is in the range of 4-5, 1 point is added to the modified preoperative CAPRA score. Finally, if the initial biopsy Gleason score is in the range of 4-5 and the second biopsy Gleason score is in the range of 1-5, 3 points are added to the modified preoperative CAPRA score. Depending on the value of the expression-based risk score, the overall structure of the resulting modified preoperative CAPRA score can be maintained with a minimum total score of 0 and a maximum total score of 10 by adding several points in the range of 0-3 to the modified preoperative CAPRA score.

[0040] In a preferred embodiment, the expression-based risk score is a value ranging from 1 to 5, with 3 points added to the modified preoperative CAPRA score if the value is in the range of 1 to <2, 2 points added if the value is between 2 to <3, 1 point added if the value is between 3 to <4, and no points added if the value is between 4 to <5.

[0041] Preferably, the method further comprises:

[0042] Based on the preoperative prognostic risk score, first-line treatment is recommended for the subject.

[0043] wherein the first-line treatment is selected from: (i) at least partial prostatectomy; (ii) active treatment selected from radiation therapy, hormonal therapy, chemotherapy, and combinations thereof; and (iii) active surveillance.

[0044] As described above, various national and international guidelines recommend different treatments for subjects with prostate cancer based on the risk of future disease progression and life expectancy. For example, active surveillance (AS) is generally recommended for men with very low and low-risk prostate cancer, while radical prostatectomy may be indicated for high-risk cancer. However, as previously mentioned, the known clinical risk descriptors do not effectively describe the extent of disease or its aggressiveness in all patients. For example, it has been found that within the NCCN very low-risk and low-risk groups, there is a distinct subgroup of patients whose risk of cancer recurrence after first-line treatment is 10% to 25%. Similarly, within the intermediate-risk group, there is a subgroup known to have a low risk of biochemical progression. By proposing first-line treatment for subjects based on a preoperative prognostic risk score, better recommendations can be made for certain subgroups of prostate cancer patients, such as whether to choose active surveillance or active intervention, such as radical prostatectomy.

[0045] Further preferably, the method comprises:

[0046] Normalizing the gene expression profiles to one or more reference genes selected from the group consisting of: human hypoxanthine phosphoribosyltransferase 1 (HPRT1), tubulin-alpha-1b (TUBA1B), human pumilio RNA binding family member (PUM1), and human TATA box binding protein (TBP),

[0047] The expression-based risk score is determined based on standardized gene expression profiles.

[0048] By normalizing the gene expression profiles of one or more reference genes and determining an expression-based risk score based on the normalized gene expression profiles, variability in the determination of expression-based risk scores can be reduced. This allows for differentiation between actual changes in gene expression profiles and changes due to the measurement method. In this regard, HPRT1, TUBA1B, PUM1, and TBP have been found to be particularly suitable reference genes for normalizing the PDE4D7 gene expression profile.

[0049] The gene expression profile can be determined by detecting mRNA expression using one or more primers and / or probes and / or one or more panels thereof. In addition, the gene expression profile can be determined by amplification-based methods and / or microarray analysis and / or RNA sequencing. Determining the gene expression profile can include performing real-time quantitative polymerase chain reaction (RT-qPCR) on RNA extracted from the biological sample. In other embodiments, the gene expression profile is determined by RNA sequencing, conventional PCR (using, for example, endpoint analysis by gel electrophoresis), or multiplex PCR. In the case of RT-qPCR, determining the gene expression profile can include determining the threshold cycle (Ct) value for PDE4D7 and each of the one or more reference genes. PCR can be performed using at least one primer and / or probe that measures a reference gene selected from HPRT1, TUBA1B, PUM1, and TBP.

[0050] Preferably, the one or more reference genes include at least two or at least three of HPRT1, TUBA1B, PUM1 and TBP. In a particularly preferred embodiment, the one or more reference genes include all genes of HPRT1, TUBA1B, PUM1 and TBP.

[0051] Other reference genes that may additionally or alternatively be used to normalize the PDE4D7 gene expression profile include: human actin beta, mRNA (ACTB); human 60S acidic ribosomal phosphoprotein P0 mRNA (RPLP0); polymerase (RNA) II (DNA-directed) polypeptide A, 220 kDa (POLR2A); beta-2-microglobulin (B2M); and aminolevulinic acid-delta-synthase (ALAS-1).

[0052] It is further preferred that the expression-based risk score is determined based on a gene expression profile using a scoring function derived from a gene expression profile of a biological sample from a subject with prostate cancer.

[0053] In this context, it is particularly preferred that the scoring function is based on a standardized gene expression profile, for example, a gene expression profile standardized for all of HPRT1, TUBA1B, PUM1, and TBP, and that the scoring function is derived from the corresponding standardized gene expression profile of a biological sample from a prostate cancer subject. In a preferred embodiment, the scoring function is a linear transformation that converts the standardized gene expression profile into a predetermined range of values, for example, the aforementioned range of 1-5. This transformation can be determined by considering the frequency distribution of the values ​​of the PDE4D7 standardized gene expression profile for biological samples from a population of prostate cancer subjects and by determining a transformation that converts the frequency distribution into the desired range. By using this scoring function, an expression-based risk score can be presented in a user-intuitive manner, for example, as a small range of positive values. This is similar to other categories used in clinical practice, such as histopathological grading (Gleason) or multi-parameter MRI radiological scoring (PIRADS).

[0054] In a specific embodiment, the expression-based risk score is determined as follows:

[0055] EBRS=(((PDE4D7_norm+A)*B)+1)1)

[0056] where “EBRS” is the expression-based risk score, “PDE4D7_norm” is the normalized PDE4D7 gene expression profile value, and A and B are variables.

[0057] In one example, A can be approximately 6-8, such as 6.7167499999999, B can be 0.4-0.45, such as 0.420780231744713, and the expression-based risk score can be a value in the range of 1-5 (as described above). The expression-based risk score can also be classified or categorized into one of at least two risk groups based on the value of the expression-based risk score. For example, there can be two risk groups, or three risk groups, or four risk groups, or more than four predetermined risk groups. Each risk group covers (does not overlap) a corresponding range of expression-based risk scores. For example, a risk group can include all expression-based risk scores from 1 to <2, another risk group includes all expression-based risk scores from 2 to <3, another risk group includes all expression-based risk scores from 3 to <4, and another risk group includes all expression-based risk scores from 4 to <5.

[0058] Particularly preferably, determining the gene expression profile comprises performing RT-qPCR on RNA extracted from the biological sample, wherein the Cq values ​​of PDE4D7 and each of the one or more reference genes are determined, and wherein determining the expression-based risk score comprises normalizing the Cq value of PDE4D7 using the Cq value of each of the one or more reference genes and calculating the expression-based risk score as a linear function of the normalized Cq values.

[0059] For example, a normalized Cq value for PDE4D7 can be generated by applying the following formula:

[0060] N(Cq PDE4D7 )=Mean(Cq ref_genes )–(Cq PDE4D7 ) 2)

[0061] Where N(Cq PDE4D7 ) is the normalized gene expression profile value of PDE4D7 (quantification cycle, Cq), Mean (Cq ref_genes ) is the arithmetic mean of the PCR Cq values ​​of one or more reference genes, and Cq PDE4D7 is the PCR Cq value of PDE4D7.

[0062] The gene expression profile may further include expression information from phosphodiesterase 4D variant 5 (PDE4D5) and / or from phosphodiesterase 4D variant 9 (PDE4D9), wherein an expression-based risk score is determined for the subject for each phosphodiesterase 4D variant based on the gene expression profile, and wherein a preoperative prognostic risk score for the subject is determined based on the expression-based risk score and preoperative clinical variables of the subject.

[0063] In another aspect of the present invention, a diagnostic kit is provided, comprising:

[0064] at least one primer and / or probe for determining the gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from a subject with prostate cancer; and

[0065] Optionally comprising at least one primer and / or probe for determining the gene expression profile of one or more reference genes selected from the group consisting of: human hypoxanthine phosphoribosyltransferase 1 (HPRT1), tubulin-alpha-1b (TUBA1B), human pumilio RNA-binding family member (PUM1), and human TATA box binding protein (TBP); and

[0066] Optionally comprising at least one substance for determining the level of prostate specific antigen (PSA) in a biological sample obtained from a subject; and

[0067] Instructions for calculating a preoperative prognostic risk score based on a gene expression profile of PDE4D7 and preoperative clinical variables of a subject, the instructions being stored on a computer program product that, when executed by a computer, performs a method comprising:

[0068] determining an expression-based risk score for the subject based on the gene expression profile of PDE4D7, and

[0069] determining a preoperative prognostic risk score for the subject based on the subject's expression-based risk score and preoperative clinical variables,

[0070] Optionally, wherein the method comprises:

[0071] Normalizing the gene expression profile of PDE4D7 to said one or more reference genes,

[0072] The expression-based risk score was determined based on the normalized gene expression profile of PDE4D7.

[0073] Optionally, wherein the preoperative clinical variables include prostate specific antigen (PSA) levels.

[0074] The at least one substance used to determine the prostate specific antigen (PSA) level may be, for example, a PSA-specific antibody or the like.

[0075] In another aspect of the present invention, use of the kit in a method for preoperative risk stratification of prostate cancer subjects is provided.

[0076] In another aspect of the present invention, the use of a gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in preoperative risk stratification of prostate cancer subjects is provided, comprising:

[0077] determining a gene expression profile in a biological sample obtained from a subject,

[0078] determining an expression-based risk score for the subject based on the gene expression profile, and

[0079] A preoperative prognostic risk score is determined for the subject based on the subject's expression-based risk score and preoperative clinical variables.

[0080] In another aspect of the present invention, a computer program product is provided, which includes instructions. When a computer executes the program, the instructions cause the computer to perform a method including the following:

[0081] determining a gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from a subject with prostate cancer,

[0082] determining an expression-based risk score for the subject based on the gene expression profile, and

[0083] A preoperative prognostic risk score is determined for the subject based on the subject's expression-based risk score and preoperative clinical variables.

[0084] It should be understood that a preferred embodiment of the present invention may also be any combination of the above embodiments.

[0085] These and other aspects of the invention will be apparent from and elucidated with reference to the embodiments described hereinafter. Sequence Listing <110> Royal Philips Ltd. <120> Preoperative risk stratification based on PDE4D7 expression and preoperative clinical variables <130> 2017PF02734 <160> 73 <170> PatentIn version 3.5 <210> 1 <211> 7801 <212> DNA <213> Homo sapiens <400> 1 gtggtggccg cgcacccggc cgcggctgat tcattcactt caagtgccgt gcagaaggct 60 cggcaggcgg ggcgggcgtg gggccgcggc tccgggttgg ggaccgagga gatccggctg 120 tggaccagac gctcctctgc ggggcgggca cccaagcgcg ctcgccaccc cctcgccatc 180 cgctagagcc gggctcctgg actgggactc gggcccgccg cacagttgaa aagtcgcata 240 gtggtttttc cgctcgcgtc gctgtgtgaa agttggctcg ccgctctttg cacgccctcc 300 ctggaggccg acccgagacg ccaagctgga gagaccgtgc ctccccgagg ccggccgccc 360 cgcgagcaca gcctccgccc ccgttgcact gccgggctgg gcaatatgaa ggagcagccc 420 tcatgtgccg gcaccgggca tccgagcatg gcggggtatg gcaggatggc cccctttgaa 480 ctcgctagcg gacccgtgaa gcgcttgaga actgagtccc cctttccctg tctcttcgca 540 gaggaggcct accagaaact ggccagcgag accctggagg agctggactg gtgtctggac 600 cagctagaga ccctacagac caggcactcc gtcagtgaga tggcctccaa caagtttaaa 660 aggatgctta atcgggagct cacccatctc tctgaaatga gtcggtctgg aaatcaagtg 720 tcagagttta tatcaaacac attcttagat aagcaacatg aagtggaaat tccttctcca 780 actcagaagg aaaaggagaa aaagaaaaga ccaatgtctc agatcagtgg agtcaagaaa 840 ttgatgcaca gctctagtct gactaattca agtatcccaa ggtttggagt taaaactgaa 900 caagaagatg tccttgccaa ggaactagaa gatgtgaaca aatggggtct tcatgttttc 960 agaatagcag agttgtctgg taaccggccc ttgactgtta tcatgcacac catttttcag 1020 gaacgggatt tattaaaaac atttaaaatt ccagtagata ctttaattac atatcttatg 1080 actctcgaag accattacca tgctgatgtg gcctatcaca acaatatcca tgctgcagat 1140 gttgtccagt ctactcatgt gctattatct acacctgctt tggaggctgt gtttacagat 1200 ttggagattc ttgcagcaat ttttgccagt gcaatacatg atgtagatca tcctggtgtg 1260 tccaatcaat ttctgatcaa tacaaactct gaacttgcct tgatgtacaa tgattcctca 1320 gtcttagaga accatcattt ggctgtgggc tttaaattgc ttcaggaaga aaactgtgac 1380 attttccaga atttgaccaa aaaacaaaga caatctttaa ggaaaatggt cattgacatc 1440 gtacttgcaa cagatatgtc aaaacacatg aatctactgg ctgatttgaa gactatggtt 1500 gaaactaaga aagtgacaag ctctggagtt cttcttcttg ataattattc cgataggatt 1560 caggttcttc agaatatggt gcactgtgca gatctgagca acccaacaaa gcctctccag 1620 ctgtaccgcc agtggacgga ccggataatg gaggagttct tccgccaagg agaccgagag 1680 agggaacgtg gcatggagat aagccccatg tgtgacaagc acaatgcttc cgtggaaaaa 1740 tcacaggtgg gcttcataga ctatattgtt catcccctct gggagacatg ggcagacctc 1800 gtccaccctg acgcccagga tattttggac actttggagg acaatcgtga atggtaccag agcacaatcc ctcagagccc ctctcctgca cctgatgacc cagaggaggg ccggcagggt 1980 - 1980 - 1980 - 1980 - 1980 - 1980 - 1980 - aaggacagtg gcagtcaagt ggaagaagac actagctgca gtgactccaa gactctttgt actcaagact cagagtctac tgaaattccc cttgatgac aggttgaga ggaggcagta ggggaagaag aggaaagcca gcctgaagcc tgtgtcatag atgatcgttc tcctgacacg taacagtgca aaaactttca tgcctttttt ttttttaagt agaaaaattg tttccaaagt gcatgtcaca tgccacaacc acggtcacac ctcactgtca tctgccagga cgtttgttga 2340. acaaaactga ccttgactac tcagtccagc gctcaggaat atcgtaacca gttttttcac ctccatgtca tccgagcag gtggacatct tcacgacag cgtttttaac aagatttcag cttggtagg ctgacaaagc agataaaatc tactccaaat tattttcaag agagtgtgac tcatcaggca gcccaaaagt ttattggact tggggtttct attcctttttt atttgtttgc atattttca gagaaaggc attgcacaga gtgaacttaa tggacgaagc aaaaatg 2580 tcagacag gattagcac gatctgtta ccagtaggg gaggatgagc cacagaatt 2640 gcataatttt ctaatttcaa gtcttcctga tacatgactg atagtgtgg ttcagtgagc 2700 tgcactgacc tctacatttt gtatgatatg taaaacagat tttgtaga gcttactttt 2760 attattaaat gtattgaggt attattatta aaaaaaacta tgttcagac ttcatctgcc 2820 actggttatt tttctaag gagtaacttg caagttttca gtacaatct gtgctacact 2880 ggataaaaat ctaatttatg atttactt gcaccttata gttcatagca atttactgat 2940 ttgtagtgat tcattgtttg ttttatatac caatgacttc catattttaa agagaaaaa 3000 caactttatg tgcaggaaa cccttttgt aagtctttat tattacttt gcattttgtt 3060 tcactctttc cagataagca gagttgctt tcaccagtgt ttttctcat gtgcaaagtg 3120 actatttgtt ctataatact tttatgtgtg ttatatcaa tgtgtcttaa gcttcatgca 3180 aactcagtca tcagttcgtg ttgtctgaag caagtgggag atatataat acccagtagc 3240 taaaatggtc agtctttttt agatgttttc ctacttagta tctcctaata acgttttgct 3300 gtgtcactag atgttcattt cacaagtgca tgtctttcta ataatccaca catttcatgc 3360 tctaataatc cacacatttc atgctcattt ttattgtttt tacagccagt tatagtaaga 3420 aaaaggtttt tccccttgtg ctgctttata atttagcgtg tgtctgaacc ttatccatgt 3480 ttgctagatg aggtcttgtc aaatatatca ctaccattgt caccggtgaa aagaaacagg 3540 tagttaagtt agggttaaca ttcatttcaa ccacgaggtt gtatatcatg actagctttt 3600 actcttggtt tacagagaaa agttaaacag ccaactaggc agtttttaag aatattaaca 3660 atatattaac aaacaccaat acaactaatc ctatttggtt ttaatgattt caccatggga 3720 ttaagaacta tatcaggaac atccctgaga aacggtttta agtgtagcaa ctactcttcc 3780 ttaatggaca gccacataac gtgtaggaag tcctttatca cttatcctcg atccataagc 3840 atatcttgca gaggggaact acttctttaa acacatggag ggaaagaaga tgatgccact 3900 ggcaccagag ggttagtact gtgatgcatc ctaaaatatt tattatattg gtaaaaattc 3960 tggttaaata aaaattaga gatcactctt ggctgatttc agcaccagga actgtattac 4020 agttttagag attaattcct agtgtttacc tgattatagc agttggcatc atggggcatt 4080 taattctgac tttatcccca cgtcagcctt aataaagtct tctttacctt ctctatgaag 4140 actttaaagc ccaaataatc atttttcaca ttgatattca agaattgaga tagatagaag 4200 ccaaagtggg tatctgacaa gtggaaaatc aaacgtttaa gaagaattac aactctgaaa 4260 agcatttata tgtggaactt ctcaaggagc ctcctgggga ctggaaagta agtcatcagc 4320 caggcaaatg actcatgctg aagagagtcc ccatttcagt cccctgagat ctagctgatg 4380 cttagatcct ttgaaataaa aattatgtct ttataactct gatcttttac ataaagcaga 4440 agaggaatca actagttaat tgcaaggttt ctactctgtt tcctctgtaa agatcagatg 4500 gtaatctttc aaataagaaa aaaataaaga cgtatgtttg accaagtagt ttcacaagaa 4560 tatttgggaa cttgtttctt ttaattttat ttgtccctga gtgaagtcta gaaagaaagg 4620 taagagtct agagtttatt cctctttcca aaacattctc attcctctcc tcctacact 4680 tagtatttcc cccacagagt gcctagaatc ttaataatga aaaaataa aagcagcaat 4740 atgtcattaa caatccaga cctgaaaggg taaagggtttt attackgcac taaaagg 4800 aggcttttt tttcttcc agtttgttgg ttttaatg taccgtgttg taagatacc 4860 cactaatgga caatcaatt gcagaaaagg ctcaatcc aagagacagg gactaatgca 4920 ctgtacaatc tgcttatcct tgccctc tcttgccaaa gtgtgctca gaaatatata 4980 ctgctttaaa aaagataaa agatatcct tttacaagtg gctttacatt tcctaaaatg 5040 ccataagaaa atgcaatc tgggtactgt atggggaaa aaatgtccaa gtttgtgtaa 5100 aaccagtgca ttcagcttg caagttactg aacacaataa tgctgtttta attttgtttt 5160 atacagtta aattcacaa tatgtagat agacaaatt acagacaagg aaaaaaaa 5220 cttgaatgaa atggatttta cagaaagctt tattgaatgca ttattattt 5280 ttgtgccat gcatttttt tctcaccaaa tgaccttacc tgtaatacag tcttgtttgt 5340 ctgtttacaa ccatgtattt attgcaatgt acatactgta atgttaattg taaattatct 5400 gttcttatta aaacatcatc ccatgatggg atggtgttga tatattgga aactcttggt 5460 gagagaatga atggtgtgta tacatactct gtacattttt cttttctccct gtaatatagt 5520 cttgtcacct tagacttgt ttatggaaga ttcaagaaa ctataaaata cttaaagata 5580 tataaattta aaaaaacata gctgcaggtc ttgtccca gggctgtgcc tttaactttaa 5640 ccaatatttt cttctgtttt gctgcattg aaggtaaca gtggagctag ggctgggcat 5700 tttacatcca ggctttaat tgattagaat tctgccaata ggtggatttt acaaaccac 5760 agacaacctc tgaaagattc tgagacctt tgagacaga agctcttaag tactctttgc 5820 cagggagcag cactgcatgt gtgatggttg ttgccatct gttgatcagg aactacttca 5880 gctacttgca tttgattatt tcctttttt tttttta ctcggaaaca caactgggga 5940 atatattct ttcccagtga ttataaacaa tctttttctt tttttagt ccttttggct 6000 tctagagctc ataggaaat ggacttgatt tgaaattgga gccagagtttt actcgtgttg 6060 gttatctatt catcagcttc ctgacatgtt aagagaatac attaagaga aaatactgtt 6120 ttttaatcct aaaatttttc ttccactaag ataaaccaaa tgtccttaca tatatgtaaa 6180 cccatctatt taaacgcaaa ggtgggttga tgtcagttta catagcagaa agcattcact 6240 atcctctaag atttgtttct gcaaaacttt cattgcttta gaattttaaa atttcacctt 6300 gtacaatggc cagcccctaa agcaggaaac atttataatg gattatatgg aaacatcctc 6360 ccagtacttg cccagccctt gaatcatgtg gcttttcagt gaaggaaag attctttttc 6420 taggaaaaat gagcctattt tattttatt tattttatt tttgacacaa actgtagatt 6480 ttagcagccc tggcccaaag gaatttgatt acttttgttt taaacagtac aaaggggaca 6540 ctataattac aaaaacatcc ttaactgatt tgagttgttt ttattcttt ggatatattt 6600 tcagagtggt aaattgtgtg tgagaattac aaatgattat tcttttagtg gtttcttagc 6660 ctctcttaca gcccacgggg atagtactgt acatcaatac cttcatatga aatttttata 6720 tgcaatgaaa ataaaagcat gggttgattc tgcctatta tgactcaatc tttaacaaat 6780 aaaagattat tcattttaaa ttatagttca atcagcatgt ctcttaggat actgaacgtg 6840 gttgaaatga agatagtg acatcataag ttagtactga tattcataac caataaagc 6900 caacttgagt aattttgcta cattaaaat taccaaaatt acttagatgg cctataagat 6960 taagcatggt gttttctaag caagctttga aaggggcctt ccatacttac ttaattgaat 7020 attctgggat attgaaaatt attcagatac ttgacaatta tttttggtta cctactccgc 7080 aaactacaaa gttttaagga ctcaacaata agttaatgag acacagtgtt tgctttcatg 7140 gagcttacag tctggagggg aaaaggctt aaacaatact catataatta tatatgtgat 7200 cattacaatg aaggagctca gtggggtaaa taagcaggaa cctgaacttg atctgttccg 7260 gagggccaca gaaggcttcc ttgaggcctt gagaaagtga tttgcatctg agttctgaag 7320 gattgtaaga ggtaactagg gaaaaagttg acaggaagag gaaggggatc cagacaagaa 7380 7440 gtgagagagt aggcagggcc tggagccgca gagccattgc taaccatcct gtgtgagata 7500 tcccccattc tgtagcttta ttctcataac cctgctcaat tttctttata acacttctca 7560 cagatttata tacgtgtttg ttttgttat ctgtctctcc caccagacca cagctccatg 7620 agagcaaggt ctttgcttac caatatatca ctagcactta aaactatgcc tggtacacag 7680 taggttctta atatgtgttg aatatagcca tcaaattgat attggatata attcaatctg 7740 ataagatatt ttgagatatt aaagagtttt taacttgata ccataaaaaa aaaaaaaaaa 7800 at 7801 <210> 2 <211> 585 <212> PRT <213> Homo sapiens <400> 2 Met Lys Glu Gln Pro Ser Cys Ala Gly Thr Gly His Pro Ser Met Ala 1 5 10 15 Gly Tyr Gly Arg Met Ala Pro Phe Glu Leu Ala Ser Gly Pro Val Lys 20 25 30 Arg Leu Arg Thr Glu Ser Pro Phe Pro Cys Leu Phe Wing Glu Glu Wing 35 40 45 Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu 50 55 60 Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala 65 70 75 80 Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser 85 90 95 Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr 100 105 110 Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys 115 120 125 Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys 130 135 140 Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe 145 150 155 160 Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp 165 170 175 Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly 180 185 190 Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp 195 200 205 Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu 210 215 220 Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn 225 230 235 240 Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr 245 250 255 Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile 260 265 270 Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln 275 280 285 Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser 290 295 300 Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln 305 310 315 320 Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln 325 330 335 Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser 340 345 350 Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys 355 360 365 Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg 370 375 380 Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro 385 390 395 400 Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu 405 410 415 Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile 420 425 430 Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val 435 440 445 Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp 450 455 460 Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn 465 470 475 480 Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro 485 490 495 Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe 500 505 510 Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser 515 520 525 Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu 530 535 540 Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val 545 550 555 560 Glu Glu Glu Ala Val Gly Glu Glu Glu Glu Ser Gln Pro Glu Ala Cys 565 570 575 Val Ile Asp Asp Arg Ser Pro Asp Thr 580 585 <210> 3 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> PDE4D1D2_forward primer <400> 3 aatatgaagg agcagccctc a 21 <210> 4 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PDE4D1D2_reverse primer <400> 4 gtctcgctgg ccagtttc 18 <210> 5 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> PDE4D1D2 probe <400> 5 catccgagca tggcggga 18 <210> 6 <211> 7715 <212> DNA <213> Homo sapiens <400> 6 gtggtggccg cgcacccggc cgcggctgat tcattcactt caagtgccgt gcagaaggct 60 cggcaggcgg ggcgggcgtg gggccgcggc tccgggttgg ggaccgagga gatccggctg 120 tggaccagac gctcctctgc ggggcgggca cccaagcgcg ctcgccaccc cctcgccatc 180 cgctagagcc gggctcctgg actgggactc gggcccgccg cacagttgaa aagtcgcata 240 gtggtttttc cgctcgcgtc gctgtgtgaa agttggctcg ccgctctttg cacgccctcc 300 ctggaggccg acccgagacg ccaagctgga gagaccgtgc ctccccgagg ccggccgccc 360 cgcgagcaca gcctccgccc ccgttgcact gccgggctgg gcaatatgaa ggagcagccc 420 tcatgtgccg gcaccgggca tccgagcatg gcgggaggag gcctaccaga aactggccag 480 cgagaccctg gaggagctgg actggtgtct ggaccagcta gagaccctac agaccaggca 540 ctccgtcagt gagatggcct ccaacaagtt taaaaggatg cttaatcggg agctcaccca 600 tctctctgaa atgagtcggt ctggaaatca agtgtcagag tttatatcaa acacattctt 660 agataagcaa catgaagtgg aaattccttc tccaactcag aaggaaaagg agaaaaagaa 720 aagaccaatg tctcagatca gtggagtcaa gaaattgatg cacagctcta gtctgactaa 780 ttcaagtatc ccaaggtttg gagttaaaac tgaacaagaa gatgtccttg ccaaggaact 840 agaagatgtg aacaaatggg gtcttcatgt tttcagaata gcagagttgt ctggtaaccg 900 gcccttgact gttatcatgc acaccatttt tcaggaacgg gatttattaa aaacatttaa 960 aattccagta gatactttaa ttacatatct tatgactctc gaagaccatt accatgctga 1020 tgtggcctat cacaacaata tccatgctgc agatgttgtc cagtctactc atgtgctatt 1080 atctacacct gctttggagg ctgtgtttac agatttggag attcttgcag caatttttgc 1140 cagtgcaata catgatgtag atcatcctgg tgtgtccaat caatttctga tcaatacaaa 1200 ctctgaactt gccttgatgt acaatgattc ctcagtctta gagaaccatc atttggctgt 1260 gggctttaaa ttgcttcagg aagaaaactg tgacattttc cagaatttga ccaaaaaaca 1320 aagacaatct ttaaggaaaa tggtcattga catcgtactt gcaacagata tgtcaaaaca 1380 catgaatcta ctggctgatt tgaagactat ggttgaaact aagaaagtga caagctctgg 1440 agttctctt cttgataatt attccgatag gattcaggtt cttcagaata tggtgcactg 1500 tgcagatctg agcaccca CAAAGCCCT ccagctgtac cgccagtgga cggaccgat 1560 aatggaggag ttctccgcc aaggagaccg agagaggga cgtggcatgg agataagcccc 1620 catgtgtgac aagcacaatg cttccgtgga aaatcacag gtggggcttca tagactatat 1680 tgttcatccc ctctgggaga catgggcaga cctcgtccac cctgacgccc aggatatttt 1740 ggacactttg gaggacaatc gtgaatgta ccagagcaca atccctcaga gcccctcc 1800 tgcacctgat gacccagagg agggccggca gggtcaact gagaaatttcc agtttgaact 1860 aactttagag gagatggtg agtcagacac ggaaaggac agtggcagtc aagtgaaga 1920 agacactagc tgcagtgact ccagactct tgtactca gactcagagt ctactgaat 1980 tccccttgat gaacaggttg agaggaggc agtagggaa gagaggaaa gccagcctga 2040 agcctgtgtc atagatgatc gttctcctga cacgtaacag tgcaaaact ttcatgcctt 2100 ttttttttt aagtagaaaa attgttcca aagtgcatgt cacatgccac aaccacggtc 2160 acacctcact gtcatctgcc aggacgtttg ttgaacaaaa ctgaccttga ctactcagtc 2220 cagcgctcag gaatatcgta accagttttt tcacctccat gtcatccgag caaggtggac 2280 atcttcacga acagcgtttt taacaagatt tcagcttggt agagctgaca aagcagataa 2340 aatctactcc aaattatttt caagagagtg tgactcatca ggcagcccaa aagtttattg 2400 gacttggggt ttctattcct ttttatttgt ttgcaatatt ttcaagaagaa aggcattgca 2460 cagagtgaac ttaatggacg aagcaacaaa tatgtcaaga acaggacata gcacgaatct 2520 gttaccagta ggaggagat gagccacaga aattgcataa ttttctaatt tcaagtcttc 2580 ctgatacatg actgaatagt gtggttcagt gagctgcact gacctctaca ttttgtatga 2640 tatgtaaaac agattttttg tagagcttac ttttattatt aaatgtattg aggtattata 2700 tttaaaaaaaaa actatgttca gaacttcatc tgccactggt tattttttc tagggagtaa 2760 cttgcaagtt ttcagtacaa atctgtgcta cactggataa aaatctaatt tatgaatttt 2820 acttgcacct tatagttcat agcaattaac tgatttgtag tgattcattg tttgttttat 2880 ataccaatga cttccatatt ttaaaagaga aaaacaactt tatgttgcag gaaacccttt 2940 ttgtaagtct ttattattta ctttgcattt tgtttcactc tttccagata agcagagttg 3000 ctcttcacca gtgtttttct tcatgtgcaa agtgactatt tgttctataa tacttttatg 3060 tgtgttatat caaatgtgtc ttaagcttca tgcaaactca gtcatcagtt cgtgttgtct 3120 gaagcaagtg ggagatatat aaatacccag tagctaaaat ggtcagtctt ttttagatgt 3180 tttcctactt agtatctcct aataacgttt tgctgtgtca ctagatgttc atttcacaag 3240 tgcatgtctt tctaataatc cacacatttc atgctctaat aatccacaca tttcatgctc 3300 atttttattg tttttacagc cagttatagt aagaaaaagg tttttcccct tgtgctgctt 3360 tataatttag cgtgtgtctg aaccttatcc atgtttgcta gatgaggtct tgtcaaatat 3420 atcactacca ttgtcaccgg tgaaaagaaa caggtagtta agttagggtt aacattcatt 3480 3540 acagccaact aggcagtttt taagaatatt aacaatatat taacaaacac caatacaact 3600 aatcctattt gttttaatg atttcaccat gggattaaga actatatcag gaacatccct 3660 gagaaacggt tttaagtgta gcaactactc ttccttaatg gatagccaca taacgtgtag 3720 gaagtccttt atcacttatc ctcgatccat aagcatatct tgcagagggg aactacttct 3780 ttaaacacat ggagggaag aagatgatgc cactggcacc agagggttag tactgtgatg 3840 catcctaaaa tattattat attggtaaaa attctggtta aaaaaaat tagagatcac 3900 tcttggctga ttcagcacc aggaactgta ttacagtttt agattaat tcctagtgtt 3960 tacctgatta tagcagttgg catcatgggg catttaattc tgacttatc cccacgtcag 4020 ccttataaa gtctcttta ccttcttat gagacttta aagcccaaat atcattttt 4080 cacattgata ttcaagaatt gagatagata gaagccaag tggtactctg acagtggaa 4140 aatcaaacgt ttagagaa ttacaactct gaaagcatt ttatgtgga acttctcaag 4200 gagcctcctg gggactggaa agtaagtcat cagccaggca atgactcat gctgaagaga 4260 gtccccattt cagtcccctg agatctagct gatgcttaga tcctttgaaa taaaaattat 4320 gtctttataa ctctgatctt ttacataaag cagaagagga atcaactagt taattgcaag 4380 gtttctactc tgtttcctct gtaaagatca gatggtaatc tttcaaataa gaaaaaaaata 4440 aagacgtatg tttgaccaag tagtttcaca agaatatttg ggaacttgtt tcttttaatt 4500 ttatttgtcc ctgagtgaag tctagaaaga aaggtaaaga gtctagagtt tattcctctt 4560 tccaaaacat tctcattcct ctcctcccta cacttagtat ttcccccaca gagtgcctag 4620 aatcttaata atgaataaaa taaaaagcag caatatgtca ttaacaaatc cagacctgaa 4680 agggtaaagg gtttataact gcactataata agagaggctc tttttttttc ttccagtttg 4740 ttggttttta atggtaccgt gttgtaaaga taccactaa tggacaatca aattgcagaa 4800 aaggctcaat atccaagaga cagggactaa tgcactgtac aatctgctta tccttgccct 4860 tctctcttgc caaagtgtgc ttcagaaata tatactgctt taaaaaagaa taaaaagaata 4920 tcctttaca agtggcttta catttcctaa aatgccataa gaaaatgcaa tatctgggta 4980 ctgtatgggg aaaaaaaatgt ccaagtttgt gtaaaaaccag tgcatttcag cttgcaagtt 5040 actgaacaca ataatgctgt tttaatttg ttttatatca gttaaaattc acaataatgt 5100 agatagaca attacagac aaaga aaaacttgaa tgaatggat tttacagaaa 5160 gctttatgat aatttttgaa tgcattattt atttttgtg ccatgcattt tttctcac 5220 caaatgacct tacctgtaat acagcttgt tgtctgttt acaaccatgt atttattgca 5280 atgtacatac tgtaatgtta attgtaaatt atctgttctt attaaaacat catcccatga 5340 tgggatggtg tgatatatt tggaaactct tggtgagaga atgaatggtg tgtatacata 5400 ctctgtacat tttctttc tcctgtaata tagtcttgtc accttagagc ttgtttatgg 5460 aagattcaag aaactataa atacttaaa gatatataa ttaaaaaa catagctgca 5520 ggtctttgt cccaggggctg tgccttaact ttaccata ttttctctg tttgctgca 5580 ttgaaggt aacagtggag ctaggggctgg gcattttaca tccaggcttt taattgatta 5640 gattctgcc ataggtgga ttttacaaa ccacagacaa cctctgaaag attctgagac 5700 ccttttgaga cagaagctct taagtacttc ttgccaggga gcagcactgc atgtgtgatg 5760 gttgtttgcc atctgttgat caggaactac ttcagctact tgcatttgat tatttccttt 5820 tttttttttt ttaactcgga aacacaactg gggaaatata ttctttccca gtgattataa 5880 acaatctttt tctttttttt aagtcctttt ggcttctaga gctcatagga aaatggactt 5940 gatttgaaat tggagccaga gttactcgt gttggttatc tattcatcag cttcctgaca 6000 tgttaagaga atacattaaa gagaaaaatac tgttttttaa tcctaaaatt tttcttccac 6060 taagataaac caaatgtcct tacatatatg taaacccatc tatttaaacg caaaggtggg 6120 ttgatgtcag tttacatagc agaaagcatt cactatcctc taagatttgt ttctgcaaaa 6180 ctttcattgc tttagaattt taaaatttca ccttgtacaa tggccagccc ctaaagcagg 6240 aaacatttat aatggattat atggaaacat cctcccagta cttgcccagc ccttgaatca 6300 tgtggcttt cagtgaaagg aaagattctt tttctaggaa aaatgagcct attttttt 6360 attttttt attttttgac acaaactgta gattttagca gccctggccc aaaggaattt 6420 gattactttt gttttaaaca gtacaaaggg gacactataa ttacaaaaac atccttaact 6480 gatttgagtt gttttattt ctttggatat attttcagag tggtaattg tgtgtgagaa 6540 ttacaaatga ttattcttt agtggttct tagcctct tacagcccac ggggatagta 6600 ctgtacatca ataccttcat atgaatttt tatatgcaat gaaaataaa gcatggggttg 6660 attctgccta tttatgactc aatctttac aaaaaga ttattcattt taaattatag 6720 ttcaatcagc atgtctctta ggatactgaa cgtggttgaa atgaaaggat agtgacatca 6780 taagttagta ctgatattca taaccaata aagccaactt gagtatttt gctacattaa 6840 aaattaccaa attackattag atggcctata agattaagca tggtgttttc taagcaagct 6900 ttgaaagggg ccttccatac ttacttatt gatatttctg ggatattgaa attattcag 6960 atacttgaca attatttttg gttacctact ccgcaacta CAagtttta aggactcac 7020 aaagttaa tgagacacag tgtttgcttt catggagctt acagtctgga ggggacaaag 7080 gcttaaacaa tactcatata attatatg tgatcagtac atgaggag ctcagtgggg 7140 taaatagca ggaacctgaa cttgatctgt tccggaggc cacagaaggc ttccttgagg 7200 ccttgagaaa gtgatttgca tctgagttct gaaggattgt aagaggtaac tagggaaaaa 7260 gttgacagga agaggaaggg gatccagaca agaaacattt gcaagatct tgaggcataa 7320 atgagcttga gatactgga gaactgagg aaagtgaga gagtaggcag ggcctggagc 7380 cgcagagcca ttgctacca tcctgtgtga gatatcccc attctgtagc tttattctca 7440 taaccctgct caatttctt tataacactt tatatacgtg ttgttttg 7500 ttatctgtct ctcccaccag accacagctc catgagagca aggtctttgc ttaccaatat 7560 atcactagca cttaaaacta tgcctggtac acagtaggtt cttaatatgt gttgaatata 7620 gccatcaat tgatattgga tataattca tctgataaga tattttgaga tattaaagag 7680 tttttaactt gataccataa aaaaaaaaaaaaaaaaaa 7715 <210> 7 <211> 507 <212> PRT <213> Homo sapiens <400> 7 Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His 1 5 10 15 Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser 20 25 30 Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr 35 40 45 Gln Lys Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly 50 55 60 Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro 65 70 75 80 Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu 85 90 95 Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu 100 105 110 Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu 115 120 125 Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr 130 135 140 Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His 145 150 155 160 Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu 165 170 175 Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala 180 185 190 Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser 195 200 205 Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn 210 215 220 Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu 225 230 235 240 Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln 245 250 255 Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp 260 265 270 Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu 275 280 285 Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser 290 295 300 Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser 305 310 315 320 Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile 325 330 335 Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met 340 345 350 Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser 355 360 365 Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp 370 375 380 Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu 385 390 395 400 Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro 405 410 415 Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe 420 425 430 Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys 435 440 445 Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys 450 455 460 Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu 465 470 475 480 Gln Val Glu Glu Glu Ala Val Gly Glu Glu Glu Glu Ser Gln Pro Glu 485 490 495 Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr 500 505 <210> 8 <211> 7783 <212> DNA <213> Homo sapiens <400> 8 aatacttgtt gcaataattg cccacgatag ctgctcaaac aagagagttg gaattcatct 60 gtaaaaatca ctacatgtaa cgtaggagac aagaaaaata ttaatgacag aagatctgcg 120 aacatgatgc acgtgaataa ttttcccttt agaaggcatt cctggatatg ttttgatgtg 180 gacaatggca catctgcggg acggagtccc ttggatccca tgaccagccc aggatccggg 240 ctaattctcc aagcaaattt tgtccacagt caacgacggg agtccttcct gtatcgatcc 300 gacagcgatt atgacctctc tccaaagtct atgtcccgga actcctccat tgccagtgat 360 atacacggag atgacttgat tgtgactcca ttgctcagg tcttggccag tctgcgaact 420 gtacgaaaca actttgctgc attaactaat ttgcaagatc gagcacctag caaaagatca 480 cccatgtgca accaaccatc catcaacaaa gccaccataa cagaggaggc ctaccagaaa 540 ctggccagcg agaccctgga ggagctggac tggtgtctgg accagctaga gaccctacag 600 accaggcact ccgtcagtga gatggcctcc aacaagttta aaaggatgct taatcgggag 660 ctcacccatc tctctgaaat gagtcggtct ggaaatcaag tgtcagagtt tatatcaaac 720 acattcttag ataagcaaca tgaagtggaa attccttctc caactcagaa ggaaaaggag 780 aaaaagaaaa gaccaatgtc tcagatcagt ggagtcaaga aattgatgca cagctctagt 840 ctgactaatt caagtatccc aaggtttgga gttaaaactg aacaagaaga tgtccttgcc 900 aaggaactag aagatgtgaa caaatggggt cttcatgttt tcagaatagc agagttgtct 960 ggtaaccggc ccttgactgt tatcatgcac accatttttc aggaacgggga tttattaaaa 1020 acatttaaaa ttccagtaga tactttaatt acatatctta tgactctcga agaccattac 1080 catgctgatg tggcctatca caacaatatc catgctgcag atgttgtcca gtctactcat 1140 gtgctattat ctacacctgc tttggaggct gtgtttacag atttggagat tcttgcagca 1200 atttttgcca gtgcaataca tgatgtagat catcctggtg tgtccaatca atttctgatc 1260 aatacaaact ctgaacttgc cttgatgtac aatgattcct cagtcttaga gaaccatcat 1320 ttggctgtgg gctttaaatt gcttcaggaa gaaaactgtg acattttcca gaatttgacc 1380 aaaaaaaaa gacaatcttt areaaaatg gtcattgaca tcgtacttgc aacagatatg 1440 1500 agctctggag ttcttcttct tgataattat tccgatagga ttcaggttct tcagaatatg 1560 gtgcactgtg cagatctgag caacccaaca aagcctctcc agctgtaccg ccagtggacg 1620 1680 ataagcccca tgtgtgacaa gcacaatgct tccgtggaaa aatcacaggt gggcttcata 1740 gactatattg ttcatcccct ctgggagaca tgggcagacc tcgtccaccc tgacgcccag 1800 gaattttgg acacttttgga ggacaatcgt gaatggtacc agagcacaat ccctcagagc 1860 ccctctcctg cacctgatga cccagaggag ggccggcagg gtcaaactga gaaattccag 1920 tttgaactaa ctttagagga agatggtgag tcagacacgg aaaaggacag tggcagtcaa 1980 gtggaagaag acactagctg cagtgactcc aagactcttt gtactcaaga ctcagagtct 2040 actgaaattc cccttgatga acaggttgaa gaggaggcag taggggaaga agaggaaagc 2100 cagcctgaag cctgtgtcat agatgatcgt tctcctgaca cgtaacagtg caaaaacttt 2160 catgcctttt ttttttttaa gtagaaaaat tgtttccaaa gtgcatgtca catgccacaa 2220 ccacggtcac acctcactgt catctgccag gacgtttgtt gaacaaaact gaccttgact 2280 actcagtcca gcgctcagga atatcgtaac cagttttttc acctccatgt catccgagca 2340 aggtggacat cttcacgaac agcgttttta acaagatttc agcttggtag agctgacaaa 2400 gcagataaaa tctactccaa attattttca agagagtgtg actcatcagg cagcccaaaa 2460 gttattgga cttggggttt ctattcctt ttatttgttt gcaatatttt cagaagaaag 2520 gcattgcaca gagtgaactt aatggacgaa gcaacaaata tgtcaagaac aggacatagc 2580 acgaatctgt taccagtagg aggaggatga gccacagaaa ttgcataatt ttctaatttc 2640 aagtcttcct gatacatgac tgaatagtgt ggttcagtga gctgcactga cctctacatt 2700 ttgtatgata tgtaaaacag atttttgta gagcttactt ttattattaa atgtattgag 2760 gtattatatt taaaaaaaac tatgttcaga acttcatctg cactggtta ttttttcta 2820 aggagtaact tgcaagtttt cagtacaaat ctgtgctaca ctggataaaa atctaattta 2880 tgaattttac ttgcacctta tagttcatag cattaactg atttgtagtg attcattgtt 2940 tgttttatat accaatgact tccatatttt aaagagaaa aacacttta tgttgcagga 3000 aacccttttt gtaagtcttt attattact ttgcattttg ttcacttt tccagataag 3060 cagagttgct cttcaccagt gttttcttc atgtgcaaag tgactttg ttctataata 3120 cttttatgtg tgttatatca aatgtgtctt aagctcatg caactcagt catcagttcg 3180 tgttgtctga agcaagtggg agatatata atacccagta gctaaaatgg tcagtctttt 3240 ttagatgttt tcctacttag tatctcctaa taacgtttg ctgtgtcact agatgttcat 3300 ttcacaagtg catgtctttc taataatcca cacatttcat gctctaataa tccacacatt 3360 tcatgctcat ttttattgtt tttacagcca gttatagtaa gaaaaaggtt ttccccttg 3420 tgctgcttta taatttagcg tgtgtctgaa ccttatccat gtttgctaga tgaggtcttg 3480 tcaatatat cactaccatt gtcaccggtg aaaagaaaca ggtagttaag ttaggttaa 3540 cattcatttc aaccacgagg ttgtatatca tgactagctt tactcttgg tttacagaga 3600 aaagttaaac agccaactag gcagtttta agatattaa caatatta acaacacca 3660 atacaactaa tcctatttgg ttttaatgat ttcaccatgg gattagaac tatatcagga 3720 acatccctga gaaacggttt taagtgtagc actactctt ccttaatgga cagccacata 3780 acgtgtagga agtcctttat cacttatcct cgatccataa gcatatcttg cagaggggaa 3840 ctactcttt aaacacatgg agggaagaa gatgatgcca ctggcaccag agggttagta 3900 ctgtgatgca tcctaaaata tttatat tggtaaaaat tctgttaaa taaaaaatta 3960 gagatcactc ttggctgatt tcagcaccag gaactgtatt acagttttag agattaattc 4020 ctagtgttta cctgattata gcagttggca tcatggggca ttatattctg actttatccc 4080 cacgtcagcc tttaaagt cttctttacc ttctctatga agactttaaa gccaaataa 4140 tcattttca cattgatatt caagaattga gatagataga agccaagtg ggtatctgac 4200 aagtggaaaa tcaaacgttt aagaagaatt acaactctga aaagcattta tatgtggaac 4260 ttctcaagga gcctcctggg gactggaaag taagtcatca gccaggcaaa tgactcatgc 4320 tgaagagagt ccccatttca gtcccctgag atctagctga tgcttagatc ctttgaaata 4380 aaaattatgt ctttataact ctgatctttt acataaagca gaagaggaat caactagtta 4440 attgcaaggt ttctactctg tttcctctgt aaagatcaga tggtaatctt tcaaataaga 4500 aaaaaataaa gacgtatgtt tgaccaagta gtttcacaag aatatttggg aacttgtttc 4560 ttttaatttt atttgtccct gagtgaagtc tagaaagaaa ggtaaagagt ctagagttta 4620 ttcctctttc caaaacattc tcattcctct cctccctaca cttagtattt cccccacaga 4680 gtgcctagaa tcttaataat gaataaaata aaaagcagca atatgtcatt aacaaatcca 4740 gacctgaaag ggtaaagggt ttataactgc actaataaag agaggctctt ttttttctt 4800 ccagtttgtt ggtttttaat ggtaccgtgt tgtaaagata cccactaatg gacaatcaaa 4860 ttgcagaaaa ggctcaatat ccaagagaca gggactaatg cactgtacaa tctgcttatc 4920 cttgcccttc tctcttgcca aagtgtgctt cagaaatata tactgcttta aaaaagaata 4980 aaagaatatc cttttacaag tggctttaca ttcctaaaa tgccataaga aaatgcaata 5040 tctgggtact gtatgggaa aaaatgtcc aagtttgtgt aaaaccagtg cattcagct 5100 tgcaagttac tgaacacaat aatgctgttt taatttgtt ttatatcagt taaaattcac 5160 aaatgtag atagaaaaaa ttacagaaaaaacttgaatg aaatggattt 5220 tacagaaagc tttatgataa ttttgaatg cattatttat ttttgtgcc atgcattttt 5280 tttctcacca aatgacctta cctgtaatac agtcttgttt gtctgtttac aaccatgtat 5340 ttattgcaat gtacatactg taatgttaat tgtaattat ctgttcttat taaaacatca 5400 tcccatgatg ggatggtgtt gatattttg gaaactcttg gtgagagaat gatggtgtg 5460 tatacatact ctgtacattt ttcttctc ctgtatata gtcttgtcac cttagagctt 5520 gttttaggaa gattcaagaaacttaaaaacttaaatt taaaaaaaaca 5580 tagctgcagg tctttggtcc tagggctgtg ccttaacttt aaccaatatt ttctctgtt 5640 ttgctgcatt tgaaaggtaa cagtggagct agggctgggc attttacatc caggctttta attgattaga attctgccaa tagtggatt ttacaaaacc acagacaacc tctgaaagat tctgagaccc ttttgagaca gaagctctta agtacttctt gccagggagc agcactgcat 5820 gtgtgatggt tgtttgccat ctgttgatca ggaactactt cagctacttg catttgatta tttccttttt tttttttttt aactcggaa cacaactggg gaatatt ctttcccagt gattaac aatctttttc ttttttttaa gtccttttgg cttctagagc tcataggaa atggacttga tttgaaattg gagccagagt ttactcgtgt tggttatcta ttcatcagct tcctgacatg tcctgacatg acattaaga gaaaatactg ttttttaatc ctaaaatttt tcttccacta agataaacca aatgtcctta catatatgta aacccatcta tttaaacgca aaggtgggtt gatgtcagtt tacatagcag aaagcattca ctatcctcta agatttgttt ctgcaaaact ttcattgctt tagatttta aaatttcacc ttgtacaatg gccagcccct aaagcagga acatttata tggattatat ggaaacatcc tcccagtact tgcccagccc ttgaatcatg tggcttttca gtgaaaggaa agattctttt tctaggaaaa atgagcctat 6420 tttattttat tttattttat tttttgacac aaactgtaga ttttagcagc cctggcccaa 6480 aggaatttga ttacttttgt tttaaacagt acaaagggga cactataatt acaaaaacat 6540 ccttaactga tttgagttgt ttttatttct ttggatatat tttcagagtg gtaaattgtg 6600 tgtgagaatt acaaatgatt attcttttag tggtttctta gcctctctta cagcccacgg 6660 ggatagtact gtacatcaat accttcatat gaaattttta tatgcaatga aaataaaagc 6720 atgggttgat tctgcctatt tatgactcaa tcttttacaa ataaaagatt attcatttta 6780 aattatagtt caatcagcat gtctcttagg atactgaacg tggttgaaat gaaaggatag 6840 tgacatcata agttagtact gatattcata accaaataaa gccaacttga gtaattttgc 6900 tacattaaaa attackaaa ttacttagat ggcctataag attaagcatg gtgttttcta 6960 agcaagcttt gaaaggggcc ttccatactt acttaattga atattctggg atattgaaaa 7020 ttattcagat acttgacaat tatttttggt tacctactcc gcaaactaca aagttttaag 7080 gactcaacaa taagttaatg agacacagtg tttgctttca tggagcttac agtctggagg 7140 ggacaaaggc ttaaacaata ctcatataat tatatatgtg atcagtacaa tgaaggagct 7200 cagtggggta aataagcagg aacctgaact tgatctgttc cggagggcca cagaaggctt 7260 ccttgaggcc ttgagaaagt gatttgcatc tgagttctga aggattgtaa gaggtaacta 7320 gggaaaaagt tgacaggaag aggaagggga tccagacaag aaacatttgc aaagatcttg 7380 aggcataaat gagcttgaga catctggaga aactgaggaa aagtgagaga gtaggcaggg 7440 cctggagccg cagagccatt gctaaccatc ctgtgtgaga tatcccccat tctgtagctt 7500 tattctcata accctgctca atttcttta taacacttct cacagattta tatacgtgtt 7560 tgtttttgtt atctgtctct cccaccagac cacagctcca tgagagcaag gtctttgctt 7620 accaatatat cactagcact taaaactatg cctggtacac agtaggttct tatatgtgt 7680 tgaatatagc catcaaattg atattggata taattcaatc tgataagata ttttgagata 7740 ttaaagagttt tttaacttga taccataaaa aaaaaaaaa aaa 7783 <210> 9 <211> 673 <212> PRT <213> Homo sapiens <400> 9 Met Met His Val Asn Asn Phe Pro Phe Arg Arg His Ser Trp Ile Cys 1 5 10 15 Phe Asp Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro 20 25 30 Met Thr Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His 35 40 45 Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp 50 55 60 Leu Ser Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile 65 70 75 80 His Gly Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser 85 90 95 Leu Arg Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp 100 105 110 Arg Ala Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn 115 120 125 Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr 130 135 140 Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr 145 150 155 160 Arg His Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu 165 170 175 Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln 180 185 190 Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val 195 200 205 Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Lys Arg Pro 210 215 220 Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu 225 230 235 240 Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp 245 250 255 Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val 260 265 270 Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met 275 280 285 His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro 290 295 300 Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His 305 310 315 320 Ala Asp Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln 325 330 335 Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr 340 345 350 Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val 355 360 365 Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu 370 375 380 Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu 385 390 395 400 Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln 405 410 415 Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp 420 425 430 Ile Val Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp 435 440 445 Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu 450 455 460 Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val 465 470 475 480 His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg 485 490 495 Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg 500 505 510 Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn 515 520 525 Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His 530 535 540 Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp 545 550 555 560 Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile 565 570 575 Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln 580 585 590 Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly 595 600 605 Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr 610 615 620 Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr 625,630,635,640 Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Glu Wing Val Gly Glu Glu 645,650,655 Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp 660 665 670 Thr <210> 10 <211> 8240 <212> DNA <213> Homo sapiens <400> 10 cccctcgg tagccctgag gctctggcgc cttcaagtga gaagctaagc accagcctct 60 gctgggctgc agaagcggcg gcggcggcag cagcagcagc agcatcagga aggcgctcgg 120 gccagcgcgg tgaacccggg ctgggcagca ggtcgcggag ccgcgagcca ggatggaggc 180 agagggcagc agcgcgccgg cccgggcggg cagcggagag ggcagcgaca gcgccggcgg 240 ggccacgctc aaagccccca agcatctctg gaggcacgag cagcaccacc agtacccgct 300 ccggcagccc cagttccgcc tcctgcatcc ccatcaccac ctgcccccgc cgccgccacc 360 ctcgccccag ccccagcccc agtgtccgct acagccgccg ccgccgcccc ccctgccgcc 420 gcccccgccg ccgcccgggg ctgcccgcgg ccgctacgcc tcgagcgggg ccccggccg 480 cgtccggcat cgcggctact cggacaccga gcgctacctg tactgtcgcg ccatggaccg 540 cacctcctac gcggtggaga ccggccaccg gcccggcctg aagaatcca ggatgtcctg 600 gccctcctcg ttccagggac tcaggcgttt tgatgtggac aatggcacat ctgcgggacg 660 gagtcccttg gatcccatga ccagcccagg atccgggcta attctccaag caaattttgt 720 ccacagtcaa cgacgggagt ccttcctgta tcgatccgac agcgattatg acctctctcc 780 aaagtctatg tcccggaact cctccattgc cagtgatata cacggagatg acttgattgt gactccattt gctcaggtct tggccagtct gcgaactgta cgaaacaact ttgctgcatt 900 aactaatttg caagatcgag cacctagcaa aagatcaccc atgtgcaacc aaccatccat caacaaagcc accataacag aggaggccta ccagaaactg gccagcgaga ccctggagga gctggactgg tgtctggacc agctagagac cctacagacc aggcactccg tcagtgagat 1080 ggcctccaac aagtttaaaa ggatgcttaa tcgggagctc acccatctct ctgaaatgag 1140 tcggtctgga aatcaagtgt cagagtttat atcaaacaca ttcttagata agcaacatga 1200 agtggaaatt ccttctccaa ctcagaagga aaaggagaaa aagaaaagac caatgtctca 1260 gatcagtgga gtcaagaaat tgatgcacag ctctagtctg actaattcaa gtatcccaag 1320 gttggagtt aaaactgaac aagaagatgt ccttgccaag gaactagaag atgtgaacaa 1380 atggggtctt catgttttca gaatagcaga gttgtctggt aaccggccct tgactgttat 1440 catgcacacc atttttcagg aacgggattt attaaaaaca tttaaaattc cagtagatac 1500 tttaattaca tatcttatga ctctcgaaga ccattaccat gctgatgtgg cctatcacaa 1560 caatatccat gctgcagatg ttgtccagtc tactcatgtg ctattatcta cacctgcttt 1620 ggaggctgtg tttacagatt tggagattct tgcagcaatt tttgccagtg caatacatga 1680 tgtagatcat cctggtgtgt ccaatcaatt tctgatcaat acaaactctg aacttgcctt 1740 gatgtacaat gattcctcag tcttagagaa ccatcatttg gctgtgggct ttaaattgct 1800 tcaggaagaaactgtgaca tttccagaa tttgaccaa aaaaaagac atctttaag 1860 gaaaatggtc attgacatcg tacttgcac agatatgtca aaacacatga atctactggc 1920 tgatttgaag actatggttg aaactaagaa agtgacaagc tctggattc ttctcttga 1980 taattattcc gataggattc aggttctca gatatggtg cactgtgcag atctgagcaa 2040 cccaacaaag cctctccagc tgtaccgcca gtggacggac cggataatgg aggattctt 2100 ccgccaagga gaccgagaga gggaacgtgg catggagata agcccatgt gtgacaagca 2160 caatgcttcc gtggaaaaat cacaggtggg cttcatagac tatattgttc atccccctg 2220 ggagacatgg gcagacctcg tccaccctga cgcccaggat attttggaca ctttggagga 2280 caatcgtgaa tgtaccaga gcacaatccc tcagagcccc tctcctgcac ctgatgaccc 2340 agaggagggc cggcaggggtc aactgagaa attccagtttt gaactaactt tagaggaga 2400 tggtgagtca ghacacgaaa aggacagtgg cagtcaagtg gagagaca ctagctgcag 2460 tgactccaag actcttgta ctcagactc agagtctact gaattcccc ttgatgacaca 2520 ggttgaagag gaggcagtag gggaagaga ggaaagccag cctgaagcct gtgtcataga tgatcgttct cctgacacgt aacagtgcaa aaactttcat gcctttttttt tttttaagta gaaaaattgt ttccaaagtg catgtcacat gccacaacca cggtcacacc tcactgtcat ctgccaggac gtttgttgaa caaaactgac cttgactact cagtccagcg ctcaggaata tcgtaaccag ttttttcacc tccatgtcat ccgagcaagg tggacatctt cacgaacagc gtttttaaca agatttcagc ttggtagc tgacaaagca gataaaatct actccaaatt attttcaaga gagtgtgact catcaggcag cccaaaagtt tattggactt ggggtttcta ttccttttta tttgtttgca atattttcag aagaaaggca ttgcacagag tgaacttaat ggacgaagca acaaatatgt caagacagg acatagcacg aatctgttac cagtaggagg aggatgagcc acagaattg cataattttc taatttcaag tcttcctgat acatgactga atagtgtggt tcagtgagct gcactgacct ctacattttg tatgatatgt aaaacagatt 3180 ttttgtagg cttactttta ttattaaatg tattgaggta ttattttaa aaaaaactat gttcagaact tcatctgcca ctggttattt ttttctaagg agtaacttgc aagttttcag 3300 tacaaatctg tgctacactg gataaaaatc taatttatga attttacttg caccttatag 3360 ttcatagcaa ttaactgatt tgtagtgatt cattgtttgt tttatatacc aatgacttcc 3420 atattttaaa agagaaaaac aactttatgt tgcaggaaac cctttttgta agtctttatt 3480 atttactttg cattttgttt cactctttcc agataagcag agttgctctt caccagtgtt 3540 tttcttcatg tgcaaagtga ctatttgttc tataatactt ttatgtgtgt tatatcaaat 3600 gtgtcttaag cttcatgcaa actcagtcat cagttcgtgt tgtctgaagc aagtgggaga 3660 tatataaata cccagtagct aaaatggtca gtctttttta gatgttttcc tacttagtat 3720 ctcctaataa cgttttgctg tgtcactaga tgttcatttc acaagtgcat gtctttctaa 3780 taatccacac atttcatgct ctaataatcc acacatttca tgctcatttt tattgttttt 3840 acagccagtt atagtaagaa aaaggttttt ccccttgtgc tgctttataa tttagcgtgt 3900 gtctgaacct tatccatgtt tgctagatga ggtcttgtca aatatatcac taccattgtc 3960 accggtgaaa agaaacaggt agttaagtta gggttaacat tcattcac cacgaggttg 4020 tatatcatga ctagcttta ctcttggtttt acagagaaaa gttaaacagc caactaggca 4080 gtttttaaga atattacaa atattaca aacaccata caactaatcc tattttggtttt 4140 taatgatttc accatgggat tagaactat atcaggaaca tccctgagaa acggttttaa 4200 gtgtagcaac tactctcct taatggacag ccacataacg tgtaggagt cctttatcac 4260 ttatcctcga tccataagca tatcttgcag agggaacta cttctttaaa cacatggagg 4320 gaaagaagat gatgccactg gcaccagagg gttagtactg tgatgcatcc taaaatattt 4380 attatattgg taaaaatttct gggttaataa aaaattagag atcacttg gctgatttca 4440 gcaccaggaa ctgtattaca gttttagaga ttattccta gtgttttacct gattatagca 4500 gttggcatca tggggcattt aattctgact ttacccac gtcagcctta ataaagtctt 4560 ctttaccttc tctatgaga ctttaaagcc caataatca ttttcacat tgatattca 4620 gattgagat agatagaagc caagtgggt atctgacaag tggaaatca aacgtttaag 4680 aagaattaca actctgaaaa gcatttatat gtggaacttc tcaaggagcc tcctggggac 4740 tggaaagtaa gtcatcagcc aggcaaatga ctcatgctga agagagtccc catttcagtc 4800 ccctgagatc tagctgatgc ttagatcctt tgaaataaa attatgtctt tataactctg 4860 atcttttaca taaagcagaa gaggaatcaa ctagttaatt gcaaggtttc tactctgttt 4920 cctctgtaaa gatcagatgg taatctttca aataagaaaa aaataaaagac gtatgtttga 4980 ccaagtagtt tcacaagaat atttgggaac ttgtttcttt taattttatt tgtccctgag 5040 tgaagtctag aaagaaaggt aaagagtcta gagtttattc ctctttccaa aacattctca 5100 ttcctctcct ccctacactt agtatttccc ccacagagtg cctagaatct taataatgaa 5160 taaataaaaa agcagcaata tgtcattaac aaatccagac ctgaaagggt aaagggttta 5220 5280 accgtgttgt aaagataccc actaatggac aatcaaattg cagaaaaggc tcaatatcca 5340 agagacaggg actaatgcac tgtacaatct gcttatcctt gcccttctct cttgccaaag 5400 tgtgcttcag aaatatatac tgctttaaaa aagaataaaa gaatatcctt ttacaagtgg 5460 ctttacattt cctaaaatgc cataagaaaa tgcaatatct gggtactgta tggggaaaaaa 5520 aatgtccaag tttgtgtaaa accagtgcat ttcagcttgc aagttactga acacaataat 5580 gctgttttaa ttttgtttta tatcagttaa aattcacaat aatgttagata gaacaaatta 5640 cagacaagga aagaaaaaac ttgaatgaaa tggattttac agaaagcttt atgataattt 5700 ttgaatgcat tatttatttt ttgtgccatg catttttttt ctcaccaaat gaccttacct 5760 gtaatacagt cttgtttgtc tgtttacaac catgtatta ttgcaatgta catactgtaa 5820 tgttaattgt aaattatctg ttcttattaa aacatcatcc catgatggga tggtgttgat 5880 atatttggaa actcttggtg agagaatgaa tggtgtgtat acatactctg tacatttttc 5940 ttttctcctg taatatagtc ttgtcacctt agagcttgtt tatggaagat tcaagaaaac 6000 tataaaatac ttaaaagatat ataaatttaa aaaaacatag ctgcaggtct ttggtcccag 6060 ggctgtgcct taactttaac caatattttc ttctgttttg ctgcatttga aaggtaacag 6120 tggagctagg gctgggcatt ttacatccag gcttttaatt gattagaatt ctgccaatag 6180 gtggatttta caaaaccaca gacaacctct gaagattct gagaccttt tgagacagaa 6240 gctcttaagt acttcttgcc agggagcagc actgcatgtg tgatggttgt ttgccatctg 6300 ttgatcagga actacttcag ctacttgcat ttgattattt cctttttttt tttttttaac 6360 tcggaaacac aactggggaa atatattctt tcccagtgat tataaacaat ctttttcttt 6420 tttttaagtc ctttggctt ctagagctca taggaaaatg gacttgattt gaaattggag 6480 ccagagttta ctcgtgttgg ttatctattc atcagcttcc tgacatgtta agagaataca 6540 ttaaaagaa aatactgttt tttaatccta aaatttttct tccactaaga taaaccaaat 6600 gtccttacat atatgttaac ccatctattt aaacgcaaag gtgggttgat gtcagtttac 6660 atagcagaaa gcattcacta tcctctaaga tttgtttctg caaaactttc attgctttag 6720 aattttaaaa tttcaccttg tacaatggcc agcccctaaa gcaggaaaca tttataatgg 6780 attatatgga aacatcctcc footcttgc ccagcccttg aatcatgtgg cttttcagtg 6840 aaaggaaaga ttctttttct aggaaaaatg agcctatttt attttatttt attttatttt 6900 ttgacacaaa ctgtagattt tagcagccct ggcccaaagg aatttgatta cttttgtttt 6960 aaacagtaca aaggggacac tataattaca aaaacatcct taactgattt gagttgtttt 7020 tatttctttg gatatatttt cagagtggta aattgtgtgt gagaattaca aatgattatt 7080 cttttagtgg tttcttagcc tctcttacag cccacgggga tagtactgta catcaatacc 7140 ttcatatgaa atttttatat gcaatgaaaa taaaagcatg ggttgattct gcctatttat 7200 gactcaatct tttacaaata aaagattatt cattttaaat tatagttcaa tcagcatgtc 7260 tcttaggata ctgaacgtgg ttgaaatgaa aggatagtga catcataagt tagtactgat 7320 attcataacc aaataaagcc aacttgagta attttgctac attaaaaatt accaaaatta 7380 cttagatggc ctataagatt aagcatggtg ttttctaagc aagctttgaa aggggccttc 7440 catacttact taattgaata ttctgggata ttgaaaatta ttcagatact tgacaattat 7500 ttttggttac ctactccgca aactacaaag ttttaaggac tcaacaataa gttaatgaga 7560 cacagtgttt gcttcatgg agctacagt ctggagggga caaggctta aacaatactc 7620 atataattat atatgtgatc agtacaatga aggagctcag tggggtaaat agcaggac 7680 ctgaacttga tctgttccgg agggccacag aaggctcct tgaggctg agaagtgat 7740 ttgcatctga gttctgaagg attgtagag gtaactagggg aaaagttga caggaagagg 7800 aagggatcc agacaagaaa cattgcaaa gatcttgagg cataaatgag cttgagacat 7860 ctggagaaac tgaggaaag tgagagta ggcaggcct ggaggccgcag agccattgct 7920 aaccatcctg tgtgagatat cccccattct gtagcttat tctcatacc ctgctcatt 7980 ttctttataa cacttctcac agatttatat acgtgtttgt tttgttatc tgtctctccc 8040 accagaccac agctccatga gagcaaggtc ttgcttacc atatatcac tagcactta 8100 aactatgcct ggtacacagt aggttcttaa tatgtgttga atagccat caattgata 8160 ttggatataa ttcaatctga taagatattt tgagatatta aagagttttt aacttgatac 8220 cataaaaaaaaaaaaaaa 8240 <210> 11 <211> 809 <212> PRT <213> Homo sapiens <400> 11 Met Glu Ala Glu Gly Ser Ser Ala Pro Ala Arg Ala Gly Ser Gly Glu 1 5 10 15 Gly Ser Asp Ser Ala Gly Gly Ala Thr Leu Lys Ala Pro Lys His Leu 20 25 30 Trp Arg His Glu Gln His His Gln Tyr Pro Leu Arg Gln Pro Gln Phe 35 40 45 Arg Leu Leu His Pro His His His Leu Pro Pro Pro Pro Pro Pro Ser 50 55 60 Pro Gln Pro Gln Pro Gln Cys Pro Leu Gln Pro Pro Pro Pro Pro Pro 65 70 75 80 Leu Pro Pro Pro Pro Pro Pro Pro Gly Ala Ala Arg Gly Arg Tyr Ala 85 90 95 Ser Ser Gly Ala Thr Gly Arg Val Arg His Arg Gly Tyr Ser Asp Thr 100 105 110 Glu Arg Tyr Leu Tyr Cys Arg Ala Met Asp Arg Thr Ser Tyr Ala Val 115 120 125 Glu Thr Gly His Arg Pro Gly Leu Lys Lys Ser Arg Met Ser Trp Pro 130 135 140 Ser Ser Phe Gln Gly Leu Arg Arg Phe Asp Val Asp Asn Gly Thr Ser 145 150 155 160 Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu 165 170 175 Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu 180 185 190 Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg 195 200 205 Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr 210 215 220 Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe 225 230 235 240 Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro 245 250 255 Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala 260 265 270 Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu 275 280 285 Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala 290 295 300 Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser 305 310 315 320 Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr 325 330 335 Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys 340 345 350 Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys 355 360 365 Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe 370 375 380 Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp 385 390 395 400 Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly 405 410 415 Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp 420 425 430 Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu 435 440 445 Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn 450 455 460 Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr 465 470 475 480 Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile 485 490 495 Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln 500 505 510 Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser 515 520 525 Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln 530 535 540 Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln 545 550 555 560 Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser 565 570 575 Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys 580 585 590 Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg 595 600 605 Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro 610 615 620 Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu 625 630 635 640 Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile 645 650 655 Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val 660 665 670 Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp 675 680 685 Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn 690 695 700 Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro 705 710 715 720 Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe 725 730 735 Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser 740 745 750 Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu 755 760 765 Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Gl Gn Val 770 775 780 Glu Glu Glu Ala Val Gly Glu Glu Glu Ser Gln Pro Glu Ala Cys 785 790 795 800 Val Ile Asp Asp Arg Ser Pro Asp Thr 805 <210> 12 <211> 7979 <212> DNA <213> Homo sapiens <400> 12 60. cgcagcagg ctcagacctg cttccctgga catttccggg accgtgagcg agggaaccac gttgccctgg attcttgcca gctgtacaaa gttgaccagg aaaatggctc agcagacaag cccggacact ttaacagtac ctgaagtgga taatccgcat tgtccaaacc cgtggctgaa cgaagacctt gtgaaatcct tgcgagaaaa cctgttgcag catgagaagt ccaagacagc gaggaaatcg gtttctccca agctctctcc agtgaatctct ccgagaatt cccccaggct 360. tctgcgcaga atgcttctca gcagcaacat ccccaaacag cggcgtttca cggtggcaca tacatgtttt gatgtggaca atggcacatc tgcgggacgg agtcccttgg atcccatgac 420 cagcccagga tccgggctaa ttctccaagc aaattttgtc caagtcaac gacgggagtc 480 cttcctgtat cgatccgaca gcgattatga cctctctcca aagtctatgt cccggaactc 540 ctccattgcc agtgatatac acggagatga cttgattgtg actccatttg ctcaggtctt 600 ggccagtctg cgaactgtac gaaaactt tgctgcatta actaatttgc aagatcgagc 660 acctagcaaa agatcaccca tgtgcaacca accatccatc aacaaagcca ccataacaga 720 ggaggcctac cagaaactgg ccagcgagac cctgggagg ctggactggt gtctggacca 780 gctagagacc ctacagacca ggcactccgt cagtgagatg gcctccaaca agtttaaaag 840 gatgcttaat cgggagctca cccatctctc tgaaatgagt cggtctggaa atcaagtgtc 900 agagtttata tcaaacacat tcttagataa gcaacatgaa gtggaaattc cttctccaac 960 tcagaaggaa aagagaaaa agaaaagacc aatgtctcag atcagtggag tcaagaaatt 1020 gatgcacagc tctagtctga ctaattcaag tatcccaagg tttggagtta aaactgaaca 1080 aagaagatgtc cttgccaagg aagaaga tgtgaacaaa tggggtcttc atgttttcag 1140 atagcagag ttgtctggta accggccctt gactgttatc atgcacacca ttttcagga 1200 acgggattta ttaaaaacat ttaaaattcc agtagatact ttaattacat atcttatgac 1260 tctcgaagac cattaccatg ctgatgtggc ctatcacaac aatatccatg ctgcagatgt 1320 tgtccagtct actcatgtgc tattatctac acctgctttg gaggctgtgt ttacagattt 1380 ggagattctt gcagcaattt ttgccagtgc aatacatgat gtagatcatc ctggtgtgtc 1440 caatcaattt ctgatcaata caaactctga acttgccttg atgtacaatg attcctcagt 1500 cttagagaac catcatttgg ctgtgggctt taaattgctt caggaagaaa actgtgacat 1560 tttccagaat ttgaccaaaa aaaagaca atctttaagg aaaatggtca ttgacatcgt 1620 acttgcaaca gatatgtcaa aacacatgaa tctactggct gatttgaaga ctatggttga 1680 aactaagaaa gtgacaagct ctggagttct tcttcttgat aattattccg ataggattca 1740 ggttcttcag aatatggtgc actgtgcaga tctgagcaac ccaacaaagc ctctccagct 1800 gtaccgccag tggacggacc ggataatgga ggagttcttc cgccaaggag accgagagag 1860 ggaacgtggc atggataa gcccatgtg tgacaagcac aatgctccg tggaaaaatc 1920 acaggtgggc ttcatagact atattgttca tccctctgg gagacatggg cagacctcgt 1980 ccaccctgac gcccaggata tttggacac tttggaggac atcgtgaat ggtaccagag 2040 cacaatccct cagagcccct ctcctgcacc tgatgaccca gaggaggggcc ggcagggtca 2100 aactgagaaa ttccagttg acactacttt agaggagat ggtgagtcag acacggaaaa 2160 ggacagtggc agtcaagtgg aagagacac tagctcagt gactccaga ctctttgtac 2220 tcaagactca gagtctactg aaattcccct tgatgacag gttgaagagg aggcagtagg 2280 ggaagaagg gaaagccagc ctgaagcctg tgtcatagat gatcgttctc ctgacacgta 2340 acagtgcaaa aactttcatg cctttttt ttttaagtag aaaaattgtt tccaagtgc 2400 atgtcacatg ccacaccac ggtcacacct cactgtcatc tgccaggacg ttgttgac 2460 aaaactgacc ttgactactc agtccagcgc tcaggaat cgtaccagt ttttcacct 2520 ccatgtcatc cgagcaggt ggacatctc acgaacagcg ttttacaa gatttcagct 2580 tggtagagct gacaaagcag ataaaatcta ctccaaatta ttttcaagag agtgtgactc 2640 atcaggcagc ccaaaagttt attggacttg gggtttctat tcctttttat ttgtttgcaa 2700 tattttcaga agaaaggcat tgcacagagt gaacttaatg gacgaagcaa caaatatgtc 2760 aagaacagga catagcacga atctgttacc agtaggagga ggatgagcca cagaaattgc 2820 ataatttct aatttcaagt cttcctgata catgactgaa tagtgtggtt cagtgagctg 2880 cactgacctc tacattttgt atgatatgta aaacagattt tttgtagac ttacttttat 2940 tattaaatgt attgaggtat tatatttaaa aaaaactatg ttcagaactt catctgccac 3000 tggttatttt tttctaagga gtaacttgca agttttcagt acaaatctgt gctacactgg 3060 ataaaaatct aatttatgaa ttttacttgc accttatagt tcatagcaat taactgattt 3120 gtagtgattc attgtttgtt ttatatacca atgacttcca tattttaaaa gagaaaaaca 3180 actttatgtt gcaggaaacc ctttttgtaa gtctttatta tttactttgc atttgtttc 3240 actctttcca gataagcaga gttgctcttc accagtgttt ttcttcatgt gcaaagtgac 3300 tatttgttct ataatacttt tatgtgtgtt atatcaatg tgtcttaagc ttcatgcaaa 3360 ctcagtcatc agttcgtgtt gtctgaagca agtggagat ataataac ccagtagcta 3420 aaatggtcag tctttttag atgttttcct acttagtac tcctaatac gttttgctgt 3480 gtcactagat gttcattca caagtgcatg tcttctaat aatccacaca tttcatgctc 3540 taataatcca cacattcat gctcattttt attgtttta cagccagtta tagtaagaaa 3600 aaggttttc cccttgtgct gctttatat ttagcgtgtg tctgaacctt atccatgttt 3660 gctagatgag gtcttgtcaa atatatcact accattgtca ccggtgaaaa gaaacaggta 3720 gttaagttag ggttaacatt cattcacc acgaggttgt atcatcatgac tagctttac 3780 tcttggttta cagagaaaag ttaaacagcc aactaggcag ttttagaa tattaacaat 3840 atattaacaa acaccatac aactaatcct atttggtttt aatgatttca ccatgggatt 3900 aagaactata tcaggaacat ccctgagaaa cggttttaag tgtagcaact actctctcctt 3960 aatggacagc cacataacgt gtaggaagtc ctttatcact tatcctcgat ccataagcat 4020 atcttgcaga ggggaactac ttctttaac acatggaggg aaagagatg atgccactgg 4080 caccagagggg ttagtactgt gatgcatcct aaatattta ttatattgt aaaaattctg 4140 gttaaataaa aattagaga tgtattacag 4200 ttttagagat taattcctag tgtttacctg attatagcag ttggcatcat ggggcattta 4260 attctgactt tatccccacg tcagccttaa taaagtctc tttaccttct cttagaagac 4320 tttaaagcccc aaataatcat ttttcacatt gatattcaag aattgagata gatagaagcc 4380 aaagtgggta tctgacaagt ggaaatca acgtttaaga agaattacaa ctctgaaag 4440 catttatatg tggaacttct caggagcct cctggggact ggaagtaag tcatcagcca 4500 ggcaaatgac tcatgctgaa gagagtcccc atttcagtcc cctgagatct agctgatgct 4560 tagatcctttt gaataaaaa ttatgcttt attackactctga tctttacat aaagcagaag 4620 aggaatcaac tagttaattg caagttct actctgttc ctctgtaaag atcagatggt 4680 aatctttca atagaaaaaaaagacg tatgtttgac caagtagtttt cacagaata 4740 tttgggaact tgtttctttt aattttattt gtccctgagt gaagtctaga aagaaaggta 4800 aagagtctag agtttattcc tctttccaaa acattctcat tcctctcctc cctacactta 4860 gtatttcccc cacagagtgc ctagaatctt aataatgaat aaaataaaaa gcagcaatat 4920 gtcattaaca aatccagacc tgaaagggta aagggtttat aactgcacta ataaagagag 4980 gctctttttt tttcttccag tttgttggt tttaatggta ccgtgttgta aagataccca 5040 ctaatggaca atcaaattgc agaaaaggct caatatccaa gagacaggga ctaatgcact 5100 gtacaatctg cttatccttg cccttctctc ttgccaaagt gtgcttcaga aatatatact 5160 gctttaaaaa agaataaaag aatatccttt tacaagtggc tttacatttc ctaaaatgcc 5220 ataagaaaat gcaatatctg ggtactgtat ggggaaaaaa atgtccaagt ttgtgtaaaa 5280 ccagtgcatt tcagcttgca agttactgaa cacaataatg ctgttttaat tttgttttat 5340 atcagttaaa attcacaata atgtatag aacaaattac agacaaggaa agaaaaaact 5400 tgaatgaaat ggattttaca gaaagcttta tgataatttt tgaatgcatt atttatttt 5460 tgtgccatgc atttttttc tcaccaaatg accttacctg tatacagtc ttgtttgtct 5520 gttacaacc atgtatttat tgcaatgtac atactgtaat gttaattgta aattatctgt 5580 tcttattaaa acatcatccc atgatgggat ggtgttgata tatttggaaa ctcttggtga 5640 gagaatgaat ggtgtgtata catactctgt acatttttct tttctcctgt aatatagtct 5700 tgtcacctta gagcttgttt atggaagatt caagaaaact ataaaatact taaagatata 5760 taaatttaaa aaaacatagc tgcaggtctt tggtcccagg gctgtgcctt aactttaacc 5820 aatattttct tctgttttgc tgcatttgaa aggtaacagt ggagctaggg ctgggcattt 5880 tacatccagg cttttaattg attagaattc tgccaatagg tggattttac aaaaccacag 5940 acaacctctg aaagattctg agacccttt gagacagaag ctcttaagta cttcttgcca 6000 gggagcagca ctgcatgtgt gatggttgtt tgccatctgt tgatcaggaa ctacttcagc 6060 tacttgcatt tgattatttc ctttttttt ttttttaact cggaaacaca actggggaaa 6120 tatattcttt cccagtgatt ataaacaatc ttttcttttt ttttaagtcc ttttggcttc 6180 tagagctcat aggaaaatgg acttgatttg aaattggagc cagagtttac tcgtgttggt 6240 tatctattca tcagcttcct gacatgttaa gagaatacat taagaagaa atactgtttt 6300 ttaatcctaa aatttttctt ccactaagat aaaccaaatg tccttacata tatgtaaacc 6360 catctattta aacgcaaagg tgggttgatg tcagtttaca tagcagaaag cattcactat 6420 cctctagat ttgtttctgc aaaactttca ttgctttaga attttaaaat ttcaccttgt 6480 acaatggcca gcccctaaag caggaaacat ttataatgga ttatatggaa acatcctccc 6540 agtacttgcc cagcccttga atcatgtggc ttttcagtga aaggaaaagat tcttttcta 6600 ggaaaaatga gcctatttta ttttatttta ttttattttt tgacacaaac tgtagatttt 6660 agcagccctg gcccaaagga atttgattac ttttgttttta aacagtacaa aggggacact 6720 ataattacaa aaacatcctt aactgatttg agttgtttt atttctttgg atatattttc 6780 agagtggtaa attgtgtgtg agaattacaa atgattattc ttttagtggt ttcttagcct 6840 ctcttacagc ccacggggat agtactgtac atcaatacct tcatatgaaa tttttatatg 6900 caatgaaat aaaagcatgg gttgattctg cctatttatg actcaatctt ttacaaataa aagattattc attttaatt atagttcaat cagcatgtct cttaggatac tgaacgtggt tgaatgaaa ggatagtgac atcataagtt agtactgata ttcataacca aataagcca acttgagtaa ttttgctaca ttaaaatta ccaaaattac ttagatggcc tataagatta agcatggtgt tttctaagca agctttgaaa ggggccttcc atacttactt aattgaat tctgggatat tgaaaattat tcagatactt gacaattatt tttggttacc tactccgcaa actacaaagt tttaaggact actacaatag ttaatgagac acagtgtttg ctttcatgga gcttacagtc tggaggggac aaaggcttaa acaatactca father's father tatgtgatca gtacaatgaa ggagctcagt ggggtaaata agcaggaacc tgaacttgat ctgttccgga gggccacaga aggcttcctt gaggccttga gaaagtgatt tgcatctgag ttctgaagga ttgtaagagg taactaggga aaaagttgac aggagagg aggggatcca gacaagaaac atttgcaaag atcttgaggc ataaatgagc ttgagacatc tggagaaact gaggaaaagt gagagtag gcagggcctg gagccgcaga gccattgcta accatcctgt gtgagatatc 7680 ccccattctg tagctttatt ctcataaccc tgctcaattt tctttataac acttctcaca 7740 gatttatata cgtgtttgtt tttgttatct gtctctccca ccagaccaca gctccatgag 7800 agcaaggtct ttgcttacca atatatcact agcacttaaa actatgcctg gtacacagta 7860 ggttcttaat atgtgttgaa tatagccatc aaattgatat tggatataat tcaatctgat 7920 aagatatttt gagatattaa agagttttta acttgatacc ataaaaaaaaaaaaaaaaaa 7979 <210> 13 <211> 745 <212> PRT <213> Homo sapiens <400> 13 Met Ala Gln Gln Thr Ser Pro Asp Thr Leu Thr Val Pro Glu Val Asp 1 5 10 15 Asn Pro His Cys Pro Asn Pro Trp Leu Asn Glu Asp Leu Val Lys Ser 20 25 30 Leu Arg Glu Asn Leu Leu Gln His Glu Lys Ser Lys Thr Ala Arg Lys 35 40 45 Ser Val Ser Pro Lys Leu Ser Pro Val Ile Ser Pro Arg Asn Ser Pro 50 55 60 Arg Leu Leu Arg Arg Met Leu Leu Ser Ser Asn Ile Pro Lys Gln Arg 65 70 75 80 Arg Phe Thr Val Ala His Thr Cys Phe Asp Val Asp Asn Gly Thr Ser 85 90 95 Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu 100 105 110 Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu 115 120 125 Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg 130 135 140 Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu Ile Val Thr 145 150 155 160 Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe 165 170 175 Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro 180 185 190 Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala 195 200 205 Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu 210 215 220 Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala 225 230 235 240 Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser 245 250 255 Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr 260 265 270 Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys 275 280 285 Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys 290 295 300 Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe 305 310 315 320 Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp 325 330 335 Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly 340 345 350 Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp 355 360 365 Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu 370 375 380 Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn 385 390 395 400 Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr 405 410 415 Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile 420 425 430 Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln 435 440 445 Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser 450 455 460 Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln 465 470 475 480 Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln 485 490 495 Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser 500 505 510 Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys 515 520 525 Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg 530 535 540 Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro 545 550 555 560 Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu 565 570 575 Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile 580 585 590 Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val 595 600 605 Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp 610 615 620 Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn 625 630 635 640 Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro 645 650 655 Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe 660 665 670 Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser 675 680 685 Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu 690 695 700 Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val 705 710 715 720 Glu Glu Glu Ala Val Gly Glu Glu Glu Glu Ser Gln Pro Glu Ala Cys 725 730 735 Val Ile Asp Asp Arg Ser Pro Asp Thr 740 745 <210> 14 <211> 19 <212> DNA <213> Artificial Sequence <220> <223> PDE4D5_forward primer <400> 14 gcttctcagc agcaacatc 19 <210> 15 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> PDE4D5_reverse primer <400> 15 tgccattgtc cacatcaaaa 20 <210> 16 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> PDE4D5 probe <400> 16 acagcggcgt ttcacggtgg caca 24 <210> 17 <211> 7591 <212> DNA <213> Homo sapiens <400> 17 agttccttat ttggtagctt ttgacaggac tagcctttct tgcaactaag catcttgaca 60 tacattattc attaagccct ggagctcggg agagaaagat gcagaccctt agatctttag 120 atattccttt atcacgtgga ttttctttat tcagaatagt tgctgaattt tgtgccattc 180 tggagtctta caaatggcat gtattcgatg ggaagacggc tggatgggat ttaatgcgag 240 gctttcttat gtatacttaa ttaccaaaaa tctttaaaaa ctcatactct gcgtggcttg 300 tggaggttgt taaagtgtcg agattttgaa gctaaataca ttttagagct tactatatat 360 atacatatat atatatatac atataatcaa tcaaaaatgc ctgaagcaaa ctatttactg 420 tcagtgtctt ggggctacat aaagtttaaa aggatgctta atcgggagct cacccatctc 480 tctgaaatga gtcggtctgg aaatcaagtg tcagagttta tatcaaacac attcttagat 540 aagcaacatg aagtggaaat tccttctcca actcagaagg aaaaggagaa aaagaaaaga 600 ccaatgtctc agatcagtgg agtcaagaaa ttgatgcaca gctctagtct gactaattca 660 agtatcccaa ggtttggagt taaaactgaa caagaagatg tccttgccaa ggaactagaa 720 gatgtgaaca aatggggtct tcatgttttc agaatagcag agttgtctgg taaccggccc 780 ttgactgtta tcatgcacac catttttcag gaacgggatt tattaaaaac atttaaaatt 840 ccagtagata ctttaattac atatcttatg actctcgaag accattacca tgctgatgtg 900 gcctatcaca acaatatcca tgctgcagat gttgtccagt ctactcatgt gctattatct 960 acacctgctt tggaggctgt gtttacagat ttggagattc ttgcagcaat ttttgccagt 1020 gcaatacatg atgtagatca tcctggtgtg tccaatcaat ttctgatcaa tacaaactct 1080 gaacttgcct tgatgtacaa tgattcctca gtcttagaga accatcattt ggctgtgggc 1140 tttaaattgc ttcaggaaga aaactgtgac attttccaga atttgaccaa aaaacaaaga 1200 caatctttaa ggaaaatggt cattgacatc gtacttgcaa cagatatgtc aaaacacatg 1260 aatctactgg ctgatttgaa gactatggtt gaaactaaga aagtgacaag ctctggagtt 1320 cttcttcttg ataattattc cgataggatt caggttcttc agaatatggt gcactgtgca 1380 gatctgagca accccaacaaa gcctctccag ctgtaccgcc agtggacgga ccggataatg gaggagttct tccgccaagg agaccgagag agggacgtg gcatggagat aagccccatg 1560. tgtgacaagc acaatgcttc cgtggaaaaa tcacaggtgg gcttcataga ctatattgtt catcccctct gggagacatg ggcagacctc gtccaccctg acgcccagga tattttggac 1620 actttggagg acaatcgtga atggtaccag agcacaatcc ctcagagccc ctctcctgca 1680. cctgatgacc cagaggaggg ccggcagggt caaactgaga aattccagtt tgaactaact ttagaggaag atggtgagtc agacacggaa aaggacagtg gcagtcaagt ggaagaagac actagctgca gtgactccaa actctttgt actcaagact cagagtctac tgaaattccc cttgatgaac aggttgaaga ggaggcagta ggggaagaag aggaaagcca gcctgaagcc tgtgtcatag atgatcgttc tcctgacacg taacagtgca aaaactttca tgcctttttt ttttttaagt agaaaaattg tttccaaagt gcatgtcaca tgccacaacc acggtcacac ctcactgtca tctgccagga cgtttgttga acaaaactga ccttgactac tcagtccagc gctcaggaat atcgtaacca gttttcac ctccatgtca tccgagcaag gtggacatct 2160 tcacgaacag cgttttaac aagatttcag cttggtagag ctgacaagc agataaaatc 2220 tactccaaat tatttcaag agagtgtgac tcatcaggca gcccaaagt tattggact 2280 tggggttctt atttcctttt atttgtttgc atattttca gagaaaggc attgcacaga 2340 gtgaacttaa tggacgaagc aaaataatg tcahacag gatagcac gatctgtta 2400 ccagtaggag gaggatgagc cacagaaatt gcatatttt ctaatttca gtcttcctga 2460 tacatgactg atagtgtgg ttcagtgagc tgcactgacc tctacatttt gtatgatatg 2520 taaaacagat ttttgtaga gcttactttt attattaat gtattgaggt attattatta 2580 aaaaaaacta tgttcagaac ttcatctgcc actggttatt tttctaag gagtacttg 2640 caagttttca gtacaaatct gtgctacact ggataaaaat ctaatttatg aattttact 2700 gcaccttata gttcatagca atttaacgat tgtagtgat tcattgttg ttttatatac 2760 caatgacttc catattttaa agagaaaa caatttatg ttgcaggaaa cccttttgt 2820 aagtctttat tatttacttt gcattttgtt tcactctttc cagataagca gagttgctct 2880 tcaccagtgt ttttcttcat gtgcaaagtg actatttgtt ctataatact tttatgtgtg 2940 ttatatcaaa tgtgtcttaa gcttcatgca aactcagtca tcagttcgtg ttgtctgaag 3000 caagtgggag atatataaat acccagtagc taaaatggtc agtctttttt agatgttttc 3060 ctacttagta tctcctaata acgttttgct gtgtcactag atgttcattt cacaagtgca 3120 tgtctttcta ataatccaca catttcatgc tctaataatc cacacatttc atgctcattt 3180 ttattgtttt tacagccagt tatagtaaga aaaaggtttt tccccttgtg ctgctttata 3240 atttagcgtg tgtctgaacc ttatccatgt ttgctagatg aggtcttgtc aaatatatca 3300 ctaccattgt caccggtgaa aagaaacagg tagttaagtt agggttaaca ttcatttcaa 3360 ccacgaggtt gtatatcatg actagctttt actcttggtt tacagagaaa agttaaacag 3420 ccaactaggc agtttttaag aatattaaca atatattaac aaacaccaat acaactaatc 3480 ctatttggtt ttaatgattt caccatggga ttaagaacta tatcaggaac atccctgaga 3540 aacggtttta agtgtagcaa ctactcttcc ttaatggaca gccacataac gtgtaggaag 3600 tcctttatca cttatcctcg atccataagc atatcttgca gagggaact acttctttaa 3660 acacatggag ggaaagaga tgatgccact ggcaccagag ggttagtact gtgatgcatc 3720 ctaaaatatt tattatattg gtaaaaatttc tggttaaata aaaaattaga gatcactct 3780 ggctgatttc agcaccagga actgtattac agttttagag atttattcct agtgttttacc 3840 tgattatagc agttggcatc atggggcatt taattctgac ttatcccca cgtcagcctt 3900 aaaagtct tctttacctt ctctatgaag actttaaagc ccaataatc atttttcaca 3960 ttgatattca agaattgaga tagatagag ccaagtggg tatctgacaa gtggaaaatc 4020 aaacgtttaa gagaattac aactctgaaa agcattatta tgtggaactt ctcaggagc 4080 ctcctgggga ctggaagta agtcatcagc caggcaatg actcatgctg aagagtcc 4140 ccattcagt cccctgagat ctagctgatg cttagatcct ttgaataaa aattatgtct 4200 ttataactct gatctttac aaagcaga agaggaatca actaagttaat tgcaggtttt 4260 ctactctgtt tcctctgtaa agatcagatg gtaatctttc aaataagaaaaataaga 4320 cgtatgtttg accaagtagt ttcacaagaa tatttgggaa cttgttttctt ttaattttat 4380 ttgtccctga gtgaagtcta gaagaaagg taaagagtct agagtttt cctctttcca 4440 aaacattctc attcctcc tccctacact tagtatttcc cccacagagt gcctagaatc 4500 ttaataatga aaaataa aaagcagcaat atgtcattaa aaatccaga cctgaaaggg 4560 taaagggttt atactgcac taataagag aggctcttt ttttctttcc agttttgttgg 4620 ttttaatgg taccgtgttg taagatacc cactaatgga caatcaatt gcagaaaagg 4680 ctcaatcc agagacagg gactaatgca ctgtacaatc tgcttacct tgccctctc 4740 tcttgccaaa gtgtgcttca gaaatatata ctgctttaaa aaagataaa agaataatcct 4800 tttacaagtg gctttacatt tcctaaaatg ccataagaaa atgcaatc tggtactgt 4860 atggggaaaa aaatgtccaa gtttgtgtaa aaccagtgca ttcagcttg caagttactg 4920 aacacataa tgctgtttta atttgtttt atatcagtta aattcacaa taatgtagat 4980 agaaaaaatt acagaaaaaaaaaaaa cttgaatgaa atggatttta cagaaagctt 5040 tatgataatt ttgaatgca tatttattt ttgtgccat gcatttttt tctcaccaaa 5100 tgaccttacc tgtaatacag tcttgtttgt ctgtttacaa ccatgtattt attgcaatgt 5160 acatactgta atgttaattg taaattatct gttcttatta aaacatcatc ccatgatggg 5220 atggtgttga tatatttgga aactctttggt gagagaatga atggtgtgta tacatactct 5280 gtacattttt cttttctcct gtaatatagt cttgtcacct tagagctgt ttatggaaga 5340 ttcaagaaaa ctataaaata cttaaagata tataaattta aaaaaacata gctgcaggtc 5400 ttggtccca gggctgtgcc ttactttaa ccaatatttt cttctgtttt gctgcatttg 5460 aaagtaaca gtggagctag ggctgggcat tttacatcca ggcttttaat tgattagaat 5520 tctgccaata ggtggatttt acaaaccac agacaacctc tgaagattc tgagaccct 5580 ttgagacaga agctcttaag tactcttgc cagggagcag cactgcatgt gtgatggttg 5640 ttgccatct gttgatcagg aactacttca gctacttgca tttgattat tcctttttt 5700 ttttttttaa ctcggaaaca caactggga aatatattct ttcccagtga ttataaacaa 5760 tctttttctt ttttttaagt ccttttggct tctagagctc ataggaaaat ggacttgatt 5820 tgaaattgga gccagagttt actcgtgttg gttatctatt catcagcttc ctgacatgtt 5880 aagagaatac attaagaga aaatactgtt ttttaatcct aaaatttttc ttccactaag 5940 ataaaccaaa tgtccttaca tatatgtaaa cccatctatt taaacgcaaa ggtgggttga 6000 tgtcagttta catagcagaa agcattcact atcctctaag atttgtttct gcaaaacttt 6060 cattgcttta gaattttaaa atttcacctt gtacaatggc cagcccctaa agcaggaaac 6120 atttataatg gattatatgg aaacatcctc ccagtacttg cccagccctt gaatcatgtg 6180 gcttttcagt gaaggaaag attcttttc taggaaaaat gagcctattt tattttattt 6240 tattttattt tttgacacaa actgtagatt ttagcagccc tggcccaaag gaatttgatt 6300 acttttgttt taaacagtac aaaggggaca ctataattac aaaaacatcc ttaactgatt 6360 tgagttgttt ttattcttt ggatatattt tcagagtggt aaattgtgtg tgagaattac 6420 aaatgattat tcttttagtg gtttcttagc ctctcttaca gcccacgggg atagtactgt 6480 acatcaatac cttcatatga aatttttata tgcaatgaaa ataaagcat gggttgattc 6540 tgcctatta tgactcaatc ttttacaaat aaaagattat tcattttaaa ttatagttca 6600 atcagcatgt ctcttaggat actgaacgtg gttgaatga areatagtg acatcataag 6660 6720 taccaaaatt acttagatgg cctataagat taagcatggt gttttctaag caagctttga 6780 aaggggcctt ccatacttac ttaattgaat attctgggat attgaaaatt attcagatac 6840 ttgacaatta tttttggtta cctactccgc aaactacaaa gttttaaagga ctcaacaata 6900 agttaatgag acacagtgtt tgctttcatg gagcttacag tctggagggg acaaaggctt 6960 aaacaatact catataatta tatatgtgat cagtacaatg aaggagctca gtggggtaaa 7020 taggagaa cctgaacttg atctgttccg gagggccaca gaaggcttcc ttgaggcctt 7080 7140 acaggaagag gaaggggatc cagacaagaa acatttgcaa agatcttgag gcataaatga 7200 gcttgagaca tctggagaaa ctgaggaaaa gtgagagagt aggcagggcc tggagccgca 7260 gagccattgc taaccatcct gtgtgagata tcccccattc tgtagcttta ttctcataac 7320 cctgctcaat tttctttata acacttctca cagatttata tacgtgtttg ttttgttat 7380 ctgtctctcc caccagacca cagctccatg agagcaaggt ctttgcttac caatatatca 7440 ctagcactta aaactatgcc tggtacacag taggttctta atatgtgttg aatatagcca 7500 tcaaattgat attggatata attcaatctg ataagatatt ttgagatatt aaagagtttt 7560 taacttgata ccataaaaaa aaaaaaaaa a 7591 <210> 18 <211> 518 <212> PRT <213> Homo sapiens <400> 18 Put Pro Glu Ala Asn Tyr Leu Leu Ser Val Ser Trp Gly Tyr Ile Lys 1 5 10 15 Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met Ser 20 25 30 Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu Asp 35 40 45 Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys Glu 50 55 60 Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu Met 65 70 75 80 His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val Lys 85 90 95 Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn Lys 100 105 110 Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg Pro 115 120 125 Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu Lys 130 135 140 Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr Leu 145 150 155 160 Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn Ile His Ala 165 170 175 Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala Leu 180 185 190 Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala Ser 195 200 205 Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln Phe Leu Ile 210 215 220 Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val Leu 225 230 235 240 Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu Asn 245 250 255 Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu Arg 260 265 270 Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser Lys His Met 275 280 285 Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val Thr 290 295 300 Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln Val 305 310 315 320 Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys Pro 325 330 335 Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe Phe 340 345 350 Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro Met 355 360 365 Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe Ile 370 375 380 Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val His 385 390 395 400 Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu Trp 405 410 415 Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp Pro 420 425 430 Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu Thr 435 440 445 Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser Gln 450 455 460 Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr Gln 465 470 475 480 Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu Glu 485 490 495 Ala Val Gly Glu Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile Asp 500 505 510 Asp Arg Ser Pro Asp Thr 515 <210> 19 <211> 8130 <212> DNA <213> Homo sapiens <400> 19 agattatagc ccagcgtacg agaagcacga gtcctatagt tggcgtaccc tgaggcctgc 60 cagttcctgc cttaatgcat atgtagtcgt aattgagttc tgacacggcc ttggatgttt 120 ctgtcctaaa tagctgacat tgcatcttca agactgtcat tccagttgc tttgtgg 180 atacgtgcag tgagatcatt vakactggaa acactagttc ccattttaat tacttaaac 240 accacgatga aaagaatac ctgtgatttg ctttctcgga gcaaagtgc ctctgaggaa 300 acactacatt ccagtaatga agaggagac ccttccgcg gatggaacc ctacttgtc 360 cggagacttt catgtcgcaa tattcagctt cccctctcg ccttcagaca gttggacaaca 420 gctgacttga aaagtgaatc agagacatt caacgaccaa ccagccctccc cctgaagatt 480 ctgccgctga ttgctatcac ttctgcagaa tccagtggtt ttgatgtgga caatggcaca 540 tctgcgggac ggagtccctt ggatcccatg accagcccag gatccgggct aattctccaa 600 gcaaatttg tccacagtca acgacgggag tccttcctgt atcgatccga cagcgattat 660 gacctctctc caaagtctat gtcccggac tcctccattg ccagtgatat acacggagat 720 gacttgattg tgactccatt tgctcaggtc ttggccagtc tgcgaactgt acgaaacaac 780 tttgctgcat tactaattt gcaagatcga gcacctagca aaagatcacc catgtgcaac caccatcca tcacaaagc caccataca gaggaggcct accagaact ggccagcgag accctggagg agctggactg gtgtctggac cagctagaga ccctacagac caggcactcc 960 gtcagtgaga tggcctccaa caagtttaaa aggatgctta atcgggagct cacccatctc tctgaatga gtcggtctgg aaatcaagtg tcagagttta tatcaaacac attcttagat aagcaacatg aagtggaaat tccttctcca actcagaagg aaaaggagaa aaagaaaga ccaatgtctc agatcagtgg agtcaagaaa ttgatgcaca gctctagtct gactaattca agtatcccaa ggtttggagt taaaactgaa caagaagatg tccttgccaa ggaactagaa gatgtgaaca aatggggtct tcatgttttc agaatagcag agttgtctgg taaccggccc ttgactgtta tcatgcacac catttttcag gaacgggatt tattaaaaac atttaaaatt 1380 ccagtagata ctttaattac atatcttatg actctcgaag accattacca tgctgatgtg 1440 gcctatcaca acaatatcca tgctgcagat gttgtccagt ctactcatgt gctattatct 1500 acacctgctt tggaggctgt gtttacagat ttggagattc ttgcagcaat ttttgccagt 1560 gcaatacatg atgtagatca tcctggtgtg tccaatcaat ttctgatcaa tacaaactct 1620 gaacttgcct tgatgtacaa tgattcctca gtcttagaga accatcattt ggctgtgggc 1680 tttaaattgc ttcaggaaga aaactgtgac attttccaga atttgaccaa aaaacaaaga 1740 caatctttaa ggaaaatggt cattgacatc gtacttgcaa cagatatgtc aaaacacatg 1800 aatctactgg ctgatttgaa gactatggtt gaaactaaga aagtgacaag ctctggagtt 1860 cttcttcttg ataattattc cgataggatt caggttcttc agaatatggt gcactgtgca 1920 gatctgagca acccaacaaa gcctctccag ctgtaccgcc agtggacgga ccggataatg 1980 gaggagttct tccgccaagg agaccgagag agggaacgtg gcatggagat aagccccatg 2040 2100. tgtgacaagc acaatgcttc cgtggaaaaa tcacaggtgg gcttcataga ctatattgtt catcccctct gggagacatg ggcagacctc gtccaccctg acgcccagga tattttggac 2160 actttggagg acaatcgtga atggtaccag agcacaatcc ctcagagccc ctctcctgca cctgatgacc cagaggaggg ccggcagggt caaactgaga aattccagtt tgaactaact ttagaggaag atggtgagtc agacacggaa aaggacagtg gcagtcaagt ggaagaagac actagctgca gtgactccaa actctctgt actcaagact cagagtctac tgaaattccc cttgatgaac aggttgaaga ggaggcagta ggggaagaag aggaaagcca gcctgaagcc tgtgtcatag atgatcgttc tcctgacacg taacagtgca aaaactttca tgcctttttt ttttttaagt agaaaaattg tttccaaagt gcatgtcaca tgccacaacc acggtcacac ctcactgtca tctgccagga cgtttgttga acaaaactga ccttgactac tcagtccagc gctcaggaat atcgtaacca gttttttcac ctccatgtca tccgagcaag gtggacatct tcacgaacag cgtttttaac aagatttcag cttggtagag ctgacaaagc agataaaatc tactccaaat tatttcaag agagtgtgac tcatcaggca gcccaaagt tattggact 2820 tggggttctt atttccttttttgtttgc atattttca gagaaaggc attgcacaga 2880 gtgaacttaa tggacgaagc aaaaatg tcagacag gatagcac gatctgtta 2940 ccagtaggag gaggatgagc cacagaaatt gcatatttt ctaatttca gtcttcctga 3000 tacatgactg atagtgtgg ttcagtgagc tgcactgacc tctacatttt gtatgatatg 3060 taaaacagat ttttgtaga gcttacttt attattaat gtattgaggt attattatta 3120 aaaaaaacta tgttcagaac ttcatctgcc actggttatt ttttctaag gagtacttg 3180 caagttttca gtacaaatct gtgctacact ggataaaaat ctaatttatg aattttact 3240 gcaccttata gttcatagca atttaacgat tgtagtgat tcattgttg ttttatatac 3300 caatgacttc catattttaa agagaaaa caatttatg ttgcaggaaa ccctttttgt 3360 aagtctttat tattacttt gcattttgtt tcactcttc cagataagca gagttgctct 3420 tcaccagtgt tttcttcat gtgcaaagtg actatttgtt ctataatact tttatgtgtg 3480 ttatatcaaa tgtgtcttaa gcttcatgca aactcagtca tcagttcgtg ttgtctgaag 3540 caagtgggag atatataaat acccagtagc taaaatggtc agtctttttt agatgttttc 3600 ctacttagta tctcctaata acgttttgct gtgtcactag atgttcattt cacaagtgca 3660 tgtctttcta ataatccaca catttcatgc tctaataatc cacacatttc atgctcattt 3720 ttattgtttt tacagccagt tatagtaaga aaaaggtttt tccccttgtg ctgctttata 3780 atttagcgtg tgtctgaacc ttatccatgt ttgctagatg aggtcttgtc aaatatatca 3840 ctaccattgt caccggtgaa aagaaacagg tagttaagtt agggttaaca ttcatttcaa 3900 ccacgaggtt gtatatcatg actagctttt actcttggtt tacagagaaa agttaaacag 3960 ccaactaggc agtttttaag aatattaaca atatattaac aaacaccaat acaactaatc 4020 ctatttggtt ttaatgattt caccatggga ttaagaacta tatcaggaac atccctgaga 4080 aacggtttta agtgtagcaa ctactcttcc ttaatggaca gccacataac gtgtaggaag 4140 tcctttatca cttatcctcg atccataagc atatcttgca gaggggaact acttctttaa 4200 acacatggag ggaaagaga tgatgccact ggcaccagag ggttagtact gtgatgcatc 4260 ctaaaatatt tattatattg gtaaaaatttc tggttaaata aaaaattaga gatcactct 4320 ggctgatttc agcaccagga actgtattac agttttagag atttattcct agtgttttacc 4380 tgattatagc agttggcatc atggggcatt taattctgac ttatcccca cgtcagcctt 4440 aaaagtct tctttacctt ctctatgaag actttaaagc ccaataatc atttttcaca 4500 ttgatattca agaattgaga tagatagaag ccaagtggg tatctgacaa gtggaaaatc 4560 aaacgtttaa gagaattac aactctgaaa agcattatta tgtggaactt ctcaggagc 4620 ctcctgggga ctggaagta agtcatcagc caggcaatg actcatgctg aagagagtcc 4680 ccatttcagt cccctgagat ctagctgatg cttagatcct ttgaataaa aattatgtct 4740 ttataactct gatctttac attaagcaga agaggaatca actaagttaat tgcaggtttt 4800 ctactctgtt tcctctgtaa agatcagatg gtaatctttc aaataagaaaaataaga 4860 cgtatgtttg accaagtagt ttcacaagaa tatttgggaa cttgttttctt ttaattttat 4920 ttgtccctga gtgaagtcta gaagaaagg taaagagtct agagtttt cctctttcca 4980 aaacattctc attcctcc tccctacact tagtatttcc cccacagagt gcctagaatc 5040 ttaataatga aaaataa aaagcagcaat atgtcattaa aaatccaga cctgaaaggg 5100 taaagggttt atactgcac taataagag aggcttttt ttttctttcc agttttgttgg 5160 ttttaatgg taccgtgttg taagatacc cactaatgga caatcaatt gcagaaaagg 5220 ctcaatcc agagacagg gactaatgca ctgtacaatc tgcttacct tgccctctc 5280 tcttgccaaa gtgtgcttca gaaatatata ctgctttaaa aaagataaa agatatcct 5340 tttacaagtg gctttacatt tcctaaaatg ccataagaaa atgcaatc tggtactgt 5400 atggggaaaa aaatgtccaa gtttgtgtaa aaccagtgca ttcagcttg caagttactg 5460 aacacataa tgctgtttta atttgtttt atatcagtta aattcacaa taatgtagat 5520 agaaaaattt acagaaagg aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaagct 5580 tatgataatt ttgaatgca ttatttttt ttgtgccat gcatttttt tctcaccaaa 5640 tgaccttacc tgtaatacag tcttgtttgt ctgtttacaa ccatgtattt attgcaatgt 5700 acatactgta atgttaattg taaattatct gttcttatta aaacatcatc ccatgatggg 5760 atggtgttga tatatttgga aactctttggt gagagaatga atggtgtgta tacatactct 5820 gtacatttt cttttctcct gtaatatagt cttgtcacct tagagcttt ttatggaaga 5880 ttcaagaaaa ctataaaata cttaaagata tataaattta aaaaaacata gctgcaggtc 5940 tttggtccca gggctgtgcc ttactttaa ccaatatttt cttctgtttt gctgcatttg 6000 aaagtaaca gtggagctag ggctgggcat tttacatcca ggctttaat tgattagaat 6060 tctgccaata ggtggatttt acaaaccac agacaacctc tgaagattc tgagaccct 6120 ttgagacaga agctcttaag tactcttgc cagggagcag cactgcatgt gtgatggttg 6180 ttgccatct gttgatcagg aactacttca gctacttgca tttgattat tcctttttt 6240 tttttttaa ctcggaaaca caactgggga atatattct ttcccagtga ttaaacaa 6300 tctttttctt ttttaagt ccttttggct tctgagctc ataggaaat ggacttgatt 6360 tgaaattgga gccagagttt actcgtgttg gttatctatt catcagcttc ctgacatgtt 6420 aagagaatac attaagaga aaatactgtt ttttaatcct aaaatttttc ttccactaag 6480 ataaaccaaa tgtccttaca tatatgtaaa cccatctatt taaacgcaaa ggtgggttga 6540 tgtcagttta catagcagaa agcattcact atcctctaag atttgtttct gcaaaacttt 6600 cattgcttta gaattttaaa atttcacctt gtacaatggc cagcccctaa agcaggaaac 6660 atttataatg gattatatgg aaacatcctc ccagtacttg cccagccctt gaatcatgtg 6720 gcttttcagt gaaggaaag attcttttc taggaaaaat gagcctattt tattttattt 6780 tattttattt tttgacacaa actgtagatt ttagcagccc tggcccaaag gaatttgatt 6840 acttttgttt taaacagtac aaaggggaca ctataattac aaaaacatcc ttaactgatt 6900 tgagttgttt ttattcttt ggatatattt tcagagtggt aaattgtgtg tgagaattac 6960 aaatgattat tcttttagtg gtttcttagc ctctcttaca gcccacgggg atagtactgt 7020 acatcaatac cttcatatga aatttttata tgcaatgaaa ataaagcat gggttgattc 7080 tgcctatta tgactcaatc ttttacaaat aaaagattat tcattttaaa ttatagttca 7140 atcagcatgt ctcttaggat actgaacgtg gttgaatga areatagtg acatcataag 7200 7260 taccaaaatt acttagatgg cctataagat taagcatggt gttttctaag caagctttga 7320 aaggggcctt ccatacttac ttaattgaat attctgggat attgaaaatt attcagatac 7380 ttgacaatta tttttggtta cctactccgc aaactacaaa gttttaaagga ctcaacaata 7440 agttaatgag acacagtgtt tgctttcatg gagcttacag tctggagggg acaaaggctt 7500 aaacaatact catataatta tatatgtgat cagtacaatg aaggagctca gtggggtaaa 7560 taggagaa cctgaacttg atctgttccg gagggccaca gaaggcttcc ttgaggcctt 7620 7680 acaggaagag gaaggggatc cagacaagaa acatttgcaa agatcttgag gcataaatga 7740 gcttgagaca tctggagaaa ctgaggaaaa gtgagagagt aggcagggcc tggagccgca 7800 gagccattgc taaccatcct gtgtgagata tcccccattc tgtagcttta ttctcataac 7860 cctgctcaat tttctttata acacttctca cagatttata tacgtgtttg ttttgttat 7920 ctgtctctcc caccagacca cagctccatg agagcaaggt ctttgcttac caatatatca 7980 ctagcactta aaactatgcc tggtacacag taggttctta atatgtgttg aatatagcca 8040 tcaaattgat attggatata attcaatctg ataagatatt ttgagatatt aaagagtttt 8100 taacttgata ccataaaaaa aaaaaaaaa 8130 <210> 20 <211> 748 <212> PRT <213> Homo sapiens <400> 20 Met Lys Arg Asn Thr Cys Asp Leu Leu Ser Arg Ser Lys Ser Ala Ser 1 5 10 15 Glu Glu Thr Leu His Ser Ser Asn Glu Glu Glu Asp Pro Phe Arg Gly 20 25 30 With Glu Pro Tyr Leu Val Arg Arg Leu Ser Cys Arg Asn Ile Gln Leu 35 40 45 Pro Pro Leu Ala Phe Arg Gln Leu Glu Gln Ala Asp Leu Lys Ser Glu 50 55 60 Ser Glu Asn Ile Gln Arg Pro Thr Ser Leu Pro Leu Lys Ile Leu Pro 65 70 75 80 Leu Ile Ala Ile Thr Ser Ala Glu Ser Ser Gly Phe Asp Val Asp Asn 85 90 95 Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly 100 105 110 Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu 115 120 125 Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser 130 135 140 Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly Asp Asp Leu 145 150 155 160 Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg 165 170 175 Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys 180 185 190 Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr 195 200 205 Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp 210 215 220 Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser 225 230 235 240 Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr 245 250 255 His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile 260 265 270 Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro 275 280 285 Thr Gln Lys Glu Lys Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser 290 295 300 Gly Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile 305 310 315 320 Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu 325 330 335 Leu Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu 340 345 350 Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr Ile Phe Gln 355 360 365 Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile 370 375 380 Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp Val Ala Tyr 385 390 395 400 His Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr His Val Leu 405 410 415 Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu 420 425 430 Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His Pro Gly Val 435 440 445 Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr 450 455 460 Asn Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val Gly Phe Lys 465 470 475 480 Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys 485 490 495 Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr 500 505 510 Asp Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val 515 520 525 Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr 530 535 540 Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys Ala Asp Leu 545 550 555 560 Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg 565 570 575 Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly 580 585 590 Met Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser Val Glu Lys 595 600 605 Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr 610 615 620 Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu 625 630 635 640 Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser 645 650 655 Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys 660 665 670 Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu 675 680 685 Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser 690 695 700 Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp 705 710 715 720 Glu Gln Val Glu Glu Glu Ala Val Gly Glu Glu Glu Glu Ser Gln Pro 725 730 735 Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr 740 745 <210> 21 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> PDE4D7_forward primer <400> 21 gaacattcaa cgaccaacca 20 <210> 22 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> PDE4D7_reverse primer <400> 22 tgccattgtc cacatcaaaa 20 <210> 23 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> PDE4D7 probe <400> 23 ctgccgctga ttgctatcac ttctgca 27 <210> 24 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> PDE4D7 Forward Primer 2 <400> 24 cgctgattgc tatcacttct gc 22 <210> 25 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> Primary PDE4D7 Reverse <400> 25 gtcgttgact gtggacaaaa tttg 24 <210> 26 <211> 34 <212> DNA <213> Artificial Sequence <220> <223> PDE4D7 Probe 2 <400> 26 ttcccttgga tcccatgacc agcccataag ggaa 34 <210> 27 <211> 8130 <212> DNA <213> Homo sapiens <400> 27 agattatagc ccagcgtacg agaagcacga gtcctatagt tggcgtaccc tgaggcctgc 60 cagttcctgc cttaatgcat atgtagtcgt aattgagttc tgacacggcc ttggatgttt 120 ctgtcctaaa tagctgacat tgcatcttca agactgtcat tccagttggc ttttgagtgg 180 atacgtgcag tgagatcatt vakactggaa acactagttc ccattttaat tacttaaac 240 accacgatga aaagaatac ctgtgatttg ctttctcgga gcaaagtgc ctctgaggaa 300 acactacatt ccagtaatga agaggagac ccttccgcg gatggaacc ctacttgtc 360 cggagacttt catgtcgcaa tattcagctt cccctctcg ccttcagaca gttggacaaca 420 gctgacttga aaagtgaatc agagacatt caacgaccaa ccagccctccc cctgaagatt 480 ctgccgctga ttgctatcac ttctgcagaa tccagtggtt ttgatgtgga caatggcaca 540 tctgcgggac ggagtccctt ggatcccatg accagcccag gatccgggct aattctccaa 600 gcaaatttg tccacagtca acgacgggag tccttcctgt atcgatccga cagcgattat 660 gacctctctc caaagtctat gtcccggaac tcctccattg ccagtgatat acacggagat 720 gacttgattg tgactccatt tgctcaggtc tggccagtc tgcgaactgt acgaaacaac 780 tttgctgcat taactaattt gcagatcga gcacctagca aagatcacc catgtgcaac 840 scaccatcca tcaacaagc scaccaca gaggaggcct accagaact ggccagcgag 900 accctggagg agctggactg gtgtctggac cagtagaga ccctacagac caggcactcc 960 gtcagtgaga tggcctccaa caagtttaaa aggatgctta atcgggagct cacccatctc 1020 tctgaaatga gtcggtctgg aaatcaagtg tcagagttta tatcaacac attcttagat 1080 aagcaacatg aagtggaat tccttctcca actcagaagg aaaggagaa aaagaaaga 1140 ccaatgtctc agatcagtgg agtcaagaa ttgatgcaca gctctagtct gactattca 1200 agtatcccaa ggtttggagt taaactgaa ggaagatg tccttgccaa ggaactagaa 1260 gatgtgaaca aatggggtct tcatgttttc agaatagcag agttgtctgg taaccggccc 1320 ttgactgtta tcatgcacac cattttcag gaacgggatt tattaaaaac atttaaaatt 1380 ccagtagata ctttaattac atatcttatg actctcgaag accattacca tgctgatgtg 1440 gcctatcaca acaatatcca tgctgcagat gttgtccagt ctactcatgt gctattatct 1500 acacctgctt height height shoes height height shoes height 1560 gcaatacatg atgtagatca tcctggtgtg tccaatcaat ttctgatcaa tacaactct 1620 gaacttgcct tgatgtacaa tgattcctca gtcttagaga accatcattt ggctgtgggc 1680 tttaaattgc ttcaggaga aactgtgac attttccaga atttgaccaa aaaacaaaga 1740 caatctttaa ggaaaatggt cattgacatc gtacttgcaa cagatgtc aaaacacatg 1800 aatctactgg ctgatttgaa gactatggtt gaactaaga aagtgacaag ctctggagtt 1860 cttctcttg atattattc cgataggatt caggttctc agaatatggt gcactgtgca 1920 gatctgagca acccaaaa gcctctccag ctgtaccgcc agtggacgga ccggataatg 1980 gaggagttct tccgccaagg agaccgagag agggacgtg gcatggagat aagccccatg 2040 tgtgacaagc acatgctc cgtggaaaaa tcacaggtgg gcttcataga ctatattgtt 2100 catcccctct gggagacatg ggcagacctc gtccaccctg acggcccagga tattttggac 2160 actttggagg acaatcgtga atggtaccag agcacaatcc ctcagagccc ctctcctgca 2220 cctgatgacc cagaggagggg ccggcaggggt caactgaga aattccagtt tgaactact 2280 ttagaggaag atggtgagtc agacacggaa aaggacagtg gcagtcaagt ggaagagac 2340 actagctgca gtgactccaa gactctttgt actcaagact cagagtctac tgaaattccc 2400 2460 tgtgtcatag atgatcgttc tcctgacacg taacagtgca aaaactttca tgcctttttt 2520 ttttttaagt agaaaaattg tttccaaagt gcatgtcaca tgccacaacc acggtcacac 2580 ctcactgtca tctgccagga cgtttgttga acaaaactga ccttgactac tcagtccagc 2640 gctcaggaat atcgtaacca gttttttcac ctccatgtca tccgagcaag gtggacatct 2700 tcacgaacag cgtttttaac aagatttcag cttggtagag ctgacaaagc agataaaatc 2760 tactccaaat tattttcaag agagtgtgac tcatcaggca gcccaaaagt ttatggact 2820 tggggtttct attcctttt atttgtttgc aatatttca gaaaggc attgcacaga 2880 gtgaacttaa tggacgaagc aacaaatatg tcaagaacag gacatagcac gaatctgtta 2940 ccagtaggag gaggatgagc cacagaaatt gcaaatttt ctaatttcaa gtcttcctga 3000 tacatgactg aatagtgtgg ttcagtgagc tgcactgacc tctacatttt gtatgatatg 3060 taaaacagat ttttgtaga gcttactttt attattaaat gtattgaggt attattatta 3120 aaaaaaacta tgttcagaac ttcatctgcc actggttatt ttttctaag gagtaacttg 3180 caagttttca gtacaaatct gtgctacact ggataaaaat ctaatttatg aattttactt 3240 gcaccttata gttcatagca attaactgat ttgtagtgat tcattgtttg ttttatatac 3300 caatgacttc catattttaa aagagaaaaa caactttatg ttgcaggaaa cccttttgtgt 3360 aagtcttat tatttacttt gcattttgtt tcactctttc cagataagca gagttgctct 3420 tcaccagtgt ttttcttcat gtgcaaagtg actatttgtt ctataatact tttatgtgtg 3480 ttatatcaaa tgtgtcttaa gcttcatgca aactcagtca tcagttcgtg ttgtctgaag 3540 caagtgggag atatataaat acccagtagc taaaatggtc agtcttttt agatgttttc 3600 ctacttagta tctcctaata acgttttgct gtgtcactag atgttcattt cacaagtgca 3660 tgtctttcta ataatccaca catttcatgc tctaataatc cacacatttc atgctcattt 3720 ttattgtttt tacagccagt tatagtaaga aaaaggtttt tccccttgtg ctgctttata 3780 atttagcgtg tgtctgaacc ttatccatgt ttgctagatg aggtcttgtc aaatatatca 3840 ctaccattgt caccggtgaa aagaaacagg tagttaagtt agggttaaca ttcatttcaa 3900 ccacgaggtt gtatatcatg actagctttt actcttggtt tacagagaaa agttaaacag 3960 ccaactaggc agtttttaag aatattaaca atatattaac aaacaccaat acaactaatc 4020 ctatttggtt ttaatgattt caccatggga ttaagaacta tatcaggaac atccctgaga 4080 aacggtttta agtgtagcaa ctactcttcc ttaatggaca gccacataac gtgtaggaag 4140 tcctttatca cttatcctcg atccataagc atatcttgca gaggggaact acttctttaa 4200 acacatggag ggaaagaaga tgatgccact ggcaccagag ggttagtact gtgatgcatc 4260 ctaaaatatt tattatattg gtaaaaattc tggttaaata aaaaattaga gatcactctt 4320 ggctgatttc agcaccagga actgtattac agttttagag attaattcct agtgtttacc 4380 tgattatagc agttggcatc atggggcatt taattctgac tttatcccca cgtcagcctt 4440 aataaagtct tctttacctt ctctatgaag actttaaagc ccaaataatc atttttcaca 4500 ttgatattca agaattgaga tagatagaag ccaagtggg tatctgacaa gtggaaaatc 4560 aaacgtttaa gagaattac aactctgaaa agcattatta tgtggaactt ctcaggagc 4620 ctcctgggga ctggaagta agtcatcagc caggcaatg actcatgctg aagagagtcc 4680 ccatttcagt cccctgagat ctagctgatg cttagatcct ttgaataaa aattatgtct 4740 ttataactct gatctttac attaagcaga agaggaatca actaagttaat tgcaggtttt 4800 ctactctgtt tcctctgtaa agatcagatg gtaatctttc aaataagaaaaataaga 4860 cgtatgtttg accaagtagt ttcacaagaa tatttgggaa cttgttttctt ttaattttat 4920 ttgtccctga gtgaagtcta gaagaaagg taaagagtct agagtttt cctctttcca 4980 aaacattctc attcctcc tccctacact tagtatttcc cccacagagt gcctagaatc 5040 ttaataatga aaaataa aaagcagcaat atgtcattaa aaatccaga cctgaaaggg 5100 taaagggttt atactgcac taataagag aggcttttt ttttctttcc agttttgttgg 5160 ttttaatgg taccgtgttg taagatacc cactaatgga caatcaatt gcagaaaagg 5220 ctcaatcc agagacagg gactaatgca ctgtacaatc tgcttacct tgccctctc 5280 tcttgccaaa gtgtgcttca gaaatatata ctgctttaaa aaagataaa agatatcct 5340 tttacaagtg gctttacatt tcctaaaatg ccataagaaa atgcaatc tggtactgt 5400 atggggaaaa aaatgtccaa gtttgtgtaa aaccagtgca ttcagcttg caagttactg 5460 aacacataa tgctgtttta atttgtttt atatcagtta aattcacaa taatgtagat 5520 agaaaaattt acagaaagg aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaagct 5580 tatgataatt ttgaatgca ttatttttt ttgtgccat gcatttttt tctcaccaaa 5640 tgaccttacc tgtaatacag tcttgtttgt ctgtttacaa ccatgtattt attgcaatgt 5700 acatactgta atgttaattg taaattatct gttcttatta aaacatcatc ccatgatggg 5760 atggtgttga tatatttgga aactctttggt gagagaatga atggtgtgta tacatactct 5820 gtacatttt cttttctcct gtaatatagt cttgtcacct tagagcttt ttatggaaga 5880 ttcaagaaaa ctataaaata cttaaagata tataaattta aaaaaacata gctgcaggtc 5940 tttggtccca gggctgtgcc ttaactttaa ccaatatttt cttctgtttt gctgcatttg 6000 aaaggtaaca gtggagctag ggctggggcat tttacatcca ggcttttaat tgattagaat 6060 tctgccaata ggtggatttt acaaaaccac agaaccctc tgaaagattc tgagaccctt 6120 ttgagacaga agctcttaag tacttcttgc cagggagcag cactgcatgt gtgatggttg 6180 tttgccatct gttgatcagg aactacttca gctacttgca tttgatttt tccttttttt 6240 ttttttttaa ctcggaaaca caactggga aatatattct ttcccagtga ttataaacaa 6300 tctttttctt ttttttaagt ccttttggct tctagagctc ataggaaaat ggacttgatt 6360 tgaaattgga gccagagttt actcgtgttg gttatctatt catcagcttc ctgacatgtt 6420 aagagaatac attaagaga aaatactgtt ttttaatcct aaaatttttc ttccactaag 6480 ataaaccaaa tgtccttaca tatatgtaaa cccatctatt taaacgcaaa ggtgggttga 6540 tgtcagttta catagcagaa agcattcact atcctctaag atttgtttct gcaaaacttt 6600 cattgcttta gaattttaaa atttcacctt gtacaatggc cagcccctaa agcaggaaac 6660 atttataatg gattatatgg aaacatcctc ccagtacttg cccagccctt gaatcatgtg 6720 gcttttcagt gaaggaaag attcttttc taggaaaaat gagcctattt tattttattt 6780 tattttattt tttgacacaa actgtagatt ttagcagccc tggcccaaag gaatttgatt 6840 acttttgttt taaacagtac aaaggggaca ctataattac aaaaacatcc ttaactgatt 6900 tgagttgttt ttattcttt ggatatattt tcagagtggt aaattgtgtg tgagaattac 6960 aaatgattat tcttttagtg gtttcttagc ctctcttaca gcccacgggg atagtactgt 7020 acatcaatac cttcatatga aatttttata tgcaatgaaa ataaagcat gggttgattc 7080 tgcctatta tgactcaatc ttttacaaat aaaagattat tcattttaaa ttatagttca 7140 atcagcatgt ctcttaggat actgaacgtg gttgaatga areatagtg acatcataag 7200 7260 taccaaaatt acttagatgg cctataagat taagcatggt gttttctaag caagctttga 7320 aaggggcctt ccatacttac ttaattgaat attctgggat attgaaaatt attcagatac 7380 ttgacaatta tttttggtta cctactccgc aaactacaaa gttttaaagga ctcaacaata 7440 agttaatgag acacagtgtt tgctttcatg gagcttacag tctggagggg acaaaggctt 7500 aaacaatact catataatta tatatgtgat cagtacaatg aaggagctca gtggggtaaa 7560 taggagaa cctgaacttg atctgttccg gagggccaca gaaggcttcc ttgaggcctt 7620 7680 acaggaagag gaaggggatc cagacaagaa acatttgcaa agatcttgag gcataaatga 7740 gcttgagaca tctggagaaa ctgaggaaaa gtgagagagt aggcagggcc tggagccgca 7800 gagccattgc taaccatcct gtgtgagata tcccccattc tgtagcttta ttctcataac 7860 cctgctcaat tttctttata acacttctca cagatttata tacgtgtttg tttttgttat 7920 ctgtctctcc caccagacca cagctccatg agagcaaggt ctttgcttac caatatatca 7980 ctagcactta aaactatgcc tggtacacag taggttctta atatgtgttg aatatagcca 8040 tcaaattgat attggatata attcaatctg ataagatatt ttgagatatt aaagagtttt 8100 taacttgata ccataaaaaa aaaaaaaaa 8130 <210> 28 <211> 687 <212> PRT <213> Homo sapiens <400> 28 Put Ala Phe Val Trp Asp Pro Leu Gly Ala Thr Val Pro Gly Pro Ser 1 5 10 15 Thr Arg Ala Lys Ser Arg Leu Arg Phe Ser Lys Ser Tyr Ser Phe Asp 20 25 30 Val Asp Asn Gly Thr Ser Ala Gly Arg Ser Pro Leu Asp Pro Met Thr 35 40 45 Ser Pro Gly Ser Gly Leu Ile Leu Gln Ala Asn Phe Val His Ser Gln 50 55 60 Arg Arg Glu Ser Phe Leu Tyr Arg Ser Asp Ser Asp Tyr Asp Leu Ser 65 70 75 80 Pro Lys Ser Met Ser Arg Asn Ser Ser Ile Ala Ser Asp Ile His Gly 85 90 95 Asp Asp Leu Ile Val Thr Pro Phe Ala Gln Val Leu Ala Ser Leu Arg 100 105 110 Thr Val Arg Asn Asn Phe Ala Ala Leu Thr Asn Leu Gln Asp Arg Ala 115 120 125 Pro Ser Lys Arg Ser Pro Met Cys Asn Gln Pro Ser Ile Asn Lys Ala 130 135 140 Thr Ile Thr Glu Glu Ala Tyr Gln Lys Leu Ala Ser Glu Thr Leu Glu 145 150 155 160 Glu Leu Asp Trp Cys Leu Asp Gln Leu Glu Thr Leu Gln Thr Arg His 165 170 175 Ser Val Ser Glu Met Ala Ser Asn Lys Phe Lys Arg Met Leu Asn Arg 180 185 190 Glu Leu Thr His Leu Ser Glu Met Ser Arg Ser Gly Asn Gln Val Ser 195 200 205 Glu Phe Ile Ser Asn Thr Phe Leu Asp Lys Gln His Glu Val Glu Ile 210 215 220 Pro Ser Pro Thr Gln Lys Glu Lys Glu Lys Lys Lys Arg Pro Met Ser 225 230 235 240 Gln Ile Ser Gly Val Lys Lys Leu Met His Ser Ser Ser Leu Thr Asn 245 250 255 Ser Ser Ile Pro Arg Phe Gly Val Lys Thr Glu Gln Glu Asp Val Leu 260 265 270 Ala Lys Glu Leu Glu Asp Val Asn Lys Trp Gly Leu His Val Phe Arg 275 280 285 Ile Ala Glu Leu Ser Gly Asn Arg Pro Leu Thr Val Ile Met His Thr 290 295 300 Ile Phe Gln Glu Arg Asp Leu Leu Lys Thr Phe Lys Ile Pro Val Asp 305 310 315 320 Thr Leu Ile Thr Tyr Leu Met Thr Leu Glu Asp His Tyr His Ala Asp 325 330 335 Val Ala Tyr His Asn Asn Ile His Ala Ala Asp Val Val Gln Ser Thr 340 345 350 His Val Leu Leu Ser Thr Pro Ala Leu Glu Ala Val Phe Thr Asp Leu 355 360 365 Glu Ile Leu Ala Ala Ile Phe Ala Ser Ala Ile His Asp Val Asp His 370 375 380 Pro Gly Val Ser Asn Gln Phe Leu Ile Asn Thr Asn Ser Glu Leu Ala 385 390 395 400 Leu Met Tyr Asn Asp Ser Ser Val Leu Glu Asn His His Leu Ala Val 405 410 415 Gly Phe Lys Leu Leu Gln Glu Glu Asn Cys Asp Ile Phe Gln Asn Leu 420 425 430 Thr Lys Lys Gln Arg Gln Ser Leu Arg Lys Met Val Ile Asp Ile Val 435 440 445 Leu Ala Thr Asp Met Ser Lys His Met Asn Leu Leu Ala Asp Leu Lys 450 455 460 Thr Met Val Glu Thr Lys Lys Val Thr Ser Ser Gly Val Leu Leu Leu 465 470 475 480 Asp Asn Tyr Ser Asp Arg Ile Gln Val Leu Gln Asn Met Val His Cys 485 490 495 Ala Asp Leu Ser Asn Pro Thr Lys Pro Leu Gln Leu Tyr Arg Gln Trp 500 505 510 Thr Asp Arg Ile Met Glu Glu Phe Phe Arg Gln Gly Asp Arg Glu Arg 515 520 525 Glu Arg Gly Met Glu Ile Ser Pro Met Cys Asp Lys His Asn Ala Ser 530 535 540 Val Glu Lys Ser Gln Val Gly Phe Ile Asp Tyr Ile Val His Pro Leu 545 550 555 560 Trp Glu Thr Trp Ala Asp Leu Val His Pro Asp Ala Gln Asp Ile Leu 565 570 575 Asp Thr Leu Glu Asp Asn Arg Glu Trp Tyr Gln Ser Thr Ile Pro Gln 580 585 590 Ser Pro Ser Pro Ala Pro Asp Asp Pro Glu Glu Gly Arg Gln Gly Gln 595 600 605 Thr Glu Lys Phe Gln Phe Glu Leu Thr Leu Glu Glu Asp Gly Glu Ser 610 615 620 Asp Thr Glu Lys Asp Ser Gly Ser Gln Val Glu Glu Asp Thr Ser Cys 625 630 635 640 Ser Asp Ser Lys Thr Leu Cys Thr Gln Asp Ser Glu Ser Thr Glu Ile 645 650 655 Pro Leu Asp Glu Gln Val Glu Glu Glu Ala Val Gly Glu Glu Glu Glu 660 665 670 Ser Gln Pro Glu Ala Cys Val Ile Asp Asp Arg Ser Pro Asp Thr 675 680 685 <210> 29 <211> 8395 <212> DNA <213> Homo sapiens <400> 29 ttctcactgc cctgcggtgt tttgaactgc cttcttacag acgtcataca gcccttgagg 60 aatagtttct gcctggtgag attgaatgat agttctcatt cacaaaaccc tggattctaa 120 gcagggacac acagaaatta ctttcgcagg taaatcagcc cacccagcca aagtgtggag 180 agatttgttc cttggctgac ttctttgctc cacggagagg agtgttttcc tgtgcttgcc 240 ctgaaatgga acttccttga cagctctccc gtgttacagt acctcccggt cattttcttt 300 ttctctctct ctacctgcgc tcttcgagtg tcagaaacct ttaaagctgt tactatggaa 360 ttgcaaaaaa gagatcaagt gactctttca ctatgctggt ttcccttgtg acccagatga 420 agaatcaatt cagaattcag ttcctccctt ggcattgcaa gacacagaag aaactgtcac 480 ttcctaacag cctagtactg gagtaaattc agtatgaagg aagaaagcgc tcctgcgtgt 540 tagaaccttg cccatgagct ggaccgagga caggagatgg actccaggaa aattggattt 600 cttcaagcag cctcccttgg aaatggaata tctttaaaat cttctttgca gaaagacagt 660 tagaatgtat taatcagaat agttgaagac ttattttcct ttttattttt tttcaaaatg 720 agcattatta tgaagccaag atcccgatct acaagttccc taaggactgc agaggcagtt 780 tgttttgatg tggacaatg cacatctgcg ggacggagtc ccttggatcc catgaccagc 840 ccaggatccg ggctaattct ccaagcaaat tttgtccaca gtcaacgacg ggagtccttc 900 ctgtatcgat ccgacagcga ttatgacctc tctccaaagt ctatgtcccg gaactcctcc 960 attgccagtg atatacacgg agatgacttg attgtgactc catttgctca ggtcttggcc 1020 agtctgcgaa ctgtacgaaa caactttgct gcattaacta atttgcaaga tcgagcacct 1080 agcaaaagat cacccatgtg caaccaacca tccatcaaca aagccaccat aacagaggag 1140 gcctaccaga aactggccag cgagaccctg gaggagctgg actggtgtct ggaccagcta 1200 gagaccctac agaccaggca ctccgtcagt gagatggcct ccaacaagtt taaaaggatg 1260 cttaatcggg agctcaccca tctctctgaa atgagtcggt ctggaaatca agtgtcagag 1320 tttatatcaa acacattctt agataagcaa catgaagtgg aaattccttc tccaactcag 1380 aaggaaaagg agaaaaagaa aagaccaatg tctcagatca gtggagtcaa gaaattgatg 1440 cacagctcta gtctgactaa ttcaagtatc ccaaggtttg gagttaaaac tgaacaagaa 1500 gatgtccttg ccaaggaact agaagatgtg aacaaatggg gtcttcatgt tttcagaata 1560 gcagagttgt ctggtaaccg gcccttgact gttatcatgc acaccatttt tcaggaacgg 1620 gatttattaa aaacatttaa aattccagta gatactttaa ttacatatct tatgactctc 1680 gaagaccatt accatgctga tgtggcctat caacaata tccatgctgc agatgttgtc 1740 cagtctactc atgtgctatt atctacacct gctttggagg ctgtgtttac agatttggag 1800 attcttgcag caatttttgc cagtgcaata catgatgtag atcatcctgg tgtgtccaat 1860 caatttctga tcaatacaaa ctctgaactt gccttgatgt acaatgattc ctcagtctta 1920 gagaaccatc atttggctgt gggctttaaa ttgcttcagg aagaaaactg tgacattttc 1980 cagaatttga ccaaaaaaca aagacaatct ttaaggaaaa tggtcattga catcgtactt 2040 gcaacagata tgtcaaaaca catgaatcta ctggctgatt tgaagactat ggttgaaact 2100 2160 cttcagata tggtgcactg tgcagatctg agcaacccaa caaagcctct ccagctgtac 2220 cgccagtgga cggaccggat aatggagag ttcttccgcc aaggagaccg agagggaa 2280 cgtggcatgg agataagccc catgtgtgac aagcacatg cttccgtgga aaaatcacag 2340 gtgggcttca tagactatat tgttcatccc ctctgggaga catgggcaga cctcgtccac 2400 cctgacgccc aggatatttt ggacactttg gaggacaatc gtgaatggta ccagagcaca 2460 atccctcaga gcccctctcc tgcacctgat gacccagagg agggccggca gggtcaaact 2520 gagaattcc agtttgaact aactttagag gaagatggtg agtcagacac ggaaaaggac 2580 agtggcagtc aagtggaaga agacactagc tgcagtgact ccaagactct ttgtactcaa 2640 gactcagagt ctactgaaat tccccttgat gaacaggttg aagaggaggc agtaggggaa 2700 gaagaggaaa gccagcctga agcctgtgtc atagatgatc gttctcctga cacgtaacag 2760 tgcaaaaact ttcatgcctt tttttttt aagtagaaaa attgtttcca aagtgcatgt 2820 cacatgccac aaccacggtc acacctcact gtcatctgcc aggacgtttg ttgaacaaaa 2880 ctgaccttga ctactcagtc cagcgctcag gaatatcgta accagttttt tcacctccat 2940 gtcatccgag caaggtggac atcttcacga acagcgtttt taacaagatt tcagcttggt 3000 agagctgaca aagcagataa aatctactcc aaattatttt caagagagtg tgactcatca 3060 ggcagcccaa aagtttattg gacttggggt ttctattcct ttttattgtgt ttgcaatatt 3120 ttcagagaa aggcattgca cagagtgaac ttaatggacg aagcaacaa ttgtcaaga 3180 acaggacata gcacgaatct gttaccagta ggaggat gagccacaga aattgcataa 3240 ttttctaatt tcaagcttc ctgatacatg actgaatagt gtggttcagt gagctgcact 3300 gacctctaca tttgtatga tatgtaaaac agattttg tagagcttac ttttatt 3360 aaatgtattg aggtattata tttaaaaaaa actatgttca gaacttcatc tgccactggt 3420 tattttttc taggagta cttgcaagtt ttcagtaca atctgtgcta cactggataa 3480 aaatctaatt tatgaatttt acttgcacct tagttcat agcaattac tgatttgtag 3540 tgattcattg ttgttttat ataccaatga cttccatatt ttaaaagaga aaaacaactt 3600 tatgttgcag gaaacccttt ttgtaagtct ttattatta ctttgcattt tgttcactc 3660 tttccagata agcagagttg ctctcacca gtgttttct tcatgtgcaa agtgactatt 3720 tgttctataa tacttttatg tgtgttatat caatgtgtc ttaagcttca tgcaactca 3780 gtcatcagtt cgtgttgtct gaagcaagtg ggagatatat aaatacccag tagctaaaat 3840 ggtcagtctt ttttagatgt tttcctactt agtatctcct aataacgttt tgctgtgtca 3900 ctagatgttc atttcacaag tgcatgtctt tctaataatc cacacatttc atgctctaat 3960 aatccacaca tttcatgctc atttttattg tttttacagc cagttatagt aagaaaaagg 4020 tttttcccct tgtgctgctt tataatttag cgtgtgtctg aaccttatcc atgtttgcta 4080 gatgaggtct tgtcaaatat atcactacca ttgtcaccgg tgaaaagaaa caggtagtta 4140 agttagggtt aacattcatt tcaaccacga ggttgtatat catgactagc ttttactctt 4200 ggtttacaga gaaaagttaa acagccaact aggcagtttt taagaatatt aacaatatat 4260 taacaaacac caatacaact aatcctattt ggttttaatg atttcaccat gggattaaga 4320 actatatcag gaacatccct gagaaacggt tttaagtgta gcaactactc ttccttaatg 4380 gacagccaca taacgtgtag gaagtccttt atcacttatc ctcgatccat aagcatatct 4440 tgcagagggg aactacttct ttaaacacat ggagggaaag aagatgatgc cactggcacc 4500 agagggttag tactgtgatg catcctaaaa tatttattat attggtaaaa attctggtta 4560 aaaaaaat tagagatcac tctggctga ttcagcacc aggactgta tcagtttt 4620 agagattaat tcctagtgtt tacctgatta tagcagttgg catcatgggg catttaattc 4680 tgactttatc cccacgtcag ccttataaa gtctcttta ccttcttat gagacttta 4740 aagcccaaat atcattttt cacattgata ttcagaatt gagatagata gaagccaag 4800 tgggtatctg acagtggaa atcaacgt ttagagaa ttacactct gaaagcatt 4860 tatatgtgga acttctcaag gagcctcctg gggactggaa agtaagtcat cagccaggca 4920 aatgactcat gctgaagaga gtccccattt cagtcccctg agatctagct gatgcttaga 4980 tcctttgaaa taaaattat gtctttataa ctctgatctt ttacataag cagaagagga 5040 atcaactagt taattgcaag gtttctactc tgtttcctct gtaagatca gatggtaatc 5100 tttcaataa gaaaaaaata aagacgtatg tttgaccaag tagtttcaca agaatattg 5160 ggaacttgtt tcttttaatt ttattgtcc ctgagtgaag tctagaaga aaggtaaga 5220 gtctagagtt tattcctct tccaaacat tctcattcct ctcctcccta cacttagtat 5280 ttcccccaca gagtgcctag atcttaata atgaataaaa taaaaagcag caatgtca 5340 ttaacaaatc cagacctgaa agggtaagg gtttataact gcactataa agagaggctc 5400 ttttttttc ttccagttg ttggtttta atggtaccgt gttgtaaaga tacccactaa 5460 tggacaatca aattgcagaa aaggctcaat atccagaga cagggactaa tgcactgtac 5520 aatctgctta tccttgccct tctctctgc caagtgtgc ttcagaata tatactgctt 5580 taaaaaagaa taaaagaata tccttttaca agtggcttta cattcctaa atgccataa 5640 gaaaatgcaa tatctgggta ctgtatgggg aaaaaatgt ccaagtttgt gtaaaaccag 5700 tgcatttcag cttgcaagtt actgaacaca ataatgctgt ttatatttg ttatatca 5760 gttaaaatttc acaataatgt agatagaca attackacagac aaggaaa aaacttgaa 5820 tgaaatggat tttacagaa gctttatgat aattttgaa tgcattattt attttgtg 5880 ccatgcatttt tttctcac caaatgacct tacctgtaat acagcttgt tgtctgttt 5940 acaaccatgt atttattgca atgtacatac tgtaatgtta attgtaaatt atctgttctt 6000 attaaaacat catcccatga tgggatggtg ttgatatatt tggaaactct tggtgagaga 6060 atgaatggtg tgtatacata ctctgtacat ttttcttttc tcctgtaata tagtcttgtc 6120 accttagagc ttgtttatgg aagattcaag aaaactataa aatacttaaa gatatataaa 6180 tttaaaaaaa catagctgca ggtctttggt cccagggctg tgccttaact ttaaccaata 6240 tttcttctg ttttgctgca tttgaaaggt aacagtggag ctagggctgg gcattttaca 6300 tccaggcttt taattgatta gaattctgcc aataggtgga ttttacaaaa ccacagacaa 6360 cctctgaaag attctgagac cttttgaga cagaagctct taagtacttc ttgccaggga 6420 gcagcactgc atgtgtgatg gttgtttgcc atctgttgat caggaactac ttcagctact 6480 tgcatttgat tatttcctttt tttttttt ttaactcgga aacacaactg gggaaatata 6540 ttctttccca gtgattataa acaatctttt tcttttttt aagtcctttt ggcttctaga 6600 gctcatagga aaatggactt gatttgaaat tggagccaga gttactcgt gttggttatc 6660 tattcatcag cttcctgaca tgttaagaga atacattaaa gagaaaatac tgttttttaa 6720 tcctaaaatt tttcttccac taagataaac caaatgtcct tacatatatg taaacccatc 6780 tatttaaacg caaaggtggg ttgatgtcag tttacatagc agaaagcatt cactatcctc 6840 taagatttgt ttctgcaaaa ctttcattgc tttagaattt taaaatttca ccttgtacaa 6900 tggccagccc ctaaagcagg aaacatttat aatggattat atggaaacat cctcccagta 6960 cttgcccagc ccttgaatca tgtggcttt cagtgaaagg aaagattctt tttctaggaa 7020 aaatgagcct attttttt attttttt attttttgac acaaactgta gattttagca 7080 gccctggccc aaaggaattt gattactttt gttttaaaca gtacaaaggg gacactataa 7140 ttacaaaaac atccttaact gatttgagtt gtttttattt ctttggatat attttcagag 7200 tggtaaattg tgtgtgagaa ttacaaatga ttatctttt agtggtttct tagcctctct 7260 tacagcccac ggggatagta ctgtacatca ataccttcat atgaaatttt tatatgcaat 7320 gaaataaaaa gcatgggttg attctgccta tttatgactc aatcttttac aaataaaaga 7380 ttattcattt taaattatag ttcaatcagc atgtctctta ggatactgaa cgtggttgaa 7440 atgaaaggat agtgacatca tagttagta ctgatattca taaccaata aagccaactt 7500 gagtaatttt gctacattaa aattaccaa attackattag atggcctata agattaagca 7560 tggtgttttc taagcaagct tgaagggg ccttccatac ttactttatt gatatttctg 7620 ggatattgaa attattcag atacttgaca attatttg gttacctact ccgcaaacta 7680 caaagtttta aggactcaac ataagttaa tgagacacag tgtttgcttt catggagctt 7740 acagtctgga ggggacaaag gcttaaacaa tactcatata attatatg tgatcagtac 7800 aatgaaggag ctcagtgggg taaatagca ggaacctgaa cttgatctgt tccggaggc 7860 cacagaaggc ttccttgagg ccttgagaaa gtgatttgca tctgagttct gaaggattgt 7920 aagaggtaac tagggaaaa gttgacagga agaggaaggg gatccagaca agaaacattt 7980 gcaaagtct tgaggcataa atgagcttga gatactgga gaactgagg aaagtgaga 8040 gagtaggcag ggcctggagc cgcagagcca ttgctacca tcctgtgtga gatatccccc 8100 attctgtagc tttattctca taaccctgct caatttctt tataacactt ctcacagatt 8160 tatatacgtg ttgttttg tatatctgtct ctcccaccag accacagctc catgagagca 8220 aggtctttgc ttaccaatat atcactagca cttaaaacta tgcctgtac acagtaggtt 8280 cttaatatgt gttgaata gccatcaaat tgatattgga tataattca tctgataaga 8340 tattttgaga tattaagag tttttaactt gataccataa aaaaaaaaaaaaaaaaaa 8395 <210> 30 <211> 679 <212> PRT <213> Homo sapiens <400> 30 Met Ser Ile Met Lys Pro Arg Ser Arg Ser Thr Ser Ser Leu Arg 1 5 10 15 Thr Ala Glu Ala Val Cys Phe Asp Val Asp Asn Gly Thr Ser Ala Gly 20 25 30 Arg Ser Pro Leu Asp Pro Met Thr Ser Pro Gly Ser Gly Leu Ile Leu 35 40 45 Gln Ala Asn Phe Val His Ser Gln Arg Arg Glu Ser Phe Leu Tyr Arg 50 55 60 Ser Asp Ser Asp Tyr Asp Leu Ser Pro Lys Ser Met Ser Arg Asn Ser 65 70 75 80 Asp Is Not His Gly Asp Asp Leu Is Val Thr Pro Phe 85 90 95 Ala Gln Val Leu Ala Ser Leu Arg Thr Val Arg Asn Asn Phe Ala Ala 100 105 110 Leu Thr Asn Leu Gln Asp Arg Ala Pro Ser Lys Arg Ser Pro Met Cys 115 120 125 Asn Gln Pro Ser Ile Asn Lys Ala Thr Ile Thr Glu Glu Ala Tyr Gln 130 135 140 Lys Leu Ala Ser Glu Thr Leu Glu Glu Leu Asp Trp Cys Leu Asp Gln 145 150 155 160 Leu Glu Thr Leu Gln Thr Arg His Ser Val Ser Glu Met Ala Ser Asn 165 170 175 Lys Phe Lys Arg Met Leu Asn Arg Glu Leu Thr His Leu Ser Glu Met 180 185 190 Ser Arg Ser Gly Asn Gln Val Ser Glu Phe Ile Ser Asn Thr Phe Leu 195 200 205 Asp Lys Gln His Glu Val Glu Ile Pro Ser Pro Thr Gln Lys Glu Lys 210 215 220 Glu Lys Lys Lys Arg Pro Met Ser Gln Ile Ser Gly Val Lys Lys Leu 225 230 235 240 Met His Ser Ser Ser Leu Thr Asn Ser Ser Ile Pro Arg Phe Gly Val 245 250 255 Lys Thr Glu Gln Glu Asp Val Leu Ala Lys Glu Leu Glu Asp Val Asn 260 265 270 Lys Trp Gly Leu His Val Phe Arg Ile Ala Glu Leu Ser Gly Asn Arg 275 280 285 Pro Leu Thr Val Ile Met His Thr Ile Phe Gln Glu Arg Asp Leu Leu 290 295 300 Lys Thr Phe Lys Ile Pro Val Asp Thr Leu Ile Thr Tyr Leu Met Thr 305 310 315 320 Leo Glu Asp His Tyr His Ala Asp Val Ala Tyr His Asn Asn Ile His 325 330 335 Ala Ala Asp Val Val Gln Ser Thr His Val Leu Leu Ser Thr Pro Ala 340 345 350 Leu Glu Ala Val Phe Thr Asp Leu Glu Ile Leu Ala Ala Ile Phe Ala 355 360 365 Ser Ala Ile His Asp Val Asp His Pro Gly Val Ser Asn Gln Phe Leu 370 375 380 Ile Asn Thr Asn Ser Glu Leu Ala Leu Met Tyr Asn Asp Ser Ser Val 385 390 395 400 Leu Glu Asn His His Leu Ala Val Gly Phe Lys Leu Leu Gln Glu Glu 405 410 415 Asn Cys Asp Ile Phe Gln Asn Leu Thr Lys Lys Gln Arg Gln Ser Leu 420 425 430 Arg Lys Met Val Ile Asp Ile Val Leu Ala Thr Asp Met Ser Lys His 435 440 445 Met Asn Leu Leu Ala Asp Leu Lys Thr Met Val Glu Thr Lys Lys Val 450 455 460 Thr Ser Ser Gly Val Leu Leu Leu Asp Asn Tyr Ser Asp Arg Ile Gln 465 470 475 480 Val Leu Gln Asn Met Val His Cys Ala Asp Leu Ser Asn Pro Thr Lys 485 490 495 Pro Leu Gln Leu Tyr Arg Gln Trp Thr Asp Arg Ile Met Glu Glu Phe 500 505 510 Phe Arg Gln Gly Asp Arg Glu Arg Glu Arg Gly Met Glu Ile Ser Pro 515 520 525 Met Cys Asp Lys His Asn Ala Ser Val Glu Lys Ser Gln Val Gly Phe 530 535 540 Ile Asp Tyr Ile Val His Pro Leu Trp Glu Thr Trp Ala Asp Leu Val 545 550 555 560 His Pro Asp Ala Gln Asp Ile Leu Asp Thr Leu Glu Asp Asn Arg Glu 565 570 575 Trp Tyr Gln Ser Thr Ile Pro Gln Ser Pro Ser Pro Ala Pro Asp Asp 580 585 590 Pro Glu Glu Gly Arg Gln Gly Gln Thr Glu Lys Phe Gln Phe Glu Leu 595 600 605 Thr Leu Glu Glu Asp Gly Glu Ser Asp Thr Glu Lys Asp Ser Gly Ser 610 615 620 Gln Val Glu Glu Asp Thr Ser Cys Ser Asp Ser Lys Thr Leu Cys Thr 625 630 635 640 Gln Asp Ser Glu Ser Thr Glu Ile Pro Leu Asp Glu Gln Val Glu Glu 645 650 655 Glu Ala Val Gly Glu Glu Glu Glu Ser Gln Pro Glu Ala Cys Val Ile 660 665 670 Asp Asp Arg Ser Pro Asp Thr 675 <210> 31 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> PDE4D9_forward primer <400> 31 atgagcatta ttatgaagcc aagatc 26 <210> 32 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> PDE4D9_reverse first <400> 32 gtgccattgt ccacatcaaa ac <210> 33 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> PDE4D9 probe <400> 33 ctacaagttc cctaaggact gcagagg <210> 34 <211> 1435 <212> DNA <213> Homo sapiens <400> 34 ggcggggcct gcttctcctc agcttcaggc ggctgcgacg agccctcagg cgaacctctc ggctttcccg cggcggcgccg cctcttgctg cgcctccgcc tcctcctctg ctccgccacc 120 ggcttcctcc tcctgagcag tcagcccgcg cgccggccgg ctccgttatg gcgacccgca 180 gccctggcgt cgtgattagt gatgatgaac caggttatga ccttgattta ttttgcatac ctaatcatta tgctgaggat ttggaaaggg tgtttattcc tcatggacta attatggaca ggactgaacg tcttgctcga gatgtgatga aggagatggg aggccatcac attgtagccc 360 tctgtgtgct caagggggc tataaattct ttgctgacct gctggattac atcaaagcac 420 tgaatagaaa tagtgataga tccattccta tgactgtaga tttatcaga ctgaagagct 480 attgtaatga ccagtcaaca gggacacataa aagtaattgg tggagatgat ctctcaactt 540 taactggaaa gaatgtcttg attgtggaag atataattga cactggcaaa acaatgcaga 600 ctttgctttc cttggtcagg foottaatc caaagatggt caaggtcgca agcttgctgg 660 tgaaaaggac cccacgaagt gttggatata agccagactt tgttggattt gaaattccag 720 acaagtttgt tgtaggatat gcccttgact ataatgaata cttcagggat ttgaatcatg 780 tttgtgtcat tagtgaaact ggaaaagcaa aatacaaagc ctaagatgag agttcaagtt 840 gagtttggaa acatctggag tcctattgac atcgccagta aaattatcaa tgttctagtt 900 ctgtggccat ctgcttagta gagctttttg catgtatctt ctaagaattt tatctgtttt 960 gtactttaga aatgtcagtt gctgcattcc taaactgttt atttgcacta tgagcctata 1020 gactatcagt tcccttggg cggattgttg tttaacttgt aaatgaaaaa attctcttaa 1080 accacagcac tattgagtga aacattgaac tcatatctgt aagaataaa gagagatat 1140 attagtttt taattgtat tttaattttt attatatgcag gaagaatag aagtgattga 1200 atattgttaa ttataccacc gtgtgttaga aaagtaagaa gcagtcaattt ttcacatcaa 1260 agacagcatc taagaagttt tgttctgtcc tggaattatt ttagtagtt ttcagtaatg 1320 ttgactgtat ttccaactt gttcaatta ttaccagtga atctttgtca gcagttccct 1380 tttaaatgca atcataaa ttcccaaaa tttaaaaaaaaaaaaaaaaaaaaaaaaa 1435 <210> 35 <211> 218 <212> PRT <213> Homo sapiens <400> 35 Met Ala Thr Arg Ser Pro Gly Val Val Ile Ser Asp Asp Glu Pro Gly 1 5 10 15 Tyr Asp Leu Asp Leu Phe Cys Ile Pro Asn His Tyr Ala Glu Asp Leu 20 25 30 Glu Arg Val Phe Ile Pro His Gly Leu Ile Met Asp Arg Thr Glu Arg 35 40 45 Leu Ala Arg Asp Val Met Lys Glu Met Gly Gly His His Ile Val Ala 50 55 60 Leu Cys Val Leu Lys Gly Gly Tyr Lys Phe Phe Ala Asp Leu Leu Asp 65 70 75 80 Tyr Ile Lys Ala Leu Asn Arg Asn Ser Asp Arg Ser Ile Pro Met Thr 85 90 95 Val Asp Phe Ile Arg Leu Lys Ser Tyr Cys Asn Asp Gln Ser Thr Gly 100 105 110 Asp Ile Lys Val Ile Gly Gly Asp Asp Leu Ser Thr Leu Thr Gly Lys 115 120 125 Asn Val Leu Ile Val Glu Asp Ile Ile Asp Thr Gly Lys Thr Met Gln 130 135 140 Thr Leu Leu Ser Leu Val Arg Gln Tyr Asn Pro Lys Met Val Lys Val 145 150 155 160 Ala Ser Leu Leu Val Lys Arg Thr Pro Arg Ser Val Gly Tyr Lys Pro 165 170 175 Asp Phe Val Gly Phe Glu Ile Pro Asp Lys Phe Val Val Gly Tyr Ala 180 185 190 Leu Asp Tyr Asn Glu Tyr Phe Arg Asp Leu Asn His Val Cys Val Ile 195 200 205 Ser Glu Thr Gly Lys Ala Lys Tyr Lys Ala 210 215 <210> 36 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> HPRT1_forward primer <400> 36 gaggatttgg aaagggtgtt tatt 24 <210> 37 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> Primer HPRT1_reverse <400> 37 acagagggct acaatgtgat g 21 <210> 38 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> HPRT1 probe <400> 38 acgtcttgct cgagatgtga tgaagg 26 <210> 39 <211> 1771 <212> DNA <213> Homo sapiens <400> 39 ggcggccagg ccgggcgcgg agtgggcgcg cggggccgga ggaggggcca gcgaccgcgg 60 caccgcctgt gcccgcccc ccctccgcag ccgctactta agaggctcca gcgccggccc 120 cgccctagtg cgttacttac ctcgactctt agcttgtcgg ggacggtaac cgggacccgg 180 tgtctgctcc tgtcgccttc gcctcctaat ccctagccac tatgcgtgag tgcatctcca 240 tccacgttgg ccaggctggt gtccagattg gcaatgcctg ctgggagctc tactgcctgg 300 aacacggcat ccagcccgat ggccagatgc caagtgacaa gaccattggg ggaggagatg 360 actccttcaa caccttcttc agtgagacgg gcgctggcaa gcacgtgccc cgggctgtgt 420 ttgtagactt ggaacccaca gtcattgatg aagttcgcac tggcacctac cgccagctct 480 tccaccctga gcagctcatc acaggcaagg aagatgctgc caataactat gcccgagggc 540 actacaccat tggcaaggag atcattgacc ttgtgttgga ccgaattcgc aagctggctg 600 accagtgcac cggtcttcag ggcttcttgg ttttccacag ctttggtggg ggaactggtt 660 ctgggttcac ctccctgctc atggaacgtc tctcagttga ttatggcaag aagtccaagc 720 tggagttctc catttaccca gcaccccagg tttccacagc tgtagttgag ccctacaact 780 ccatcctcac cacccacacc accctggagc actctgattg tgccttcatg gtagacaatg 840 aggccatcta tgacatctgt cgtagaaacc tcgatatcga gcgcccaacc tacactaacc 900 ttaaccgcct tattagccag attgtgtcct ccatcactgc ttccctgaga ttgatggag 960 ccctgaatgt tgacctgaca gaattccaga ccaacctggt gccctacccc cgcatccact 1020 tccctctggc cacatatgcc cctgtcatct ctgctgagaa agcctaccat gaacagcttt 1080 ctgtagcaga gatcaccaat gcttgctttg agccagccaa ccagatggtg aaatgtgacc 1140 ctcgccatgg taaatacatg gcttgctgcc tgttgtaccg tggtgacgtg gttcccaaag 1200 atgtcaatgc tgccattgcc accatcaaaa ccaagcgcag catccagttt gtggattggt 1260 gccccactgg cttcaaggtt ggcatcaact accagcctcc cactgtggtg cctggtggag 1320 acctggccaa ggtacagaga gctgtgtgca tgctgagcaa caccacagcc attgctgagg 1380 cctgggctcg ctggaccac aagtttgacc tgatgtatgc caagcgtgcc tttgttcact 1440 ggtacgtggg tgaggggatg gaggaaggcg agttttcaga ggcccgtgaa gatatggctg 1500 cccttgagaa ggattatgag gaggttggtg tggattctgt tgaaggagag ggtgaggaag 1560 aaggagagga atactaatta tccattcctt ttggccctgc agcatgtcat gctcccagaa 1620 tttcagcttc agcttaactg acagacgtta aagctttctg gttagattgt tttcacttgg 1680 tgatcatgtc ttttccatgt gtacctgtaa tatttttcca tcatatctca aagtaaagtc 1740 attaacatca aaaaaaaaaa aaaaaaaaaa a 1771 <210> 40 <211> 451 <212> PRT <213> Homo sapiens <400> 40 Met Arg Glu Cys Ile Ser Ile His Val Gly Gln Ala Gly Val Gln Ile 1 5 10 15 Gly Asn Ala Cys Trp Glu Leu Tyr Cys Leu Glu His Gly Ile Gln Pro 20 25 30 Asp Gly Gln Met Pro Ser Asp Lys Thr Ile Gly Gly Gly Asp Asp Ser 35 40 45 Phe Asn Thr Phe Phe Ser Glu Thr Gly Ala Gly Lys His Val Pro Arg 50 55 60 Ala Val Phe Val Asp Leu Glu Pro Thr Val Ile Asp Glu Val Arg Thr 65 70 75 80 Gly Thr Tyr Arg Gln Leu Phe His Pro Glu Gln Leu Ile Thr Gly Lys 85 90 95 Glu Asp Ala Ala Asn Asn Tyr Ala Arg Gly His Tyr Thr Ile Gly Lys 100 105 110 Glu Ile Ile Asp Leu Val Leu Asp Arg Ile Arg Lys Leu Ala Asp Gln 115 120 125 Cys Thr Gly Leu Gln Gly Phe Leu Val Phe His Ser Phe Gly Gly Gly 130 135 140 Thr Gly Ser Gly Phe Thr Ser Leu Leu Met Glu Arg Leu Ser Val Asp 145 150 155 160 Tyr Gly Lys Lys Ser Lys Leu Glu Phe Ser Ile Tyr Pro Ala Pro Gln 165 170 175 Val Ser Thr Ala Val Val Glu Pro Tyr Asn Ser Ile Leu Thr Thr His 180 185 190 Thr Thr Leu Glu His Ser Asp Cys Ala Phe Met Val Asp Asn Glu Ala 195 200 205 Ile Tyr Asp Ile Cys Arg Arg Asn Leu Asp Ile Glu Arg Pro Thr Tyr 210 215 220 Thr Asn Leu Asn Arg Leu Ile Ser Gln Ile Val Ser Ser Ile Thr Ala 225 230 235 240 Ser Leu Arg Phe Asp Gly Ala Leu Asn Val Asp Leu Thr Glu Phe Gln 245 250 255 Thr Asn Leu Val Pro Tyr Pro Arg Ile His Phe Pro Leu Ala Thr Tyr 260 265 270 Ala Pro Val Ile Ser Ala Glu Lys Ala Tyr His Glu Gln Leu Ser Val 275 280 285 Ala Glu Ile Thr Asn Ala Cys Phe Glu Pro Ala Asn Gln Met Val Lys 290 295 300 Cys Asp Pro Arg His Gly Lys Tyr Met Ala Cys Cys Leu Leu Tyr Arg 305 310 315 320 Gly Asp Val Val Pro Lys Asp Val Asn Ala Ala Ile Ala Thr Ile Lys 325 330 335 Thr Lys Arg Ser Ile Gln Phe Val Asp Trp Cys Pro Thr Gly Phe Lys 340 345 350 Val Gly Ile Asn Tyr Gln Pro Pro Thr Val Val Pro Gly Gly Asp Leu 355 360 365 Ala Lys Val Gln Arg Ala Val Cys Met Leu Ser Asn Thr Thr Ala Ile 370 375 380 Ala Glu Ala Trp Ala Arg Leu Asp His Lys Phe Asp Leu Met Tyr Ala 385 390 395 400 Lys Arg Ala Phe Val His Trp Tyr Val Gly Glu Gly Met Glu Glu Gly 405 410 415 Glu Phe Ser Glu Ala Arg Glu Asp Met Ala Ala Leu Glu Lys Asp Tyr 420 425 430 Glu Glu Val Gly Val Asp Ser Val Glu Gly Glu Gly Glu Glu Glu Gly 435 440 445 Glu Glu Tyr 450 <210> 41 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> TUBA1B_forward primer <400> 41 tgactccttc aacaccttct tc 22 <210> 42 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> TUBA1B_reverse primer <400> 42 tgccagtgcg aacttcat 18 <210> 43 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> TUBA1B probe <400> 43 ccgggctgtg tttgtagact tgga 24 <210> 44 <211> 5416 <212> DNA <213> Homo sapiens <400> 44 agtgggccgc catgttgtcg gagtgaaagg taagggggag cgagagcgcc agagagagaa 60 gatcgggggg ctgaaatcca tcttcatcct accgctccgc ccgtgttggt ggaatgagcg 120 ttgcatgtgt cttgaagaga aaagcagtgc tttggcagga ctctttcagc ccccacctga 180 aacatcaccc tcaagaacca gctaatccca acatgcctgt tgttttgaca tctggaacag 240 ggtcgcaagc gcagccacaa ccagctgcaa atcaggctct tgcagctggg actcactcca 300 gccctgtccc aggatctata ggagttgcag gccgttccca ggacgacgct atggtggact 360 acttctttca gaggcagcat ggtgagcagc ttgggggagg aggaagtgga ggaggcggct 420 ataataatag caaacatcga tggcctactg gggataacat tcatgcagaa catcaggtgc 480 gttccatgga tgaactgaat catgatttc aagcacttgc tctggaggga agagcgatgg 540 gagagcagct cttgccaggt aaaaagtttt gggaaacaga tgaatccagc aaagatggac 600 caaaaggaat attcctgggt gatcaatggc gagacagtgc ctggggaaca tcagatcatt 660 cagtttccca gccaatcatg gtgcagagaa gacctggtca gagtttccat gtgaacagtg 720 aggtcaattc tgtactgtcc ccacgatcgg agagtggggg actaggcgtt agcatggtgg 780 agtatgtgtt gagctcatcc ccgggcgatt cctgtctaag aaaaggagga tttggcccaa 840 gggatgcaga cagtgatgaa aacgacaaag gtgaaaagaa gaacaagggt acgtttgatg 900 gagataagct aggagatttg aaggaggagg gtgatgtgat ggacaagacc aatggtttac 960 cagtgcagaa tgggattgat gcagacgtca aagattttag ccgtacccct ggtaattgcc 1020 agaactctgc taatgaagtg gatcttctgg gtccaaacca gaatggttct gagggcttag 1080 cccagctgac cagcaccaat ggtgccaagc ctgtggagga tttctccaac atggagtccc 1140 agagtgtccc cttggacccc atggaacatg tgggcatgga gcctcttcag tttgattatt 1200 caggcacgca ggtacctgtg gactcagcag cagcaactgt gggacttttt gactacaatt 1260 ctcaacaaca gctgttccaa agacctaatg cgcttgctgt ccagcagttg acagctgctc 1320 agcagcagca gtatgcactg gcagctgctc atcagccgca catcggttta gctcccgctg 1380 cgtttgtccc caatccatac atcatcagcg ctgctccccc agggacggac ccctacacag 1440 ctggattggc tgcagcagcg acactaggcc cagctgtggt ccctcaccag tattatggag 1500 ttactccctg gggagtctac cctgccagtc ttttccagca gcaagctgcc gctgccgctg 1560 cagcaactaa ttcagctaat caacagacca ccccacaggc tcagcaagga cagcagcagg 1620 ttctccgtgg aggagccagc caacgtcctt tgaccccaaa ccagaaccag cagggacagc 1680 aaacggatcc ccttgtggca gctgcagcag tgaattctgc ccttgcattt ggacaaggtc 1740 tggcagcagg catgccaggt tatccggtgt tggctcctgc tgcttactat gaccaaactg 1800 gtgcccttgt agtgaatgca ggcgcgagaa atggtcttgg agctcctgtt cgacttgtag 1860 ctcctgcccc agtcatcatt agttcctcag ctgcacaagc agctgttgca gcagccgcag 1920 cttcagcaaa tggagcagct ggtggtcttg ctggaacaac aaatggacca ttcgccctt 1980 taggaacaca gcagcctcag ccccagcccc agcagcagcc caataacaac ctggcatcca 2040 gttctttcta cggcaacaac tcttgaaca gcaattcaca gagcagctcc ctcttctccc 2100 agggctctgc ccagcctgcc aacacatcct tgggattcgg aagtagcagt tctctcggcg 2160 ccaccctggg atccgccctt ggagggtttg gaacagcagt tgcaaactcc aacactggca 2220 gtggctcccg ccgtgactcc ctgactggca gcagtgacct ttataagagg acatcgagca 2280 gcttgacccc cattggacac agtttttata acggccttag cttttcctcc tctcctggac 2340 ccgtgggcat gcctctccct agtcagggac caggacattc acagacacca cctccttccc 2400 tctcttcaca tggatcctct tcaagcttaa acctgggagg actcacgaat ggcagtggaa 2460 gatacatctc tgctgctcca ggcgctgaag ccaagtaccg cagtgcaagc agcgcctcca 2520 gcctcttcag cccgagcagc actcttttct cttcctctcg tttgcgatat ggaatgtctg 2580 atgtcatgcc ttctggcagg agcaggcttt tggaagattt tcgaaacaac cggtacccca 2640 atttacaact gcgggagatt gctggacata taatggaatt ttcccaagac cagcatgggt 2700 ccagattcat tcagctgaaa ctggagcgtg ccacaccagc tgagcgccag cttgtcttca 2760 atgaaatcct ccaggctgcc taccaactca tggtggatgt gtttggtaat tacgtcattc 2820 agaagttctt tgaatttggc agtcttgaac agaagctggc tttggcagaa cggattcgag gccacgtcct gtcattggca ctacagatgt atggctgccg tgttatccag aaagctcttg 2940 agtttattcc ttcagaccag caggtaatta atgagatggt tcgggaacta gatggccatg tcttgaagtg tgtgaaagat cagaatggca atcacgtggt tcagaaatgc attgaatgtg 3120. tacagcccca gtctttgcaa tttatcatcg atgcgtttaa gggacaggta tttgccttat ccacacatcc ttatggctgc cgagtgattc agagaatcct ggagcactgt ctccctgacc 3180. agcactccc tattttagag gagcttcacc agcacacaga gcagcttgta caggatcaat atggaaatta tgtaatccaa catgtactgg agcacggtcg tcctgaggat aaaagcaaaa ttgtagcaga aatccgaggc aatgtacttg tattgagtca gcacaaattt gcaagcaatg ttgtggagaa gtgtgttact cacgcctcac gtacggagcg cgctgtgctc atcgatgagg 3420 tgtgcaccat gaacgacggt ccccacagtg ccttatacac catgatgaag gaccagtatg ccaactacgt ggtccagaag atgattgacg tggcggagcc aggccagcgg aagatcgtca 3540. tgcataagat ccggccccac atcgcaactc ttcgtaagta cacctatggc aagcacattc 3600 tggccaagct ggagaagtac tacatgaaga acggtgttga cttagggccc atctgtggcc 3660 cccctaatgg tatcatctga ggcagtgtca cccgctgttc cctcattccc gctgacctca 3720 ctggcccact ggcaaatcca accagcaacc agaaatgttc tagtgtagag tctgagacgg 3780 gcaagtggtt gctccaggat tactccctcc tccaaaaaag gaatcaaatc cacgagtgga 3840 aaagcctttg taaatttaat tttattacac ataacatgta ctattttttt taattgacta 3900 attgccctgc tgttttactg gtgtatagga tacttgtaca taggtaacca atgtacatgg 3960 gaggccacat atttgttca ctgttgtatc tatatttcac atgtggaaac tttcagggtg 4020 gttggtttaa caaaaaaaa aagctttaaa aaaaaaagaa aaaaaggaaa aggtttttag 4080 ctcatttgcc tggccggcaa gttttgcaaa tagctcttcc ccacctcctc attttagtaa 4140 aaaacaaaca aaaacaaaaa aacctgagaa gtttgaattg tagttaaatg accccaaact 4200 ggcatttaac actgtttata aaaaatatat atatatatat atatatatat aatgaaaaag 4260 gtttcagagt tgctaaagct tcagtttgtg acattaagtt tatgaaattc taaaaaatgc cttttttgga gactatatta tgctgaagaa ggctgttcgt gaggagaga tgcgagcacc cagaacgtct tttgaggctg ggcgggtgtg attgtttact gcctactgga tttttttcta ttacattga aaggtaaat ctgattattt agcatgagaa aaaaaaatcc aactctgctt ttggtcttgc ttctaaat fathers tacttggtgt agactttgca fathers tttgtagtat tttcttgttt tgatgtctaa tctgtatcta taatgtaccc tagtagtcga acatactttt gattgtacaa ttgtacattt gtatacctgt aatgtaaatg tggagaagtt tgaatcaaca taacacgtt ttttggtaag aaaagagaat tagccagccc tgtgcattca gtgtatattc tcacctttta tggtcgtagc atatagtgtt gtatattgta aattgtaatt tcaaccagaa gtaaattttt ttcttttgaa ggaataaatg ttctttatac agcctagtta atgtttaaaa agaaaaaaat agcttggttt tatttgtcat ctagtctcaa gtatagcgag attctttcta aatgttattc aagattgagt tctcactagt gtttttttaa tcctaaaaaa gtaatgtttt gattttgtga cagtcaaaag gacgtgcaaa agtctagcct tgcccgagct 5040 ttccttacaa tcagagcccc tctcaccttg taaagtgtga atcgcccttc ccttttgtac 5100 agaagatgaa ctgtattttg cattttgtct acttgtaagt gaatgtaaca tactgtcaat 5160 tttccttgtt tgaataga attgtaacac tacacggtgt acatttccag agccttgtgt 5220 atatttccaa tgaacttttt tgcaagcaca cttgtaacca tatgtgtata attaacaaac 5280 ctgtgtatgc ttatgcctgg gcaactattt tttgtaactc ttgtgtagat tgtctctaaa 5340 caatgtgtga tctttatttt gaaaaataca gaactttgga atctgaaaaa aaaaaaaaa 5400 aaaaaaaaaaaaaa 5416 <210> 45 <211> 5410 <212> DNA <213> Homo sapiens <400> 45 agtgggccgc catgttgtcg gagtgaaagg taagggggag cgagagcgcc agagagagaa 60 gatcgggggg ctgaaatcca tcttcatcct accgctccgc ccgtgttggt ggaatgagcg 120 ttgcatgtgt cttgaagaga aaagcagtgc tttggcagga ctctttcagc ccccacctga 180 aacatcaccc tcaagaacca gctaatccca acatgcctgt tgttttgaca tctggaacag 240 ggtcgcaagc gcagccacaa ccagctgcaa atcaggctct tgcagctggg actcactcca 300 gccctgtccc aggatctata ggagttgcag gccgttccca ggacgacgct atggtggact 360 acttctttca gaggcagcat ggtgagcagc ttgggggagg aggaagtgga ggaggcggct 420 ataataatag caaacatcga tggcctactg gggataacat tcatgcagaa catcaggtgc 480 gttccatgga tgaactgaat catgattttc aagcacttgc tctggaggga agagcgatgg 540 gagagcagct cttgccaggt aaaaagtttt gggaaacaga tgaatccagc aaagatggac 600 caaaaggaat attcctgggt gatcaatggc gagacagtgc ctggggaaca tcagatcatt 660 cagtttccca gccaatcatg gtgcagagaa gacctggtca gagtttccat gtgaacagtg 720 aggtcaattc tgtactgtcc ccacgatcgg agagtggggg actaggcgtt agcatggtgg 780 agtatgtgtt gagctcatcc ccgggcgatt cctgtctaag aaaaggagga tttggcccaa 840 gggatgcaga cagtgatgaa aacgacaaag gtgaaaagaa gaacaagggt acgtttgatg 900 gagataagct aggagatttg aaggaggagg gtgatgtgat ggacaagacc aatggtttac cagtgcagaa tgggattgat gcagacgtca aagattttag ccgtacccct ggtaattgcc agaactctgc taatgaagtg gatcttctgg gtccaaacca gatggttct gagggcttag cccagctgac cagcaccaat ggtgccaagc ctgtggagga tttctccaac atggagtccc aggtgtccc cttggacccc atggaacatg tgggcatgga gcctcttcag tttgattatt caggcacgca ggtacctgtg caggcagcag cagcaactgt gggacttttt cactacaatt 1320. ctcaacaaca gctgttccaa agacctaatg cgcttgctgt ccagcagttg acagctgctc agcagcagca gtatgcactg gcagctgctc atcagccgca catcggttta gctcccgctg cgtttgtccc caatccatac atcatcagcg ctgctcccc agggacggac ccctacacag ctggattggc tgcagcagcg acactaggcc cagctgtggt ccctcaccag tattatggag ttactccctg gggagtctac cctgccagtc ttttccagca gcaagctgcc gctgccgctg cagcaacta ttcagctaat cacagacca ccccacaggc tcagcaagga cagcagcagg ttctccgtgg aggagccagc caacgtcctt tgaccccaaa ccagaaccag cagggacagc 1680 aaacggatcc ccttgtggca gctgcagcag tgaattctgc ccttgcattt ggacaaggtc 1740 tggcagcagg catgccaggt tatccggtgt tggctcctgc tgcttactat gaccaaactg 1800 gtgcccttgt agtgaatgca ggcgcgagaa atggtcttgg agctcctgtt cgacttgtag 1860 ctcctgcccc agtcatcatt agttcctcag ctgcacaagc agctgttgca gcagccgcag 1920 cttcagcaaa tggagcagct ggtggtcttg ctggaacaac aaatggacca tttcgccctt 1980 taggaacaca gcagcctcag ccccagcccc agcagcagcc caataacaac ctggcatcca 2040 gttctttcta cggcaacaac tctctgaaca gcaattcaca gagcagctcc ctcttctccc 2100 agggctctgc ccagcctgcc aacacatcct tgggattcgg aagtagcagt tctctcggcg 2160 ccaccctggg atccgccctt ggagggtttg gaacagcagt tgcaaactcc aacactggca 2220 gtggctcccg ccgtgactcc ctgactggca gcagtgacct ttataagagg acatcgagca 2280 gcttgacccc cattggacac agtttttata acggccttag cttttcctcc tctcctggac 2340 ccgtgggcat gcctctccct agtcagggac caggacattc acagacacca cctccttccc 2400 tctcttcaca tggatcctct tcaagcttaa acctgggagg actcacgaat ggcagtggaa 2460 gatacatctc tgctgctcca ggcgctgaag ccaagtaccg cagtgcaagc agcgcctcca 2520 gcctcttcag cccgagcagc actcttttct cttcctctcg tttgcgatat ggaatgtctg 2580 atgtcatgcc ttctggcagg agcaggcttt tggaagattt tcgaaacaac cggtacccca 2640 atttacaact gcgggagatt gctggacata taatggaatt ttcccaagac cagcatgggt 2700 ccagattcat tcagctgaaa ctggagcgtg ccacaccagc tgagcgccag cttgtcttca 2760 atgaaatcct ccaggctgcc taccaactca tggtggatgt gtttggtaat tacgtcattc 2820 agaagttctt tgaatttggc agtcttgaac agaagctggc tttggcagaa cggattcgag 2880 gccacgtcct gtcattggca ctacagatgt atggctgccg tgttatccag aaagctcttg 2940 agtttattcc ttcagaccag cagaatgaga tggttcggga actagatggc catgtcttga 3000 agtgtgtgaa agatcagaat ggcaatcacg tggttcagaa atgcattgaa tgtgtacagc 3060 cccagtcttt gcaatttatc atcgatgcgt ttaagggaca ggtatttgcc ttatccacac 3120 atccttatgg ctgccgagtg attcagagaa tcctggagca ctgtctccct gaccagacac 3180 tccctatttt agaggagctt caccagcaca cagagcagct tgtacaggat caatatggaa 3240 attatgtaat ccaacatgta ctggagcacg gtcgtcctga ggataaaagc aaaattgtag 3300 cagaaatccg aggcaatgta cttgtattga gtcagcacaa atttgcaagc aatgttgtgg 3360 agaagtgtgt tactcacgcc tcacgtacgg agcgcgctgt gctcatcgat gaggtgtgca 3420 ccatgaacga cggtccccac agtgccttat acaccatgat gaaggaccag tatgccaact 3480 acgtggtcca gaagatgatt gacgtggcgg agccaggcca gcggaagatc gtcatgcata 3540 agatccggcc ccacatcgca actcttcgta agtacaccta tggcaagcac attctggcca 3600 agctggagaa gtactacatg aagaacggtg ttgacttagg gcccatctgt ggccccccta 3660 atggtatcat ctgaggcagt gtcacccgct gttccctcat tcccgctgac ctcactggcc 3720 cactggcaaa tccaaccagc aaccagaaat gttctagtgt agagtctgag acgggcaagt 3780 ggttgctcca ggattactcc ctcctccaaa aaggaatca atccacgag tggaaagcc 3840 tttgtaaattt taatttatt acacataca tgtactattt ttttaattg actaattgcc 3900 ctgctgtttt actgtgtat aggatacttg tacataggta accaatgtac atgggaggcc 3960 acatattttg ttcactgttg tatctatatt tcacatgtgg aactttcag ggtggttggt 4020 ttaaaaaaaaaaaagctt taaaaaaaaaaaaaaag gaaaggtttt ttagctcatt 4080 tgcctgccg gcaagttttg caatagctc ttcccacct cctcatttta gtaaaaaaca 4140 aaaaaaaaaaaaacctg agaagtttga attgtagtta atgacccca aactggcatt 4200 taacactgtt taaaaaaat attattattattattattattattaatga aaggttttca 4260 gagttgctaa agcttcagtt tgtgacatta agtttagaa attctaaaaa atgccttttt 4320 tggagactat attatgctga agaagctgt tcgtgaggag gagatgcgag cacccagaac 4380 gtcttttgag gctgggcggg tgtgattgtt tactgcctac tggatttt tctattaaca 4440 ttgaaaggta aaatctgatt atttagcatg agaaaaaaaa atccactct gctttggtc 4500 4560 gtattttctt gttttgatgt ctaatctgta tctataatgt accctagtag tcgaacatac 4620 ttttgattgt acaattgtac atttgtatac ctgtaatgta aatgtggaga agtttgaatc 4680 aacataaaca cgttttttgg taagaaaaga gaattagcca gccctgtgca ttcagtgtat 4740 attctcacct tttatggtcg tagcatatag tgttgtatat tgtaaattgt aatttcaacc 4800 4860 aaaaagaaaa aaatagcttg gttttatttg tcatctagtc tcaagtatag cgagattctt 4920 tctaaatgtt attcaagatt gagttctcac tagtgttttt ttaatcctaa aaaagtaatg 4980 ttttgatttt gtgacagtca aaaggacgtg caaaagtcta gccttgcccg agctttcctt 5040 aaatcagag cccctctcac cttgtaaagt gtgaatcgcc cttccctttt gtacaagaaga 5100 tgaactgtat tttgcatttt gtctacttgt aagtgaatgt aacatactgt caattttcct 5160 tgtttgaata tagaattgta acactacacg gtgtacattt ccagagcctt gtgtatattt 5220 ccaatgaact ttttgcaag cacacttgta accatatgtg tataattaac aaacctgtgt 5280 atgcttatgc ctgggcaact atttttgta actcttgtgt agattgtctc taaacaatgt 5340 gtgatcttta tttgaaaaa tacagaactt tggaatctga aaaaaaaaa aaaaaaaaa 5400 aaaaaaaaaa 5410 <210> 46 <211> 1188 <212> PRT <213> Homo sapiens <400> 46 Met Ser Val Ala Cys Val Leu Lys Arg Lys Ala Val Leu Trp Gln Asp 1 5 10 15 Ser Phe Ser Pro His Leu Lys His His Pro Gln Glu Pro Ala Asn Pro 20 25 30 Asn Met Pro Val Val Leu Thr Ser Gly Thr Gly Ser Gln Ala Gln Pro 35 40 45 Gln Pro Ala Ala Donkey Gln Ala Leu Ala Ala Gly Thr His Dear Dear Pro 50 55 60 Val Pro Gly Ser Ile Gly Val Ala Gly Arg Ser Gln Asp Asp Ala Met 65 70 75 80 Val Asp Tyr Phe Phe Gln Arg Gln His Gly Glu Gln Leu Gly Gly Gly 85 90 95 Gly Ser Gly Gly Gly Gly Tyr Asn Asn Ser Lys His Arg Trp Pro Thr 100 105 110 Gly Asp Asn Ile His Ala Glu His Gln Val Arg Ser Met Asp Glu Leu 115 120 125 Asn His Asp Phe Gln Ala Leu Ala Leu Glu Gly Arg Ala Met Gly Glu 130 135 140 Gln Leu Leu Pro Gly Lys Lys Phe Trp Glu Thr Asp Glu Ser Ser Lys 145 150 155 160 Asp Gly Pro Lys Gly Ile Phe Leu Gly Asp Gln Trp Arg Asp Ser Ala 165 170 175 Trp Gly Thr Ser Asp His Ser Val Ser Gln Pro Ile Met Val Gln Arg 180 185 190 Arg Pro Gly Gln Ser Phe His Val Asn Ser Glu Val Asn Ser Val Leu 195 200 205 Ser Pro Arg Ser Glu Ser Gly Gly Leu Gly Val Ser Met Val Glu Tyr 210 215 220 Val Leu Ser Ser Ser Pro Gly Asp Ser Cys Leu Arg Lys Gly Gly Phe 225 230 235 240 Gly Pro Arg Asp Ala Asp Ser Asp Glu Asn Asp Lys Gly Glu Lys Lys 245 250 255 Asn Lys Gly Thr Phe Asp Gly Asp Lys Leu Gly Asp Leu Lys Glu Glu 260 265 270 Gly Asp Val Met Asp Lys Thr Asn Gly Leu Pro Val Gln Asn Gly Ile 275 280 285 Asp Ala Asp Val Lys Asp Phe Ser Arg Thr Pro Gly Asn Cys Gln Asn 290 295 300 Ser Ala Asn Glu Val Asp Leu Leu Gly Pro Asn Gln Asn Gly Ser Glu 305 310 315 320 Gly Leu Ala Gln Leu Thr Ser Thr Asn Gly Ala Lys Pro Val Glu Asp 325 330 335 Phe Ser Asn Met Glu Ser Gln Ser Val Pro Leu Asp Pro Met Glu His 340 345 350 Val Gly Met Glu Pro Leu Gln Phe Asp Tyr Ser Gly Thr Gln Val Pro 355 360 365 Val Asp Ser Ala Ala Ala Thr Val Gly Leu Phe Asp Tyr Asn Ser Gln 370 375 380 Gln Gln Leu Phe Gln Arg Pro Asn Ala Leu Ala Val Gln Gln Leu Thr 385 390 395 400 Ala Ala Gln Gln Gln Gln Tyr Ala Leu Ala Ala Ala His Gln Pro His 405 410 415 Ile Gly Leu Ala Pro Ala Ala Phe Val Pro Asn Pro Tyr Ile Ile Ser 420 425 430 Ala Ala Pro Pro Gly Thr Asp Pro Tyr Thr Ala Gly Leu Ala Ala Ala 435 440 445 Ala Thr Leu Gly Pro Ala Val Val Pro His Gln Tyr Tyr Gly Val Thr 450 455 460 Pro Trp Gly Val Tyr Pro Ala Ser Leu Phe Gln Gln Gln Ala Ala Ala 465 470 475 480 Ala Ala Ala Ala Thr Asn Ser Ala Asn Gln Gln Thr Thr Pro Gln Ala 485 490 495 Gln Gln Gly Gln Gln Gln Val Leu Arg Gly Gly Ala Ser Gln Arg Pro 500 505 510 Leu Thr Pro Asn Gln Asn Gln Gln Gly Gln Gln Thr Asp Pro Leu Val 515 520 525 Ala Ala Ala Ala Val Asn Ser Ala Leu Ala Phe Gly Gln Gly Leu Ala 530 535 540 Path Gly Met Pro Gly Tyr Pro Val Leu Path Pro Path Path Tyr Tyr Asp 545 550 555 560 Gln Thr Gly Ala Leu Val Val Asn Ala Gly Ala Arg Asn Gly Leu Gly 565 570 575 Ala Pro Val Arg Leu Val Ala Pro Ala Pro Val Ile Ile Ser Ser Ser 580 585 590 Ala Ala Gln Ala Ala Val Ala Ala Ala Ala Ala Ser Ala Asn Gly Ala 595 600 605 Ala Gly Gly Leu Ala Gly Thr Thr Asn Gly Pro Phe Arg Pro Leu Gly 610 615 620 Thr Gln Gln Pro Gln Pro Gln Pro Gln Gln Gln Pro Asn Asn Asn Leu 625 630 635 640 Ala Ser Ser Ser Phe Tyr Gly Asn Asn Ser Leu Asn Ser Asn Ser Gln 645 650 655 Ser Ser Ser Leu Phe Ser Gln Gly Ser Ala Gln Pro Ala Asn Thr Ser 660 665 670 Leu Gly Phe Gly Ser Ser Ser Ser Leu Gly Ala Thr Leu Gly Ser Ala 675 680 685 Leu Gly Gly Phe Gly Thr Ala Val Ala Asn Ser Asn Thr Gly Ser Gly 690 695 700 Ser Arg Arg Asp Ser Leu Thr Gly Ser Ser Asp Leu Tyr Lys Arg Thr 705 710 715 720 Ser Ser Ser Leu Thr Pro Ile Gly His Ser Phe Tyr Asn Gly Leu Ser 725 730 735 Phe Ser Ser Ser Pro Gly Pro Val Gly Met Pro Leu Pro Ser Gln Gly 740 745 750 Pro Gly His Ser Gln Thr Pro Pro Pro Ser Leu Ser Ser His Gly Ser 755 760 765 Ser Ser Ser Leu Asn Leu Gly Gly Leu Thr Asn Gly Ser Gly Arg Tyr 770 775 780 Ile Ser Ala Ala Pro Gly Ala Glu Ala Lys Tyr Arg Ser Ala Ser Ser 785 790 795 800 Ala Ser Ser Leu Phe Ser Pro Ser Ser Thr Leu Phe Ser Ser Ser Arg 805 810 815 Leu Arg Tyr Gly Met Ser Asp Val Met Pro Ser Gly Arg Ser Arg Leu 820 825 830 Leu Glu Asp Phe Arg Asn Asn Arg Tyr Pro Asn Leu Gln Leu Arg Glu 835 840 845 Ile Ala Gly His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser Arg 850 855 860 Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro Ala Glu Arg Gln Leu 865 870 875 880 Val Phe Asn Glu Ile Leu Gln Ala Ala Tyr Gln Leu Met Val Asp Val 885 890 895 Phe Gly Asn Tyr Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu Glu 900 905 910 Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His Val Leu Ser Leu 915 920 925 Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys Ala Leu Glu Phe 930 935 940 Ile Pro Ser Asp Gln Gln Val Ile Asn Glu Met Val Arg Glu Leu Asp 945 950 955 960 Gly His Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His Val Val 965 970 975 Gln Lys Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe Ile Ile 980 985 990 Asp Ala Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly 995 1000 1005 Cys Arg Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro Asp Gln 1010 1015 1020 Thr Leu Pro Ile Leu Glu Glu Leu His Gln His Thr Glu Gln Leu 1025 1030 1035 Val Gln Asp Gln Tyr Gly Asn Tyr Val Ile Gln His Val Leu Glu 1040 1045 1050 His Gly Arg Pro Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg 1055 1060 1065 Gly Asn Val Leu Val Leu Ser Gln His Lys Phe Ala Ser Asn Val 1070 1075 1080 Val Glu Lys Cys Val Thr His Ala Ser Arg Thr Glu Arg Ala Val 1085 1090 1095 Leu Ile Asp Glu Val Cys Thr Met Asn Asp Gly Pro His Ser Ala 1100 1105 1110 Leu Tyr Thr Met Met Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln 1115 1120 1125 Lys Met Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile Val Met 1130 1135 1140 His Lys Ile Arg Pro His Ile Ala Thr Leu Arg Lys Tyr Thr Tyr 1145 1150 1155 Gly Lys His Ile Leu Ala Lys Leu Glu Lys Tyr Tyr Met Lys Asn 1160 1165 1170 Gly Val Asp Leu Gly Pro Ile Cys Gly Pro Pro Asn Gly Ile Ile 1175 1180 1185 <210> 47 <211> 1186 <212> PRT <213> Homo sapiens <400> 47 Met Ser Val Ala Cys Val Leu Lys Arg Lys Ala Val Leu Trp Gln Asp 1 5 10 15 Ser Phe Ser Pro His Leu Lys His His Pro Gln Glu Pro Ala Asn Pro 20 25 30 Asn Met Pro Val Val Leu Thr Ser Gly Thr Gly Ser Gln Ala Gln Pro 35 40 45 Gln Pro Ala Ala Asn Gln Ala Leu Ala Ala Gly Thr His Ser Ser Pro 50 55 60 Val Pro Gly Ser Ile Gly Val Ala Gly Arg Ser Gln Asp Asp Ala Met 65 70 75 80 Val Asp Tyr Phe Phe Gln Arg Gln His Gly Glu Gln Leu Gly Gly Gly 85 90 95 Gly Ser Gly Gly Gly Gly Tyr Asn Asn Ser Lys His Arg Trp Pro Thr 100 105 110 Gly Asp Asn Ile His Ala Glu His Gln Val Arg Ser Met Asp Glu Leu 115 120 125 Asn His Asp Phe Gln Ala Leu Ala Leu Glu Gly Arg Ala Met Gly Glu 130 135 140 Gln Leu Leu Pro Gly Lys Lys Phe Trp Glu Thr Asp Glu Ser Ser Lys 145 150 155 160 Asp Gly Pro Lys Gly Ile Phe Leu Gly Asp Gln Trp Arg Asp Ser Ala 165 170 175 Trp Gly Thr Ser Asp His Ser Val Ser Gln Pro Ile Met Val Gln Arg 180 185 190 Arg Pro Gly Gln Ser Phe His Val Asn Ser Glu Val Asn Ser Val Leu 195 200 205 Ser Pro Arg Ser Glu Ser Gly Gly Leu Gly Val Ser Met Val Glu Tyr 210 215 220 Val Leu Ser Ser Ser Pro Gly Asp Ser Cys Leu Arg Lys Gly Gly Phe 225 230 235 240 Gly Pro Arg Asp Ala Asp Ser Asp Glu Asn Asp Lys Gly Glu Lys Lys 245 250 255 Asn Lys Gly Thr Phe Asp Gly Asp Lys Leu Gly Asp Leu Lys Glu Glu 260 265 270 Gly Asp Val Met Asp Lys Thr Asn Gly Leu Pro Val Gln Asn Gly Ile 275 280 285 Asp Ala Asp Val Lys Asp Phe Ser Arg Thr Pro Gly Asn Cys Gln Asn 290 295 300 Ser Ala Asn Glu Val Asp Leu Leu Gly Pro Asn Gln Asn Gly Ser Glu 305 310 315 320 Gly Leu Ala Gln Leu Thr Ser Thr Asn Gly Ala Lys Pro Val Glu Asp 325 330 335 Phe Ser Asn Met Glu Ser Gln Ser Val Pro Leu Asp Pro Met Glu His 340 345 350 Val Gly Met Glu Pro Leu Gln Phe Asp Tyr Ser Gly Thr Gln Val Pro 355 360 365 Val Asp Ser Ala Ala Ala Thr Val Gly Leu Phe Asp Tyr Asn Ser Gln 370 375 380 Gln Gln Leu Phe Gln Arg Pro Asn Ala Leu Ala Val Gln Gln Leu Thr 385 390 395 400 Ala Ala Gln Gln Gln Gln Tyr Ala Leu Ala Ala Ala His Gln Pro His 405 410 415 Ile Gly Leu Ala Pro Ala Ala Phe Val Pro Asn Pro Tyr Ile Ile Ser 420 425 430 Ala Ala Pro Pro Gly Thr Asp Pro Tyr Thr Ala Gly Leu Ala Ala Ala 435 440 445 Ala Thr Leu Gly Pro Ala Val Val Pro His Gln Tyr Tyr Gly Val Thr 450 455 460 Pro Trp Gly Val Tyr Pro Ala Ser Leu Phe Gln Gln Gln Ala Ala Ala 465 470 475 480 Ala Ala Ala Ala Thr Asn Ser Ala Asn Gln Gln Thr Thr Pro Gln Ala 485 490 495 Gln Gln Gly Gln Gln Gln Val Leu Arg Gly Gly Ala Ser Gln Arg Pro 500 505 510 Leu Thr Pro Asn Gln Asn Gln Gln Gly Gln Gln Thr Asp Pro Leu Val 515 520 525 Ala Ala Ala Ala Val Asn Ser Ala Leu Ala Phe Gly Gln Gly Leu Ala 530 535 540 Path Gly Met Pro Gly Tyr Pro Val Leu Path Pro Path Path Tyr Tyr Asp 545 550 555 560 Gln Thr Gly Ala Leu Val Val Asn Ala Gly Ala Arg Asn Gly Leu Gly 565 570 575 Path Pro Val Arg Leu Val Path Pro Path Pro Val Ile Ile Ser Ser Ser 580 585 590 Ala Ala Gln Ala Ala Val Ala Ala Ala Ala Ser Ala Asn Gly Ala 595 600 605 Ala Gly Gly Leu Ala Gly Thr Thr Asn Gly Pro Phe Arg Pro Leu Gly 610 615 620 Thr Gln Gln Pro Gln Pro Gln Pro Gln Gln Gln Pro Asn Asn Asn Leu 625 630 635 640 Ala Ser Ser Ser Phe Tyr Gly Asn Asn Ser Leu Asn Ser Asn Ser Gln 645 650 655 Ser Ser Ser Leu Phe Ser Gln Gly Ser Ala Gln Pro Ala Asn Thr Ser 660 665 670 Leu Gly Phe Gly Ser Ser Ser Ser Leu Gly Ala Thr Leu Gly Ser Ala 675 680 685 Leu Gly Gly Phe Gly Thr Ala Val Ala Asn Ser Asn Thr Gly Ser Gly 690 695 700 Ser Arg Arg Asp Ser Leu Thr Gly Ser Ser Asp Leu Tyr Lys Arg Thr 705 710 715 720 Ser Ser Ser Leu Thr Pro Ile Gly His Ser Phe Tyr Asn Gly Leu Ser 725 730 735 Phe Ser Ser Ser Pro Gly Pro Val Gly Met Pro Leu Pro Ser Gln Gly 740 745 750 Pro Gly His Ser Gln Thr Pro Pro Pro Ser Leu Ser Ser His Gly Ser 755 760 765 Ser Ser Ser Leu Asn Leu Gly Gly Leu Thr Asn Gly Ser Gly Arg Tyr 770 775 780 Ile Ser Ala Ala Pro Gly Ala Glu Ala Lys Tyr Arg Ser Ala Ser Ser 785 790 795 800 Ala Ser Ser Leu Phe Ser Pro Ser Ser Thr Leu Phe Ser Ser Ser Arg 805 810 815 Leu Arg Tyr Gly Met Ser Asp Val Met Pro Ser Gly Arg Ser Arg Leu 820 825 830 Leu Glu Asp Phe Arg Asn Asn Arg Tyr Pro Asn Leu Gln Leu Arg Glu 835 840 845 Ile Ala Gly His Ile Met Glu Phe Ser Gln Asp Gln His Gly Ser Arg 850 855 860 Phe Ile Gln Leu Lys Leu Glu Arg Ala Thr Pro Ala Glu Arg Gln Leu 865 870 875 880 Val Phe Asn Glu Ile Leu Gln Ala Ala Tyr Gln Leu Met Val Asp Val 885 890 895 Phe Gly Asn Tyr Val Ile Gln Lys Phe Phe Glu Phe Gly Ser Leu Glu 900 905 910 Gln Lys Leu Ala Leu Ala Glu Arg Ile Arg Gly His Val Leu Ser Leu 915 920 925 Ala Leu Gln Met Tyr Gly Cys Arg Val Ile Gln Lys Ala Leu Glu Phe 930 935 940 Ile Pro Ser Asp Gln Gln Asn Glu Met Val Arg Glu Leu Asp Gly His 945 950 955 960 Val Leu Lys Cys Val Lys Asp Gln Asn Gly Asn His Val Val Gln Lys 965 970 975 Cys Ile Glu Cys Val Gln Pro Gln Ser Leu Gln Phe Ile Ile Asp Ala 980 985 990 Phe Lys Gly Gln Val Phe Ala Leu Ser Thr His Pro Tyr Gly Cys Arg 995 1000 1005 Val Ile Gln Arg Ile Leu Glu His Cys Leu Pro Asp Gln Thr Leu 1010 1015 1020 Pro Ile Leu Glu Glu Leu His Gln His Thr Glu Gln Leu Val Gln 1025 1030 1035 Asp Gln Tyr Gly Asn Tyr Val Ile Gln His Val Leu Glu His Gly 1040 1045 1050 Arg Pro Glu Asp Lys Ser Lys Ile Val Ala Glu Ile Arg Gly Asn 1055 1060 1065 Val Leu Val Leu Ser Gln His Lys Phe Ala Ser Asn Val Val Glu 1070 1075 1080 Lys Cys Val Thr His Ala Ser Arg Thr Glu Arg Ala Val Leu Ile 1085 1090 1095 Asp Glu Val Cys Thr Met Asn Asp Gly Pro His Ser Ala Leu Tyr 1100 1105 1110 Thr Met Met Lys Asp Gln Tyr Ala Asn Tyr Val Val Gln Lys Met 1115 1120 1125 Ile Asp Val Ala Glu Pro Gly Gln Arg Lys Ile Val Met His Lys 1130 1135 1140 Ile Arg Pro His Ile Ala Thr Leu Arg Lys Tyr Thr Tyr Gly Lys 1145 1150 1155 His Ile Leu Ala Lys Leu Glu Lys Tyr Tyr Met Lys Asn Gly Val 1160 1165 1170 Asp Leu Gly Pro Ile Cys Gly Pro Pro Asn Gly Ile Ile 1175 1180 1185 <210> 48 <211> 22 <212> DNA <213> Artificial Sequence <220> <223> PUM1_forward primer <400> 48 gccagcttgt cttcaatgaa at 22 <210> 49 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> PUM1_reverse primer <400> 49 caaagccagc ttctgttcaa g 21 <210> 50 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> PUM1 probe <400> 50 atccaccatg agttggtagg cagc 24 <210> 51 <211> 1921 <212> DNA <213> Homo sapiens <400> 51 ggcggaagtg acattatcaa cgcgcgccag gggttcagtg aggtcgggca ggttcgctgt 60 ggcgggcgcc tgggccgccg gctgtttaac ttcgcttccg ctggcccata gtgatctttg 120 cagtgaccca gcatcactgt ttcttggcgt gtgaagataa cccaaggaat tgaggaagtt 180 gctgagaaga gtgtgctgga gatgctctag gaaaaaattg aatagtgaga cgagttccag 240 cgcaagggtt tctggtttgc caagaagaaa gtgaacatca tggatcagaa caacagcctg 300 ccaccttacg ctcagggctt ggcctcccct cagggtgcca tgactccccgg aatccctatc 360 tttagtccaa tgatgcctta tggcactgga ctgaccccac agcctattca gaacaccaat 420 agtctgtcta ttttggaa gcaacaaagg cagcagcagc aacaacaaca gcagcagcag 480 540 cagcagcagc agcagcagca acaggcagtg gcagctgcag ccgttcagca gtcaacgtcc 600 cagcaggcaa cagggaac ctcaggccag gcaccacagc tcttccactc agagactctc 660 acaactgcac ccttgccggg caccactcca ctgtatccct cccccatgac tcccatgacc 720 cccatcactc ctgccacgcc agcttcggag agttctggga ttgtaccgca gctccaaaat 780 attgtatcca cagtgaatct tggttgtaaa cttgacctaa agaccattgc acttcgtgcc 840 cgaaacgccg aatataatcc caagcggttt gctgcggtaa tcatgaggat aagagagcca 900 cgaaccacgg cactgatttt cagttctggg aaaatggtgt gcacaggagc caagagtgaa 960 gaacagtcca gactggcagc aagaaaatat gctagagttg tacagaagtt gggtttcca 1020 gctaagttct tggacttcaa gattcagaat atggtgggga gctgtgatgt gaagtttcct 1080 ataaggttag aaggccttgt gctcacccac caacaattta gtagttatga gccagagtta 1140 tttcctggtt taatctacag aatgatcaaa cccagaattg ttctccttat ttttgtttct 1200 ggaaaagttg tattaacagg tgctaaagtc agagcagaaa tttatgaagc atttgaaaac 1260 atctacccta ttctaaaggg attcaggaag acgacgtaat ggctctcatg tacccttgcc 1320 tcccccaccc ccttcttttt ttttttttaa acaaatcagt ttgttttggt acctttaaat 1380 ggtggtgttg tgagaagatg gatgttgagt tgcagggtgt ggcaccaggt gatgcccttc 1440 tgtaagtgcc caccgcggga tgccgggaag gggcattatt tgtgcactga gaacaccgcg 1500 cagcgtgact gtgagttgct cataccgtgc tgctatctgg gcagcgctgc ccatttattt 1560 atatgtagat tttaaacact gctgttgaca agttggtttg agggagaaaa ctttaagtgt 1620 taaagccacc tctataattg attggacttt ttaattttaa tgtttttccc catgaaccac 1680 agtttttata tttctaccag aaaagtaaaa atctttttta aaagtgttgt ttttctaatt 1740 tataactcct aggggttatt tctgtgccag acacattcca cctctccagt attgcaggac 1800 agaatatatg tgttaatgaa aatgaatggc tgtacatatt ttttctttc ttcagagtac 1860 tctgtacaat aaatgcagtt tataaaagtg ttagattgtt gttaaaaaaa aaaaaaaaa 1920 in 1921 <210> 52 <211> 339 <212> PRT <213> Homo sapiens <400> 52 Put Asp Gln Donkey Donkey Ser Leu Pro Pro Tyr Ala Gln Gly Leu Ala Ser 1 5 10 15 Pro Gln Gly Ala Met Thr Pro Gly Ile Pro Ile Phe Ser Pro Met Met 20 25 30 Pro Tyr Gly Thr Gly Leu Thr Pro Gln Pro Ile Gln Asn Thr Asn Ser 35 40 45 Leu Ser Ile Leu Glu Glu Gln Gln Arg Gln Gln Gln Gln Gln Gln Gln 50 55 60 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln 65 70 75 80 Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Gln Ala 85 90 95 Val Ala Ala Ala Ala Val Gln Gln Ser Thr Ser Gln Gln Ala Thr Gln 100 105 110 Gly Thr Ser Gly Gln Ala Pro Gln Leu Phe His Ser Gln Thr Leu Thr 115 120 125 Thr Ala Pro Leu Pro Gly Thr Thr Pro Leu Tyr Pro Ser Pro Met Thr 130 135 140 Pro Met Thr Pro Ile Thr Pro Ala Thr Pro Ala Ser Glu Ser Ser Gly 145 150 155 160 Ile Val Pro Gln Leu Gln Asn Ile Val Ser Thr Val Asn Leu Gly Cys 165 170 175 Lys Leu Asp Leu Lys Thr Ile Ala Leu Arg Ala Arg Asn Ala Glu Tyr 180 185 190 Asn Pro Lys Arg Phe Ala Ala Val Ile Met Arg Ile Arg Glu Pro Arg 195 200 205 Thr Thr Ala Leu Ile Phe Ser Ser Gly Lys Met Val Cys Thr Gly Ala 210 215 220 Lys Ser Glu Glu Gln Ser Arg Leu Ala Ala Arg Lys Tyr Ala Arg Val 225 230 235 240 Val Gln Lys Leu Gly Phe Pro Ala Lys Phe Leu Asp Phe Lys Ile Gln 245 250 255 Asn Met Val Gly Ser Cys Asp Val Lys Phe Pro Ile Arg Leu Glu Gly 260 265 270 Leu Val Leu Thr His Gln Gln Phe Ser Ser Tyr Glu Pro Glu Leu Phe 275 280 285 Pro Gly Leu Ile Tyr Arg Met Ile Lys Pro Arg Ile Val Leu Leu Ile 290 295 300 Phe Val Ser Gly Lys Val Val Leu Thr Gly Ala Lys Val Arg Ala Glu 305 310 315 320 Ile Tyr Glu Ala Phe Glu Asn Ile Tyr Pro Ile Leu Lys Gly Phe Arg 325 330 335 Lys Thr Thr <210> 53 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> TBP_forward primer <400> 53 gccaagaaga aagtgaacat cat 23 <210> 54 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> TBP_reverse primer <400> 54 atagggattc cgggagtcat 20 <210> 55 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> TBP probe <400> 55 tcagaacaac agcctgccac ctta <210> 56 <211> 1852 <212> DNA <213> Homo sapiens <400> 56 accgccgaga ccgcgtccgc cccgcgagca cagagcctcg cctttgccga tccgccgccc gtccacaccc gccgccagct caccatggat gatgatatcg ccgcgctcgt cgtcgacaac ggctccggca tgtgcaaggc cggcttcgcg ggcgacgatg ccccccgggc cgtcttcccc 180 tccatcgtgg ggcgccccag gcaccagggc gtgatggtgg gcatgggtca gaaggattcc 240 tatgtgggcg acgaggccca gagcaagaga ggcatcctca ccctgaagta ccccatcgag 300 360. ccggcatcg tcaccaactg ggacgacatg gagaaaatct ggcaccacac cttctacaat gagctgcgtg tggctcccga ggagcacccc gtgctgctga ccgaggcccc cctgaacccc 420 aaggccaacc gcgagaagat gacccagatc atgtttgaga ccttcaacac cccagccatg 480 tacgttgcta tccaggctgt gctatccctg tacgcctctg gccgtaccac tggcatcgtg 540 atggactccg gtgacggggt cacccacact gtgcccatct acgaggggta tgccctcccc 600 catgccatcc tgcgtctgga cctggctggc cgggacctga ctgactacct catgaagatc 660 ctcaccgagc gcggctacag cttcaccacc acggccgagc gggaaatcgt gcgtgacatt 720 aaggagaagc tgtgctacgt cgccctggac ttcgagcaag agatggccac ggctgcttcc 780 agctcctccc tggagaagag ctacgagctg cctgacggcc aggtcatcac cattggcaat 840 gagcggttcc gctgccctga ggcactcttc cagccttcct tcctgggcat ggagtcctgt 900 ggcatccacg aaactacctt caactccatc atgaagtgtg acgtggacat ccgcaaagac 960 ctgtacgcca acacagtgct gtctggcggc accaccatgt accctggcat tgccgacagg 1020 atgcagaagg agatcactgc cctggcaccc agcacaatga agatcaagat cattgctcct 1080 cctgagcgca agtactccgt gtggatcggc ggctccatcc tggcctcgct gtccaccttc 1140 cagcagatgt ggatcagcaa gcaggagtat gacgagtccg gcccctccat cgtccaccgc 1200 aaatgcttct aggcggacta tgacttagtt gcgttacacc ctttcttgac aaaacctaac 1260 ttgcgcagaa aacaagatga gattggcatg gctttatttg ttttttttgt tttgttttgg 1320 tttttttttt ttttggct tgactcagga tttaaaaact ggaacggtga aggtgacagc 1380 agtcggttgg agcgagcatc ccccaaagtt cacaatgtgg ccgaggactt tgattgcaca 1440 ttgttgtttt tttaatagtc attccaaata tgagatgcgt tgttacagga agtcccttgc 1500 catcctaaaa gccaccccac ttctctctaa ggagaatggc ccagtcctct cccaagtcca 1560 cacaggggag gtgatagcat tgctttcgtg taaattatgt aatgcaaaat ttttttaatc 1620 ttcgccttaa tactttttta ttttgtttta ttttgaatga tgagccttcg tgccccccct 1680 tcccccttt ttgtccccca acttgagatg tatgaaggct tttggtctcc ctgggagtgg 1740 gtggaggcag ccagggctta cctgtacact gacttgagac cagttgaata aaagtgcaca 1800 cttaaaaat gaaaaaaaaa aaaaaaaaa aaaaaaaaaa aaaaaaaaa aa 1852 <210> 57 <211> 375 <212> PRT <213> Homo sapiens <400> 57 Met Asp Asp Asp Ile Ala Ala Leu Val Val Asp Asn Gly Ser Gly Met 1 5 10 15 Cys Lys Ala Gly Phe Ala Gly Asp Asp Ala Pro Arg Ala Val Phe Pro 20 25 30 Ser Ile Val Gly Arg Pro Arg His Gln Gly Val Met Val Gly Met Gly 35 40 45 Gln Lys Asp Ser Tyr Val Gly Asp Glu Ala Gln Ser Lys Arg Gly Ile 50 55 60 Leu Thr Leu Lys Tyr Pro Ile Glu His Gly Ile Val Thr Asn Trp Asp 65 70 75 80 Asp Met Glu Lys Ile Trp His His Thr Phe Tyr Asn Glu Leu Arg Val 85 90 95 Ala Pro Glu Glu His Pro Val Leu Leu Thr Glu Ala Pro Leu Asn Pro 100 105 110 Lys Ala Asn Arg Glu Lys Met Thr Gln Ile Met Phe Glu Thr Phe Asn 115 120 125 Thr Pro Ala Met Tyr Val Ala Ile Gln Ala Val Leu Ser Leu Tyr Ala 130 135 140 Ser Gly Arg Thr Thr Gly Ile Val Met Asp Ser Gly Asp Gly Val Thr 145 150 155 160 His Thr Val Pro Ile Tyr Glu Gly Tyr Ala Leu Pro His Ala Ile Leu 165 170 175 Arg Leu Asp Leu Ala Gly Arg Asp Leu Thr Asp Tyr Leu Met Lys Ile 180 185 190 Leu Thr Glu Arg Gly Tyr Ser Phe Thr Thr Thr Ala Glu Arg Glu Ile 195 200 205 Val Arg Asp Ile Lys Glu Lys Leu Cys Tyr Val Ala Leu Asp Phe Glu 210 215 220 Gln Glu Met Ala Thr Ala Ala Ser Ser Ser Ser Leu Glu Lys Ser Tyr 225 230 235 240 Glu Leu Pro Asp Gly Gln Val Ile Thr Ile Gly Asn Glu Arg Phe Arg 245 250 255 Cys Pro Glu Ala Leu Phe Gln Pro Ser Phe Leu Gly Met Glu Ser Cys 260 265 270 Gly Ile His Glu Thr Thr Phe Asn Ser Ile Met Lys Cys Asp Val Asp 275 280 285 Ile Arg Lys Asp Leu Tyr Ala Asn Thr Val Leu Ser Gly Gly Thr Thr 290 295 300 Met Tyr Pro Gly Ile Ala Asp Arg Met Gln Lys Glu Ile Thr Ala Leu 305 310 315 320 Ala Pro Ser Thr Met Lys Ile Lys Ile Ile Ala Pro Pro Glu Arg Lys 325 330 335 Tyr Ser Val Trp Ile Gly Gly Ser Ile Leu Ala Ser Leu Ser Thr Phe 340 345 350 Gln Gln Met Trp Ile Ser Lys Gln Glu Tyr Asp Glu Ser Gly Pro Ser 355 360 365 Ile Val His Arg Lys Cys Phe 370 375 <210> 58 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> ACTB_forward primer <400> 58 ccaaccgcga gaagatga 18 <210> 59 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> ACTB_reverse primer <400> 59 ccagaggcgt acagggatag 20 <210> 60 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> ACTB probe <400> 60 ccatgtacgt tgctatccag gct 23 <210> 61 <211> 1229 <212> DNA <213> Homo sapiens <400> 61 gtctgacggg cgatggcgca gccaatagac aggagcgcta tccgcggttt ctgattggct 60 actttgtcg cattataaaa ggcacgcgcg ggcgcgaggc cctctctcg ccaggcgtcc 120 tcgtggaagt gacatcgtct ttaaaccctg cgtggcaatc cctgacgcac cgccgtgatg 180 cccagggaag acagggcgac ctggaagtcc aactacttcc ttaagatcat ccaactattg 240 gatgattatc cgaaatgttt cattgtggga gcagacaatg tgggctccaa gcagatgcag 300 cagatccgca tgtcccttcg cgggaaggct gtggtgctga tgggcaagaa caccatgatg 360 cgcaaggcca tccgagggca cctggaaaac aacccagctc tggagaaact gctgcctcat 420 atccggggga atgtgggctt tgtgttcacc aaggaggacc tcactgagat cagggacatg 480 ttgctggcca ataaggtgcc agctgctgcc cgtgctggtg ccattgcccc atgtgaagtc 540 actgtgccag cccagaacac tggtctcggg cccgagaaga cctccttttt ccaggcttta 600 ggtatcacca ctaaaatctc caggggcacc attgaaatcc tgagtgatgt gcagctgatc 660 aagactggag acaaagtggg agccagcgaa gccacgctgc tgaacatgct caacatctcc 720 cccttctcct ttgggctggt catccagcag gtgttcgaca atggcagcat ctacaaccct 780 gaagtgcttg atatcacaga ggaaactctg cattctcgct tcctggaggg tgtccgcaat 840 gttgccagtg tctgtctgca gattggctac ccaactgttg catcagtacc ccattctatc 900 atcaacgggt acaaacgagt cctggccttg tctgtggaga cggattacac cttcccactt 960 gctgaaaagg tcaaggcctt cttggctgat ccatctgcct ttgtggctgc tgcccctgtg 1020 gctgctgcca ccacagctgc tcctgctgct gctgcagccc cagctaaggt tgaagccaag 1080 gaagagtcgg aggagtcgga cgaggatatg ggatttggtc tctttgacta atcaccaaaa 1140 agcaaccaac ttagccagtt ttatttgcaa aacaaggaaa taaaggctta cttctttaaa 1200 aagtaaaaaaa aaaaaaaaaaa aaaaaaaaa 1229 <210> 62 <211> 317 <212> PRT <213> Homo sapiens <400> 62 Met Pro Arg Glu Asp Arg Ala Thr Trp Lys Ser Asn Tyr Phe Leu Lys 1 5 10 15 Ile Ile Gln Leu Leu Asp Asp Tyr Pro Lys Cys Phe Ile Val Gly Ala 20 25 30 Asp Asn Val Gly Ser Lys Gln Met Gln Gln Ile Arg Met Ser Leu Arg 35 40 45 Gly Lys Ala Val Val Leu Met Gly Lys Asn Thr Met Met Arg Lys Ala 50 55 60 Ile Arg Gly His Leu Glu Asn Asn Pro Ala Leu Glu Lys Leu Leu Pro 65 70 75 80 His Ile Arg Gly Asn Val Gly Phe Val Phe Thr Lys Glu Asp Leu Thr 85 90 95 Glu Ile Arg Asp Met Leu Leu Ala Asn Lys Val Pro Ala Ala Ala Arg 100 105 110 Ala Gly Ala Ile Ala Pro Cys Glu Val Thr Val Pro Ala Gln Asn Thr 115 120 125 Gly Leu Gly Pro Glu Lys Thr Ser Phe Phe Gln Ala Leu Gly Ile Thr 130 135 140 Thr Lys Ile Ser Arg Gly Thr Ile Glu Ile Leu Ser Asp Val Gln Leu 145 150 155 160 Ile Lys Thr Gly Asp Lys Val Gly Ala Ser Glu Ala Thr Leu Leu Asn 165 170 175 Met Leu Asn Ile Ser Pro Phe Ser Phe Gly Leu Val Ile Gln Gln Val 180 185 190 Phe Asp Asn Gly Ser Ile Tyr Asn Pro Glu Val Leu Asp Ile Thr Glu 195 200 205 Glu Thr Leu His Ser Arg Phe Leu Glu Gly Val Arg Asn Val Ala Ser 210 215 220 Val Cys Leu Gln Ile Gly Tyr Pro Thr Val Ala Ser Val Pro His Ser 225 230 235 240 Ile Ile Asn Gly Tyr Lys Arg Val Leu Ala Leu Ser Val Glu Thr Asp 245 250 255 Tyr Thr Phe Pro Leu Ala Glu Lys Val Lys Ala Phe Leu Ala Asp Pro 260 265 270 Ser Ala Phe Val Ala Ala Ala Pro Val Ala Ala Ala Thr Thr Ala Ala 275 280 285 Pro Ala Ala Ala Ala Ala Pro Ala Lys Val Glu Ala Lys Glu Glu Ser 290 295 300 Glu Glu Ser Asp Glu Asp Met Gly Phe Gly Leu Phe Asp 305 310 315 <210> 63 <211> 317 <212> PRT <213> Homo sapiens <400> 63 Met Pro Arg Glu Asp Arg Ala Thr Trp Lys Ser Asn Tyr Phe Leu Lys 1 5 10 15 Ile Ile Gln Leu Leu Asp Asp Tyr Pro Lys Cys Phe Ile Val Gly Ala 20 25 30 Asp Asn Val Gly Ser Lys Gln Met Gln Gln Ile Arg Met Ser Leu Arg 35 40 45 Gly Lys Ala Val Val Leu Met Gly Lys Asn Thr Met Met Arg Lys Ala 50 55 60 Ile Arg Gly His Leu Glu Asn Asn Pro Ala Leu Glu Lys Leu Leu Pro 65 70 75 80 His Ile Arg Gly Asn Val Gly Phe Val Phe Thr Lys Glu Asp Leu Thr 85 90 95 Glu Ile Arg Asp Met Leu Leu Ala Asn Lys Val Pro Ala Ala Ala Arg 100 105 110 Ala Gly Ala Ile Ala Pro Cys Glu Val Thr Val Pro Ala Gln Asn Thr 115 120 125 Gly Leu Gly Pro Glu Lys Thr Ser Phe Phe Gln Ala Leu Gly Ile Thr 130 135 140 Thr Lys Ile Ser Arg Gly Thr Ile Glu Ile Leu Ser Asp Val Gln Leu 145 150 155 160 Ile Lys Thr Gly Asp Lys Val Gly Ala Ser Glu Ala Thr Leu Leu Asn 165 170 175 Met Leu Asn Ile Ser Pro Phe Ser Phe Gly Leu Val Ile Gln Gln Val 180 185 190 Phe Asp Asn Gly Ser Ile Tyr Asn Pro Glu Val Leu Asp Ile Thr Glu 195 200 205 Glu Thr Leu His Ser Arg Phe Leu Glu Gly Val Arg Asn Val Ala Ser 210 215 220 Val Cys Leu Gln Ile Gly Tyr Pro Thr Val Ala Ser Val Pro His Ser 225 230 235 240 Ile Ile Asn Gly Tyr Lys Arg Val Leu Ala Leu Ser Val Glu Thr Asp 245 250 255 Tyr Thr Phe Pro Leu Ala Glu Lys Val Lys Ala Phe Leu Ala Asp Pro 260 265 270 Ser Ala Phe Val Ala Ala Ala Pro Val Ala Ala Ala Thr Thr Ala Ala 275 280 285 Pro Ala Ala Ala Ala Ala Pro Ala Lys Val Glu Ala Lys Glu Glu Ser 290 295 300 Glu Glu Ser Asp Glu Asp Met Gly Phe Gly Leu Phe Asp 305 310 315 <210> 64 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> RPLP0_forward first <400> 64 taaccctgc gtggcaat <210> 65 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> RPLP0_reverse first <400> 65 acattcgga taatcatcca atagttg <210> 66 <211> 24 <212> DNA <213> Artificial Sequence <220> <223> RPLP0 probe <400> 66 aagtagttgg acttccaggt cgcc <210> 67 <211> 2458 <212> DNA <213> Homo sapiens <400> 67 cagaagaagg cagcgcccaa ggcgcatgcg cagcggtcac tcccgctgta tattaaggcg ccggcgatcg cggcctgagg ctgctcccgg acaagggcaa cgagcgtttc gtttggactt 120 ctcgacttga gtgcccgcct ccttcgccgc cgcctctgca gtcctcagcg cagttatgcc 180 cagttcttcc cgctgtgggg acacgaccac ggaggaatcc ttgcttcagg gactcgggac 240 cctgctggac cccttcctcg ggtttagggg atgtggggac caggagaaag tcaggatccc 300 taagagtctt ccctgcctgg atggatgagt ggcttcttct ccacctagat tctttccaca 360 ggagccagca tacttcctga acatggagag tgttgttcgc cgctgcccat tcttatcccg 420 agtcccccag gcctttctgc agaaagcagg caaatctctg ttgttctatg cccaaaactg 480 ccccaagatg atggaagttg gggccaagcc agcccctcgg gcattgtcca ctgcagcagt 540 acactaccaa cagatcaaag aaacccctcc ggccagtgag aaagacaaaa ctgctaaggc 600 caaggtccaa cagactcctg atggatccca gcagagtcca gatggcacac agcttccgtc 660 tggacacccc ttgcctgcca caagccaggg cactgcaagc aaatgccctt tcctggcagc 720 acagatgaat cagagaggca gcagtgtctt ctgcaaagcc agtcttgagc ttcaggagga 780 tgtgcaggaa atgaatgccg tgaggaaaga ggttgctgaa acctcagcag gccccagtgt 840 ggttagtgtg aaaaccgatg gaggggatcc cagtggactg ctgaagaact tccaggacat 900 catgcaaaag caaagaccag aaagagtgtc tcatcttctt caagataact tgccaaaatc 960 tgtttccact tttcagtatg atcgtttctt tgagaaaaaa attgatgaga aaaagaatga 1020 ccacacctat cgagttttta aaactgtgaa ccggcgagca cacatcttcc ccatggcaga 1080 tgactattca gactccctca tcaccaaaaa gcaagtgtca gtctggtgca gtaatgacta 1140 cctaggaatg agtcgccacc cacgggtgtg tggggcagtt atggacactt tgaaacaaca 1200 tggtgctggg gcaggtggta ctagaaatat ttctggaact agtaaattcc atgtggactt 1260 agagcgggag ctggcagacc tccatgggaa agatgccgca ctcttgtttt cctcgtgctt 1320 tgtggccaat gactcaaccc tcttcaccct ggctaagatg atgccaggct gtgagattta 1380 ctctgattct gggaaccatg cctccatgat ccaagggatt cgaaacagcc gagtgccaaa 1440 gtacatcttc cgccacaatg atgtcagcca cctcagagaa ctgctgcaaa gatctgaccc 1500 ctcagtcccc aagattgtgg catttgaaac tgtccattca atggatgggg cggtgtgccc 1560 actggaagag ctgtgtgatg tggcccatga gtttggagca atcaccttcg tggatgaggt 1620 ccacgcagtg gggctttatg gggctcgagg cggagggatt ggggatcggg atggagtcat 1680 gccaaaaatg gacatcattt ctggaacact tggcaaagcc tttggttgtg ttggagggta 1740 catcgccagc acgagttctc tgattgacac cgtacggtcc tatgctgctg gcttcatctt 1800 caccacctct ctgccaccca tgctgctggc tggagccctg gagtctgtgc ggatcctgaa 1860 gagcgctgag ggacgggtgc ttcgccgcca gcaccagcgc aacgtcaaac tcatgagaca 1920 gatgctaatg gatgccggcc tccctgttgt ccactgcccc agccacatca tccctgtgcg 1980 ggttgcagat gctgctaaaa acacagaagt ctgtgatgaa ctaatgagca gacataacat 2040 ctacgtgcaa gcaatcaatt accctacggt gccccgggga gaagagctcc tacggattgc 2100 ccccacccct caccacacac cccagatgat gaactacttc cttgagaatc tgctagtcac 2160 atggaagcaa gtggggctgg aactgaagcc tcattcctca gctgagtgca acttctgcag 2220 gaggccactg cattttgag tgatgagtga aagagagag tcctatttct caggcttgag caagttggta tctgctcagg cctgagcatg acctcaatta tttcacttaa ccccaggcca ttatcatatc cagatggtct tcagagttgt ctttatatgt gattaagtt atattaaatt ttaatctata gtaaaaacat agtcctgga ataattctt gcttaaatgg tgaaaaaa <210> 68 <211> 2281 <212> DNA <213> Homo sapiens <400> 68 cagaagaagg cagcgcccaa ggcgcatgcg cagcggtcac tcccgctgta tattaaggcg ccggcgatcg cggcctgagg ctgctcccgg acaagggcaa cgagcgtttc gtttggactt 120 ctcgacttga gtgcccgcct ccttcgccgc cgcctctgca gtcctcagcg cagtctttcc 180 acaggagcca gcatacttcc tgaacatgga gagtgttgtt cgccgctgcc cattcttatc ccgagtcccc caggcctttc tgcagaaagc aggcaaatct ctgttgttct atgcccaaaa 360. ctgccccaag atgatggaag ttggggccaa gccagcccct cgggcattgt ccactgcagc agtacactac caacagatca aagaaacccc tccggccagt gagaagaca aaactgctaa ggccaaggtc caacagactc ctgatggatc ccagcagagt ccagatggca cacagcttcc gtctggacac cccttgcctg ccacaagcca gggcactgca agcaaatgcc ctttcctggc 540 agcacagatg aatcagagag gcagcagtgt cttctgcaaa gccagtcttg agcttcagga ggatgtgcag gaatgaatg ccgtgagga agaggttgct gaaacctcag caggccccag tgtggttagt gtgaaaaccg atggagggga tcccagtgga ctgctgaaga acttccagga 720 catcatgca aagcaaagac cagaaagagt gtctcatctt cttcaagata acttgccaaa atctgtttcc acttttcagt atgatcgttt ctttgagaaa aaaattgatg agaaaaaaga 840 tgaccacacc tatcgagttt ttaaaactgt gaaccggcga gcacacatct tccccatggc agatgactat tcagactccc tcatcaccaa aaagcaagtg tcagtctggt gcagtaatga ctacctagga atgagtcgcc acccacgggt gtgtggggca gttatggaca ctttgaaaca acatggtgct ggggcaggtg gtactgaaaa tatttctgga actagtaaat tccatgtgga cttagagcgg gagctggcag acctccatgg gaaagatgcc gcactcttgt tttcctcgtg 1140 ctttgtggcc aatgactcaa ccctcttcac cctggctaag atgatgccag gctgtgagat 1200 ttactctgat tctgggaacc atgcctccat gatccaaggg attcgaaaca gccgagtgcc 1260 aaagtacatc ttccgccaca atgatgtcag ccacctcaga gaactgctgc aaagatctga 1320 cccctcagtc cccaagattg tggcatttga aactgtccat tcaatggatg gggcggtgtg 1380 cccactggaa gagctgtgtg atgtggccca tgagtttgga gcaatcacct tcgtggatga 1440 ggtccacgca gtggggcttt atggggctcg aggcggaggg attggggatc gggatggagt 1500 catgccaaaa atggacatca tttctggaac acttggcaaa gcctttggtt gtgttggagg 1560 gtacatcgcc agcacgagtt ctctgattga caccgtacgg tcctatgctg ctggcttcat 1620 cttcaccacc tctctgccac ccatgctgct ggctggagcc ctggagtctg tgcggatcct 1680 gaagagcgct gagggacggg tgcttcgccg ccagcaccag cgcaacgtca aactcatgag 1740 acagatgcta atggatgccg gcctccctgt tgtccactgc cccagccaca tcatccctgt 1800 gcgggttgca gatgctgcta aaaacacaga agtctgtgat gaactaatga gcagacataa 1860 catctacgtg caagcaatca attaccctac ggtgccccgg ggagaagagc tcctacggat 1920 tgcccccacc cctcaccaca caccccagat gatgaactac ttccttgaga atctgctagt 1980 cacatggaag caagtggggc tggaactgaa gcctcattcc tcagctgagt gcaacttctg 2040 caggaggcca ctgcattttg aagtgatgag tgaaagagag aagtcctatt tctcaggctt 2100 gagcaagttg gtatctgctc aggcctgagc atgacctcaa ttatttcact taaccccagg 2160 ccattatcat atccagatgg tcttcagagt tgtctttata tgtgaattaa gttatattaa 2220 attttaatct atagtaaaaa catagtcctg gaaataaatt cttgcttaaa tggtgaaaaa 2280 a 2281 <210> 69 <211> 640 <212> PRT <213> Homo sapiens <400> 69 Met Glu Ser Val Val Arg Arg Cys Pro Phe Leu Ser Arg Val Pro Gln 1 5 10 15 Ala Phe Leu Gln Lys Ala Gly Lys Ser Leu Leu Phe Tyr Ala Gln Asn 20 25 30 Cys Pro Lys Met Met Glu Val Gly Ala Lys Pro Ala Pro Arg Ala Leu 35 40 45 Ser Thr Ala Ala Val His Tyr Gln Gln Ile Lys Glu Thr Pro Pro Ala 50 55 60 Ser Glu Lys Asp Lys Thr Ala Lys Ala Lys Val Gln Gln Thr Pro Asp 65 70 75 80 Gly Ser Gln Gln Ser Pro Asp Gly Thr Gln Leu Pro Ser Gly His Pro 85 90 95 Leu Pro Ala Thr Ser Gln Gly Thr Ala Ser Lys Cys Pro Phe Leu Ala 100 105 110 Ala Gln Met Asn Gln Arg Gly Ser Ser Val Phe Cys Lys Ala Ser Leu 115 120 125 Glu Leu Gln Glu Asp Val Gln Glu Met Asn Ala Val Arg Lys Glu Val 130 135 140 Ala Glu Thr Ser Ala Gly Pro Ser Val Val Ser Val Lys Thr Asp Gly 145 150 155 160 Gly Asp Pro Ser Gly Leu Leu Lys Asn Phe Gln Asp Ile Met Gln Lys 165 170 175 Gln Arg Pro Glu Arg Val Ser His Leu Leu Gln Asp Asn Leu Pro Lys 180 185 190 Ser Val Ser Thr Phe Gln Tyr Asp Arg Phe Phe Glu Lys Lys Ile Asp 195 200 205 Glu Lys Lys Asn Asp His Thr Tyr Arg Val Phe Lys Thr Val Asn Arg 210 215 220 Arg Ala His Ile Phe Pro Met Ala Asp Asp Tyr Ser Asp Ser Leu Ile 225 230 235 240 Thr Lys Lys Gln Val Ser Val Trp Cys Ser Asn Asp Tyr Leu Gly Met 245 250 255 Ser Arg His Pro Arg Val Cys Gly Ala Val Met Asp Thr Leu Lys Gln 260 265 270 His Gly Ala Gly Ala Gly Gly Thr Arg Asn Ile Ser Gly Thr Ser Lys 275 280 285 Phe His Val Asp Leu Glu Arg Glu Leu Ala Asp Leu His Gly Lys Asp 290 295 300 Ala Ala Leu Leu Phe Ser Ser Cys Phe Val Ala Asn Asp Ser Thr Leu 305 310 315 320 Phe Thr Leu Ala Lys Met Met Pro Gly Cys Glu Ile Tyr Ser Asp Ser 325 330 335 Gly Asn His Ala Ser Met Ile Gln Gly Ile Arg Asn Ser Arg Val Pro 340 345 350 Lys Tyr Ile Phe Arg His Asn Asp Val Ser His Leu Arg Glu Leu Leu 355 360 365 Gln Arg Ser Asp Pro Ser Val Pro Lys Ile Val Ala Phe Glu Thr Val 370 375 380 His Ser Met Asp Gly Ala Val Cys Pro Leu Glu Glu Leu Cys Asp Val 385 390 395 400 Ala His Glu Phe Gly Ala Ile Thr Phe Val Asp Glu Val His Ala Val 405 410 415 Gly Leu Tyr Gly Ala Arg Gly Gly Gly Ile Gly Asp Arg Asp Gly Val 420 425 430 Met Pro Lys Met Asp Ile Ile Ser Gly Thr Leu Gly Lys Ala Phe Gly 435 440 445 Cys Val Gly Gly Tyr Ile Ala Ser Thr Ser Ser Leu Ile Asp Thr Val 450 455 460 Arg Ser Tyr Ala Ala Gly Phe Ile Phe Thr Thr Ser Leu Pro Pro Met 465 470 475 480 Leu Leu Ala Gly Ala Leu Glu Ser Val Arg Ile Leu Lys Ser Ala Glu 485 490 495 Gly Arg Val Leu Arg Arg Gln His Gln Arg Asn Val Lys Leu Met Arg 500 505 510 Gln Met Leu Met Asp Ala Gly Leu Pro Val Val His Cys Pro Ser His 515 520 525 Ile Ile Pro Val Arg Val Ala Asp Ala Ala Lys Asn Thr Glu Val Cys 530 535 540 Asp Glu Leu Met Ser Arg His Asn Ile Tyr Val Gln Ala Ile Asn Tyr 545 550 555 560 Pro Thr Val Pro Arg Gly Glu Glu Leu Leu Arg Ile Ala Pro Thr Pro 565 570 575 His His Thr Pro Gln Met Met Asn Tyr Phe Leu Glu Asn Leu Leu Val 580 585 590 Thr Trp Lys Gln Val Gly Leu Glu Leu Lys Pro His Ser Ser Ala Glu 595 600 605 Cys Asn Phe Cys Arg Arg Pro Leu His Phe Glu Val Met Ser Glu Arg 610 615 620 Glu Lys Ser Tyr Phe Ser Gly Leu Ser Lys Leu Val Ser Ala Gln Ala 625 630 635 640 <210> 70 <211> 640 <212> PRT <213> Homo sapiens <400> 70 Met Glu Ser Val Val Arg Arg Cys Pro Phe Leu Ser Arg Val Pro Gln 1 5 10 15 Ala Phe Leu Gln Lys Ala Gly Lys Ser Leu Leu Phe Tyr Ala Gln Asn 20 25 30 Cys Pro Lys Met Met Glu Val Gly Ala Lys Pro Ala Pro Arg Ala Leu 35 40 45 Ser Thr Ala Ala Val His Tyr Gln Gln Ile Lys Glu Thr Pro Pro Ala 50 55 60 Ser Glu Lys Asp Lys Thr Ala Lys Ala Lys Val Gln Gln Thr Pro Asp 65 70 75 80 Gly Ser Gln Gln Ser Pro Asp Gly Thr Gln Leu Pro Ser Gly His Pro 85 90 95 Leu Pro Ala Thr Ser Gln Gly Thr Ala Ser Lys Cys Pro Phe Leu Ala 100 105 110 Ala Gln Met Asn Gln Arg Gly Ser Ser Val Phe Cys Lys Ala Ser Leu 115 120 125 Glu Leu Gln Glu Asp Val Gln Glu Met Asn Ala Val Arg Lys Glu Val 130 135 140 Ala Glu Thr Ser Ala Gly Pro Ser Val Val Ser Val Lys Thr Asp Gly 145 150 155 160 Gly Asp Pro Ser Gly Leu Leu Lys Asn Phe Gln Asp Ile Met Gln Lys 165 170 175 Gln Arg Pro Glu Arg Val Ser His Leu Leu Gln Asp Asn Leu Pro Lys 180 185 190 Ser Val Ser Thr Phe Gln Tyr Asp Arg Phe Phe Glu Lys Lys Ile Asp 195 200 205 Glu Lys Lys Asn Asp His Thr Tyr Arg Val Phe Lys Thr Val Asn Arg 210 215 220 Arg Ala His Ile Phe Pro Met Ala Asp Asp Tyr Ser Asp Ser Leu Ile 225 230 235 240 Thr Lys Lys Gln Val Ser Val Trp Cys Ser Asn Asp Tyr Leu Gly Met 245 250 255 Ser Arg His Pro Arg Val Cys Gly Ala Val Met Asp Thr Leu Lys Gln 260 265 270 His Gly Ala Gly Ala Gly Gly Thr Arg Asn Ile Ser Gly Thr Ser Lys 275 280 285 Phe His Val Asp Leu Glu Arg Glu Leu Ala Asp Leu His Gly Lys Asp 290 295 300 Ala Ala Leu Leu Phe Ser Ser Cys Phe Val Ala Asn Asp Ser Thr Leu 305 310 315 320 Phe Thr Leu Ala Lys Met Met Pro Gly Cys Glu Ile Tyr Ser Asp Ser 325 330 335 Gly Asn His Ala Ser Met Ile Gln Gly Ile Arg Asn Ser Arg Val Pro 340 345 350 Lys Tyr Ile Phe Arg His Asn Asp Val Ser His Leu Arg Glu Leu Leu 355 360 365 Gln Arg Ser Asp Pro Ser Val Pro Lys Ile Val Ala Phe Glu Thr Val 370 375 380 His Ser Met Asp Gly Ala Val Cys Pro Leu Glu Glu Leu Cys Asp Val 385 390 395 400 Ala His Glu Phe Gly Ala Ile Thr Phe Val Asp Glu Val His Ala Val 405 410 415 Gly Leu Tyr Gly Ala Arg Gly Gly Gly Ile Gly Asp Arg Asp Gly Val 420 425 430 Met Pro Lys Met Asp Ile Ile Ser Gly Thr Leu Gly Lys Ala Phe Gly 435 440 445 Cys Val Gly Gly Tyr Ile Ala Ser Thr Ser Ser Leu Ile Asp Thr Val 450 455 460 Arg Ser Tyr Ala Ala Gly Phe Ile Phe Thr Thr Ser Leu Pro Pro Met 465 470 475 480 Leu Leu Ala Gly Ala Leu Glu Ser Val Arg Ile Leu Lys Ser Ala Glu 485 490 495 Gly Arg Val Leu Arg Arg Gln His Gln Arg Asn Val Lys Leu Met Arg 500 505 510 Gln Met Leu Met Asp Ala Gly Leu Pro Val Val His Cys Pro Ser His 515 520 525 Ile Ile Pro Val Arg Val Ala Asp Ala Ala Lys Asn Thr Glu Val Cys 530 535 540 Asp Glu Leu Met Ser Arg His Asn Ile Tyr Val Gln Ala Ile Asn Tyr 545 550 555 560 Pro Thr Val Pro Arg Gly Glu Glu Leu Leu Arg Ile Ala Pro Thr Pro 565 570 575 His His Thr Pro Gln Met Met Asn Tyr Phe Leu Glu Asn Leu Leu Val 580 585 590 Thr Trp Lys Gln Val Gly Leu Glu Leu Lys Pro His Ser Ser Ala Glu 595 600 605 Cys Asn Phe Cys Arg Arg Pro Leu His Phe Glu Val Met Ser Glu Arg 610 615 620 Glu Lys Ser Tyr Phe Ser Gly Leu Ser Lys Leu Val Ser Ala Gln Ala 625 630 635 640 <210> 71 <211> 17 <212> DNA <213> Artificial Sequence <220> <223> ALAS-1_forward primer <400> 71 agccacatca tccctgt 17 <210> 72 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> ALAS-1_reverse primer <400> 72 cgtagatgtt atgtctgctc at 22 <210> 73 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> ALAS-1 probe <400> 73 tttagcagca tctgcaaccc gc 22 BRIEF DESCRIPTION OF THE DRAWINGS

[0087] In the following image:

[0088] Figure 1 A flowchart schematically and exemplarily illustrates an embodiment of a method for preoperative risk stratification of prostate cancer subjects.

[0089] Figure 2-7 Figure 5 shows the results of Kaplan-Meier survival analysis of the time from radical prostatectomy to PSA recurrence or initiation of any salvage therapy in a cohort of DB patients (#151). Figure 2 A categorical expression-based risk score (denoted as "PDE4D7 score") is shown; Figure 3 Preoperative CAPRA score categories (denoted as “CAPRA score”) are shown; Figure 4The preoperative CAPRA score and expression-based risk score combined model (denoted as “CAPRA&PDE4D7 score”) are shown; Figure 5 A categorical expression-based risk score (denoted as "PDE4D7 score") is shown; Figure 6 The preoperative CAPRA score category (denoted as "CAPRA score") is shown; and Figure 7 The preoperative CAPRA score and expression-based risk score combined model (denoted as "CAPRA&PDE4D7 score") are shown.

[0090] Figure 8-10 Figure 4 shows the ROC curve analysis results of biochemical recurrence (BCR) 5 years after surgery in a cohort of DB patients. Figure 8 CAPRA&PDE4D7 scores and CAPRA scores are shown; Figure 9 "CAPRA (-BxGl / +PDE4D7) Score", CAPRA Score and CAPRA Score (-BxGl) are shown; and Figure 10 CAPRA&PDE4D7 scores and CAPRA scores are shown,

[0091] Figure 11 Results of a decision curve analysis showing the net benefits of five different treatment strategies for men who experienced disease recurrence within 5 years of surgery (a total of 45 of the 151 study patients (29.8%) did not initiate first-line surgical treatment due to PSA recurrence).

[0092] Figure 12-17 The results of Kaplan Meier survival analysis of time to PSA recurrence (endpoint: BCR) for PDE4D5, PDE4D7, and PDE4D9 scores in the RP patient cohort (n=536) are shown, where Figure 12 PDE4D7 classification between fusion-positive and -negative tumors in the presence of rearranged TMPRSS2-ERG gene fusion is shown; Figure 13 PDE4D7 classification in prostate tumors without ERG gene fusion events is shown; Figure 14 PDE4D5 score categories in tumors without gene fusions are shown; Figure 15 PDE4D5 score categories in tumors without gene fusions are shown; Figure 16 PDE4D9 score categories in gene fusion-positive cancers are shown; and Figure 17 PDE4D9 score categories in gene fusion-positive cancers are shown.

[0093] Figure 18 Heat map showing TMPRSS2-ERG negative tumor samples of RP patient cohort (n=256),

[0094] Figure 19 and 20 Figure 4 shows the biochemical recurrence (BCR) progression-free survival (PFS) in the DB patient cohort with respect to the categorized CAPRA & PDE4D5 / 7 / 9 combined score. Figure 19 ) and secondary treatment-free (salvage radiation and / or androgen deprivation) survival (STFS) ( Figure 20 )'s Kapaln Meier survival analysis results,

[0095] Figure 21 and Figure 22 The results show that the biochemical recurrence (BCR) of CAPRA model, CAPRA&PDE4D7 model and CAPRA&PDE4D5 / 7 / 9 combination model in DB patient cohort was 5 years after surgery ( Figure 21 ) and 5-year second-line treatment-free survival (STFS) after surgery ( Figure 22 ) of the ROC curve analysis results,

[0096] Figure 23 Results of decision curve analyses showing the net benefits of four different treatment decision strategies for men at risk of experiencing disease recurrence within 5 years after surgery in a cohort of DB patients, and

[0097] Figure 24 Results of a decision curve analysis showing the net detriment of two different treatment decision strategies for men at risk of experiencing disease recurrence within 5 years after surgery in a cohort of DB patients.

[0098] Detailed description of implementation plan

[0099] Review of Preoperative Risk Stratification

[0100] Figure 1 A flow chart schematically and illustratively illustrates an embodiment of a method for preoperative risk stratification of prostate cancer subjects.

[0101] The method starts at step S100 .

[0102] In step S102, a biological sample is obtained from each patient in the first group of patients (objects) diagnosed with prostate cancer. Preferably, after obtaining the biological sample, for example, within a period of at least one year or at least two years or about five years, these prostate cancer patients are subjected to prostate cancer monitoring.

[0103] In step S104, a gene expression profile of PDE4D7 is obtained for each biological sample from the first group of patients, for example by performing RT-qPCR (real-time quantitative PCR) on RNA extracted from each biological sample. Exemplary gene expression profiles include expression levels (e.g., values) of PDE4D7, which can be normalized using values ​​for each of a set of reference genes, such as HPRT1, TUBA1B, PUM1, and / or TBP. In one embodiment, the gene expression profile values ​​of PDE4D7 are normalized to one or more reference genes (e.g., at least one, at least two, at least three, or preferably all of these reference genes) selected from HPRT1, TUBA1B, PUM1, and TBP.

[0104] In step S106, a scoring function for assigning an expression-based risk score is determined based on the gene expression profiles of PDE4D7 obtained from at least some of the biological samples obtained from the first group of patients and the corresponding results obtained from the monitoring. In a preferred embodiment, the scoring function is a linear transformation that converts the normalized gene expression profile into a predetermined range of values, such as the range of 1-5 described above. As described above, such a transformation can be determined by considering the frequency distribution of the normalized gene expression profile values ​​of PDE4D7 from biological samples of a population of prostate cancer subjects (herein, the first group of patients) and determining a transformation that converts the frequency distribution into a desired range. In a specific embodiment, the expression-based risk score is determined as shown in equation (1) above.

[0105] In step S108, a biological sample is obtained from a patient (subject or individual), which may be a new patient or one of the first group of patients.

[0106] In step S110, a gene expression profile of PDE4D7 is obtained, for example, by performing PCR on the biological sample. In one embodiment, the gene expression profile values ​​of PDE4D7 are normalized to one or more reference genes (e.g., at least one, at least two, at least three, or preferably all of these reference genes) selected from HPRT1, TUBA1B, PUM1, and TBP. This step is substantially the same as step S104.

[0107] Other reference genes that may be used additionally or alternatively in steps S104 and S110 include: human actin beta, mRNA (ACTB); human 60S acidic ribosomal phosphoprotein P0 mRNA (RPLP0); polymerase (RNA) II (DNA-directed) polypeptide A, 220 kDa (POLR2A); beta-2-microglobulin (B2M); and aminolevulinic acid-delta synthase (ALAS-1).

[0108] In step S112 , the obtained scoring function is used to determine an expression-based risk score for the patient based on the gene expression profile.

[0109] In step S114, a preoperative prognostic risk score for the patient is determined based on the patient's expression-based risk score and preoperative clinical variables. This is described in more detail later in the specification.

[0110] In step S116, a treatment recommendation may be provided based on the preoperative prognostic risk score, for example, to the patient or his / her guardian, physician, or another healthcare professional. To this end, the preoperative prognostic risk score may be classified into one of predetermined risk groups based on the preoperative prognostic risk score value. Providing treatment recommendations may include one or more of the following: a) proposing a treatment plan for the patient based on a specified risk group, wherein at least two risk groups are associated with different treatments; b) calculating a prediction of the risk of disease progression for the patient before or after prostate surgery; and c) calculating a prediction of the treatment response for the patient before or after prostate surgery. Exemplary treatments include at least partial prostatectomy, active treatment selected from radiotherapy, chemotherapy, and combinations thereof, and observation alone, i.e., without prostatectomy or active treatment (i.e., active surveillance).

[0111] The method ends at step S118.

[0112] Each risk group can be associated with a separate proposed treatment regimen that differs in the aggressiveness of the treatment. Each proposed treatment regimen can be based on the results of the first group of patients assigned to the risk group and is predicted to provide the least aggressive treatment that does not exceed the clinical risk threshold for prostate cancer development. In some cases, this can allow a new patient to be assigned to a risk group that proposes a less aggressive treatment approach than would be the case using other risk analysis methods, such as the Gleason score, NCCN risk classification, or preoperative CAPRA score.

[0113] In one embodiment, the gene expression profile in steps S104 and S110 is determined by detecting mRNA expression using one or more primers and / or probes and / or one or more sets thereof.

[0114] Table 3 shows the detailed description of PDE4D7 and one or more reference genes, including their transcript IDs (NCBI RefSeq) and the corresponding amino acid sequences of primer pairs and probes. The table also shows the sense primer, antisense primer, and probe sequences that specifically bind to the amplicon for each gene.

[0115] Table 1: Exemplary primer and probe nucleic acid sequences

[0116]

[0117]

[0118] To explore the prognostic power of PDE4D7 in preoperative patient risk assessment, we investigated its association with disease recurrence in the context of preoperative risk variables and algorithms, such as the preoperative CAPRA score. A model combining an expression-based risk score with preoperative variables was developed in the surgical cohort and validated in independent patients on diagnostic biopsies. The results suggest that PDE4D7 can add additional information to preoperative variables or prognostic scores based on such variables, such as the preoperative CAPRA score, allowing for better patient stratification to optimize first-line treatment decisions. Example

[0119] Patient cohorts and samples

[0120] Two patient cohorts were used: a radical prostatectomy (RP) cohort and a diagnostic biopsy (DB) cohort, whose demographics are shown in Table 2. For the RP cohort, small punch biopsies (approximately 1 mm × 2 mm) were collected from representative tumor areas of the resected prostate in 550 patients who underwent surgery sequentially between 2000 and 2004 at a large clinical center in Germany. After quality control of the study data based on predefined criteria and removal of patients receiving adjuvant hormonal therapy, 503 patient samples were found to be eligible for statistical analysis. For the DB cohort, one punch biopsy (approximately 1 mm × 2 mm) was collected from each patient's highest Gleason score–positive diagnostic biopsy. A total of 168 patients in this setting were diagnosed with prostate cancer and underwent surgery at UniversityKlinik Muenster, Germany, between 1995 and 2011. A total of 151 patients had diagnostic needle biopsies that were found to be eligible for statistical analysis.

[0121] Table 2: Demographics of the Radical Prostatectomy (RP) and Diagnostic Biopsy (DB) Patient Cohorts

[0122]

[0123]

[0124] For patient age, preoperative PSA, biopsy tumor percentage, prostate volume, and PSA density, the minimum and maximum values ​​for each cohort are shown, while the median and IQR values ​​are shown in parentheses. For CAPRA risk categories, the number and percentage of patients in each risk group are shown. For preoperative pathology, the biopsy Gleason score and Gleason grade group, as well as the clinical stage (by number and percentage of patients) are indicated. Postoperative pathology is presented as the pathological Gleason score and Gleason grade group, pathological stage, surgical margin status after prostatectomy, and tumor invasion status in the seminal vesicles and pelvic lymph nodes (by number and percentage of patients). In this regard, it is important to note that extracapsular extension is not provided as a primary parameter but is derived from the pathological stage pT3a. Follow-up shows the mean and median follow-up period in months after surgery for all patients. Outcome categories indicate the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence to metastasis (CR) after first-line treatment after surgery. Treatment categories listed the cumulative 5 and 10 years after surgery to start salvage radiotherapy (SRT) or salvage androgen deprivation therapy (SADT). Mortality is shown as prostate cancer-specific survival (PCSS) and overall survival (OS). For all outcomes, the number of people experiencing the outcome / total number of people followed up every 5 or 10 years is shown, with the percentage of events given in brackets. (B) Demographics of the diagnostic biopsy patient cohort. (N / A = not provided).

[0125] Laboratory methods

[0126] All laboratory methods used, including oligonucleotide primers and probes for RT-qPCR (quantitative real-time PCR), RNA extraction, quality control, and procedures for including / excluding samples for statistical analysis, were as described. Table 1 also lists the primers and probes used for RT-qPCR measurement of target genes of interest as well as reference genes.

[0127] result

[0128] Correlating expression-based risk scores with longitudinal clinical outcomes

[0129] A continuous expression-based risk score (ie, normalized and transformed expression of PDE4D7 transcripts to a reference gene) was correlated with preoperative clinical variables in two patient cohorts (RP and DB).

[0130] Table 3 to Table 8 show the univariate and multivariate Cox regression analysis of biochemical recurrence-free (BCR) survival rate and overall survival (OS) based on the risk score of continuous expression.In multivariate analysis, the risk score based on expression is adjusted by preoperative clinical variables, i.e., by the percentage of operative age, preoperative PSA, PSA density, biopsy Gleason grade group, tumor positive biopsy core, tumor percentage and clinical stage (see Table 3,5 and 7) or by preoperative prostate cancer risk assessment (CAPRA) scoring (see Table 4,6 and 8) and adjust.Biopsy Gleason grade group and clinical stage are modeled as categories, with the lowest category as reference.All other demographics and clinical variables and the risk score based on expression are modeled as continuous variables.All variables are input into multivariate model, and respective statistical measurements are provided in table.

[0131] Univariate Cox regression analysis showed that the risk score based on continuous expression was highly significantly associated with the time to BCR in both study patient cohorts, with HR = 0.53; 95% CI = 0.41-0.67; p < 0.0001, and HR = 0.43; 95% CI = 0.33-0.65, p < 0.0001, respectively (see Tables 3 and 7). Multivariate Cox regression analysis adjusted for preoperative variables or preoperative CAPRA score showed that the risk score based on continuous expression made a significant independent contribution to the prediction of postoperative BCR (see Tables 3, 4, 7 and 8). In addition, when testing the endpoint overall survival (OS) of the RP patient cohort, we observed similar independent predictive ability of the risk score based on continuous expression when adjusting for relevant preoperative clinical variables or preoperative CAPRA score (see Tables 5 and 6). Interestingly, however, in addition to the expression-based risk score (HR = 0.43; 95% CI = 0.29-0.62; p < 0.0001), only age (HR = 1.1; 95% CI = 1.03-1.2; p = 0.007) and clinical stage cT2 and cT3 remained significant predictors in the multivariate model. In univariate analysis, the preoperative CAPRA score was a significant predictor of overall survival (HR = 1.2; 95% CI = 1.3-1.6; p = 0.01), but it fell below statistical significance in multivariate analysis (HR = 1.2; 95% CI = 0.99-1.4; p = 0.06). In multivariate modeling, the continuous expression-based risk score also remained highly significant (HR = 0.4; 95% CI = 0.28-0.58; p < 0.0001; Tables 5 and 6).

[0132] Table 3: Univariate and multivariate Cox regression analysis of biochemical recurrence (BCR)-free survival by expression-based risk score in the RP patient cohort (#503), where the expression-based risk score was adjusted for preoperative variables in the multivariate analysis.

[0133]

[0134]

[0135] Table 4: Univariate and multivariate Cox regression analysis of biochemical recurrence (BCR)-free survival by expression-based risk score in the RP patient cohort (#503), where the expression-based risk score was adjusted for the preoperative CAPRA score in the multivariate analysis.

[0136]

[0137] Table 5: Univariate and multivariate Cox regression analysis of overall survival (OS) in the RP patient cohort (#503) with expression-based risk score adjusted for preoperative variables in the multivariate analysis.

[0138]

[0139] Table 6: Univariate and multivariate Cox regression analysis of overall survival (OS) based on expression risk score in the RP patient cohort (#503), where the expression-based risk score was adjusted for the preoperative CAPRA score in the multivariate analysis.

[0140]

[0141] Table 7: Univariate and multivariate Cox regression analysis of biochemical recurrence (BCR)-free survival by expression-based risk score in a DB patient cohort (#151), where the expression-based risk score was adjusted for preoperative variables in the multivariate analysis.

[0142]

[0143] Table 8: Univariate and multivariate Cox regression analysis of biochemical recurrence (BCR)-free survival by expression-based risk score in the DB patient cohort (#151), where the expression-based risk score was adjusted for the preoperative CAPRA score in the multivariate analysis.

[0144]

[0145] Preoperative prognostic risk score based on expression-based risk score and preoperative clinical variables

[0146] To further explore the prognostic power of PDE4D7, the benefit of combining an expression-based risk score with preoperative clinical variables for the prognosis of prostate cancer patients undergoing various treatment regimens was tested. Based on multivariate Cox regression data, it was hypothesized that the combination of the preoperative CAPRA score with the expression-based risk score would significantly improve the prognostic power of the preoperative clinical variables alone. To evaluate this hypothesis, a subcohort of 449 patients (92 events; 20.5%) from the RP patient cohort with a complete 5-year outcome history was selected and a logistic regression model was generated combining the expression-based risk score with the preoperative CAPRA score to predict the risk of biochemical recurrence 5 years after surgery. The logit(p) regression function was converted to p = 1 / (1 + e^(-logit(p)) to calculate the probability p that an individual patient will experience biochemical recurrence within 5 years after surgery.

[0147] This modeling demonstrated the independent predictive value of the expression-based risk score relative to the preoperative CAPRA index (odds ratio 0.46; 95% CI 0.3-0.69; p = 0.0002; data not shown). Next, this preoperative CAPRA score and expression-based risk score logistic regression model were independently tested in 151 patients eligible for statistical data analysis. All patients were followed up for at least 60 months after surgery. The methods used to investigate the efficacy of the preoperative CAPRA score and expression-based risk score logistic regression model were (i) Kaplan-Meier survival analysis, (ii) ROC curve analysis, and (iii) reclassification and decision curve analysis.

[0148] Figures 2 to 7 Shown are the results of Kaplan-Meier survival analysis of time after radical prostatectomy to PSA recurrence or initiation of any salvage therapy in a cohort of DB patients (#151). Figure 2-Figure 4 : Kaplan-Meier analysis of biochemical recurrence-free (BCR) survival in a cohort of DB patients, separately for categorical expression-based risk scores (in Figure 2 ) and the preoperative CAPRA score category (in Figure 3 The CAPRA score and the combined preoperative CAPRA score and expression-based risk score were expressed as “CAPRA score” in Figure 4 denoted as “CAPRA&PDE4D7 score”). Figure 5-Figure 7 : Kaplan-Meier analysis of the time to survival without initiation of any salvage treatment after surgery in a cohort of DP patients, separately for the categorized expression-based risk scores ( Figure 5 ) and the preoperative CAPRA score category (in Figure 6) and the preoperative CAPRA score expression-based risk score combination model (in Figure 7 The expression-based risk score categories were defined as follows: “PDE4D7 score (1-2)”: expression-based risk score range of 1 to <2; “PDE4D7 score (2-3)”: expression-based risk score range of 2 to <3; “PDE4D7 score (3-4)”: expression-based risk score range of 3 to <4; and “PDE4D7 score (4-5)”: expression-based risk score range of 4 to ≤5. The highest expression-based risk score category, “PDE4D7 score (4-5)”, was used as the reference category. Preoperative CAPRA score categories were defined as: “CAPRA score (0-2)”: preoperative CAPRA score ranged from 0 to 2; “CAPRA score (3-5)”: preoperative CAPRA score ranged from 3 to 5; and “CAPRA score (>5)”: preoperative CAPRA score ranged from 6 to 10. The lowest preoperative CAPRA score category, “CAPRA score (0-2)”, was used as the reference category. Based on the logit(p) function of the logistic regression model, the categories of the combined model of preoperative CAPRA score and expression-based risk score were defined according to the probability of experiencing PSA failure after surgery: “Probability (<0.15)”; “Probability (0.15 to <0.25)”; “Probability (0.25 to <0.5)”; and “Probability (0.5 to 1.0)”.

[0149] A Kaplan-Meier survival study in a cohort of DB patients demonstrated significant separation of patients at different risks of experiencing postoperative PSA recurrence or initiating any salvage therapy after radical prostatectomy based on preoperative measurement of an expression-based risk score in diagnostic biopsy punch tissue (see Figure 2 ). Regarding the logistic regression model that combined the preoperative CAPRA score and the expression-based risk score in the regression function, the probability of experiencing the endpoint calculated by the model was categorized or classified into four groups (as described above), and the hazard ratios between the lowest and highest recurrence risk groups were compared with the group of patients stratified by the preoperative CAPRA score categories alone. It was demonstrated that the addition of the expression-based risk score to the preoperative CAPRA categories resulted in a significant increase in the hazard ratio from the lowest risk group to the highest risk group (9.0 and 39.6, respectively), while the number of patients in these risk categories remained essentially the same (see Figure 3 and 4 ).

[0150] When the clinically relevant endpoint of initiation of any salvage therapy (radiation, hormonal ablation) after PSA failure was tested, the findings were consistent with previous findings, showing improved risk separation between patients at lowest and highest risk of receiving second-line therapy after surgery when the preoperative CAPRA score was combined with the expression-based risk score (see Figures 5 to 7 ).

[0151] In addition, the prediction of PSA recurrence 5 years after first-line treatment was tested using the preoperative CAPRA score and a logistic regression model that combined the preoperative CAPRA score and the expression-based risk score in a regression function and was previously developed using the RP cohort with a full 5-year follow-up (#449). Using ROC analysis, the 5-year AUC (area under the curve) was calculated to be 0.77 for the preoperative CAPRA score alone and 0.82 for the logistic regression model (see Figure 8 ). After testing, the AUCs of the two models were significantly different (p=0.004).

[0152] In another test, the benefits of adding an expression-based risk score to the preoperative CAPRA score were explored. The preoperative CAPRA index categorizes its individual components and provides weighted scores for these categories. The preoperative CAPRA score is the sum of these weighted scores (see Cooperberg MR). As mentioned above, on the one hand, the biopsy Gleason score has a significant impact on the CAPRA score. However, at the same time, the inventors found that the Gleason score varies greatly between pathologists. Therefore, the biopsy Gleason score information in the preoperative CAPRA score is replaced by the molecular information provided by the expression-based risk score. In particular, depending on the expression-based risk score value, many points in the range of 0 to 3 are in the modified preoperative CAPRA score. By doing so, the overall structure of the resulting modified preoperative CAPRA score can remain the same, with a minimum total score of 0 and a maximum total score of 10 (see Table 9).

[0153] Table 9: Biopsy Gleason score replaced by expression-based risk score in the preoperative CAPRA model

[0154]

[0155] When the model was tested for 5-year BCR outcome prediction in ROC analysis, the resulting AUC for the “CAPRA (-BxGl / +PDE4D7) score” was identical to the preoperative CAPRA score that included biopsy Gleason score information (AUC = 0.77; see Figure 9Although replacing the biopsy Gleason score with an expression-based risk score did not affect model performance, the 5-year prediction of PSA failure by the preoperative CAPRA model was significantly reduced if the biopsy Gleason information was removed from the clinical model (AUC = 0.77 vs AUC = 0.69 with and without biopsy Gleason score; p = 0.008; see Figure 9 , where the preoperative CAPRA score without biopsy Gleason information was expressed as “CAPRA score (-BxG1)”).

[0156] In the cohort of patients with biopsy Gleason ≤ 6, only a minority of men experienced PSA recurrence after surgery (21.2% in the RP and DB cohorts, respectively) or, even more relevant, progression to metastasis (1.9% in the RP cohort) or disease-specific death (1.3% in the RP cohort). Therefore, a subcohort analysis of the preoperative CAPRA score versus the combined model of the preoperative CAPRA score and the expression-based risk score was performed in the DP patient cohort including only patients with biopsy Gleason score ≥ 7 (#74). The combined model showed equivalent performance compared to testing the full cohort (AUC = 0.8 vs 0.82, respectively), whereas the performance of the preoperative CAPRA model alone was more reduced in the subcohort analysis (AUC = 0.73 vs 0.77, respectively, see Figure 10 ). This may indicate improved discriminatory performance of the combined model in patients with higher risk features.

[0157] Recently, the concept of decision curve analysis (DCA) has been introduced into clinical practice to test the value of biomarkers or prediction models (see Vickers AJ and Elkin EB, "Decision curve analysis: A novel method for evaluating prediction models", Medical Decision Making, Vol. 26, No. 6, pages 565 to 574, 2006). DCA is a net benefit analysis that compares the true positive rate with the weighted false positive rate between different risk thresholds to determine the initiation of postoperative second-line treatment due to the risk of future PSA failure. Here, in a decision curve analysis (DCA), the net benefit of second-line treatment triggered by postoperative PSA recurrence was explored for three models (i.e., expression-based risk score, preoperative CAPRA score, preoperative CAPRA score and expression-based risk score regression model). Five different treatment strategies were compared: (1, 2) treating all patients or not treating any patients; (3-5) treating according to the expression-based risk score, preoperative CAPRA score, or a combined regression model of the preoperative CAPRA score and the expression-based risk score. To this end, the true positive rate (TPR) and false positive rate (FPR) were determined for all strategies at different decision thresholds ranging from 0% to 50% in steps of 5% (see Figure 11 ). Analyses showed that all models used showed a better net benefit compared with a "treat all" strategy, while the preoperative CAPRA score and expression-based risk score regression models revealed the best net benefit among all modeled decision thresholds.

[0158] The results presented demonstrate that the CAPRA prediction model, which uses quantitative measurements of the prostate cancer biomarker PDE4D7 in biological samples from prostate cancer subjects, can provide improved risk stratification. Multiple analyses demonstrated that this risk prediction model performed better in stratifying prostate cancer patients into treatment-relevant risk categories than risk schemes based solely on preoperative clinical parameters as recommended by various currently adopted national prostate cancer guidelines.

[0159] discuss

[0160] Treatment decisions for primary localized prostate cancer depend largely on a combination of the risk of future disease progression and life expectancy. The data presented demonstrate that an expression-based risk score adds independent information to the preoperative CAPRA index for predicting disease recurrence, while in predicting overall survival (where approximately 80% of events are due to non-disease-specific deaths), the expression-based risk score remains the only variable that significantly contributes to survival prediction. Therefore, PDE4D7 may add prognostic value to clinical prediction models based on preoperative variables, such as the preoperative CAPRA score, to predict disease-specific outcome as well as to predict survival to support treatment decisions.

[0161] Recently, long-term results of the active surveillance cohort in the Gothenburg Randomized Prostate Cancer Screening Trial were published. This suggests that men with clinically low-risk disease may be at considerable risk for experiencing progressive disease under a deferred treatment regimen (see Godtman RA et al., “Long-term Results of Active Surveillance in the Gothenburg Randomized Prostate Cancer Screening Trial”). Randomized, Population-based Prostate Cancer Screening Trial", European Urology, Vol. 70, No. 5, pages 760-766, 2016. Therefore, the present inventors questioned whether people other than those with very low-risk disease are eligible for expectant management strategies. The recently published 10-year results of the ProtectT study showed similar conclusions for the active surveillance arm of the trial (see Hamdy FC et al., "10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer", New England Journal of Medicine Vol. 375, pages 1415-1424, 2016). Although there is some debate as to whether these results are applicable to contemporary practice (see Bergh RCN van den, Murphy DG, Poel HG van der, "Expectant Management for Prostate Cancer: Lessons from the past, Challenges for the Future", European Urology, Vol. 70, pages 1415-1424, 2016). 767-770, 2016), which may suggest that only patients with very low risk are safe for any progression during deferred treatment management. Although the use of clinical criteria such as the preoperative CAPRA model allows the selection of such a low-risk patient cohort (45% of the RP cohort with a 9.3% 5-year risk of BCR after surgery and 27.7% of the DP cohort with a 4.8% 5-year risk of BCR after surgery), the addition of molecular markers may allow the expansion of this very low-risk patient group. Indeed, the developed preoperative CAPRA score and expression-based risk score regression model defined a very low-risk cohort of 38 of 151 patients (25.2%) in the DB patient cohort with an NPV (negative predictive value) of 100% for the 5-year risk of PSA recurrence after treatment.

[0162] In the past few years, active surveillance (AS) has been established as a suitable and safe treatment option for men with low-risk prostate cancer (see Garisto JD and Klotz L., "Active surveillance for prostate cancer: How to do it right ", Oncology (Williston Park), Vol. 31, No. 5, pages 333 to 340 2017). A huge challenge associated with AS is the strict monitoring plan that men are advised to follow in order to avoid missing signs of progressive disease, such as elevated PSA or biopsy Gleason upgrades, which are usually triggers for switching from AS to active treatment. Longitudinal AS studies have found that over time, especially when other biopsy procedures are involved, patients' compliance with AS monitoring programs has decreased (see Bokhorst LP et al., "Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers", European Urology, Vol. 68, No. 5, 2015). This problem can be addressed by the selection algorithm proposed in this paper, which combines clinical models (such as the preoperative CAPRA score) with the prognostic genomic biomarker PDE4D7 to define a cohort of patients with little risk of progression over a 5-year period. This provides a way to enroll men in active surveillance on the basis of very limited (or no) follow-up within a given period of time after the onset of AS.

[0163] Other variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed invention, from a study of the drawings and the disclosure.

[0164] In this document, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality.

[0165] Figure 1One or more steps of the method shown may be implemented in a computer program product that can be executed on a computer. The computer program product may include a non-transitory computer-readable recording medium, such as a magnetic disk, a hard disk drive, etc., on which a control program is recorded (stored). Common forms of non-transitory computer-readable media include, for example, floppy disks, flexible disks, hard disks, magnetic tapes or any other magnetic storage media, CD-ROMs, DVDs or any other optical media, RAM, PROMs, EPROMs, FLASH-EPROMs or other memory chips or cassettes, or any other non-transitory media from which a computer can read and use.

[0166] Alternatively, one or more steps of the method may be performed in a transient medium such as a transmissive carrier wave, wherein the control program is embodied as a data signal using a transmission medium such as acoustic or light waves, such as those generated during radio wave and infrared data communications.

[0167] The exemplary methods can be implemented on one or more general purpose computers, special purpose computers, programmed microprocessors or microcontrollers and peripheral integrated circuit components, ASICs or other integrated circuits, digital signal processors, hard-wired electronic or logic circuits such as discrete component circuits, programmable logic devices such as PLDs, PLAs, FPGAs, graphics card CPUs (GPUs) or PALs, etc. In general, a finite state machine can be executed, thereby being able to execute Figure 1 Any device of the flowchart shown can be used to implement one or more steps of the risk stratification method to select a treatment plan in a prostate cancer patient. It will be appreciated that although the steps of the method can be entirely computer-implemented, in some embodiments, one or more steps can be at least partially performed manually.

[0168] The computer program instructions may also be loaded onto a computer, other programmable data processing apparatus, or other device so that a series of operational steps performed on the computer, other programmable apparatus, or other device produces a computer executable program, such that the instructions executed on the computer or other programmable apparatus provide a program for performing the functions / actions specified herein.

[0169] Although the present invention has been described so far based on the gene expression profile of PDE4D7, which may include the expression level (e.g., value) of PDE4D7, which may be normalized using the value of each of a set of reference genes, the gene expression profile may further include expression information from other PDE4D variants. For example, the other PDE4D variants may include one or more of PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D8, and PDE4D9. The diagnostic kit may then additionally comprise at least one primer and / or probe for determining the gene expression profile of each of the other PDE4D variants in a biological sample obtained from a prostate cancer subject. However, preferably, only the gene expression profile of PDE4D7 is used, in particular the expression level (e.g., value) of PDE4D7, which may be normalized using the value of each of a set of reference genes.

[0170] The term "phosphodiesterase 4D1" or "PDE4D1" relates to a splice variant 1 of the human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D1 gene, for example, as defined by the NCBI reference sequence NM_001197222.1, in particular the nucleotide sequence shown in SEQ ID NO: 1, which corresponds to the sequence of the aforementioned NCBI reference sequence of the PDE4D1 transcript, and also to the corresponding amino acid sequence, for example, as shown in SEQ ID NO: 2, which corresponds to the protein sequence encoding the PDE4D1 polypeptide as defined by the NCBI protein accession reference sequence NP_001184151.1. The term "phosphodiesterase 4D1" or "PDE4D1" also relates to an amplicon that can be generated by the primer pair PDE1D1D2_forward (SEQ ID NO: 3) and PDE1D1D2_reverse (SEQ ID NO: 4) and that can be detected by the probe SEQ ID NO: 5.

[0171] The term "phosphodiesterase 4D2" or "PDE4D2" refers to splice variant 2 of the human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D2 gene, for example, as defined by the NCBI reference sequence NM_001197221.1, in particular the nucleotide sequence shown in SEQ ID NO: 6, which corresponds to the sequence of the above-mentioned NCBI reference sequence of the PDE4D2 transcript, and also relates to the corresponding amino acid sequence, for example, as shown in SEQ ID NO: 7, which corresponds to the protein sequence encoding the PDE4D2 polypeptide as defined by the NCBI protein accession reference sequence NP_001184150.1.

[0172] The term "phosphodiesterase 4D3" or "PDE4D3" refers to splice variant 3 of human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D3 gene, for example, as defined by the NCBI reference sequence NM_006203.4, in particular the nucleotide sequence shown in SEQ ID NO: 8, which corresponds to the sequence of the above-mentioned NCBI reference sequence of the PDE4D3 transcript, and also relates to the corresponding amino acid sequence, for example, as shown in SEQ ID NO: 9, which corresponds to the protein sequence encoding the PDE4D3 polypeptide as defined by the NCBI protein accession reference sequence NP_006194.2.

[0173] The term "phosphodiesterase 4D4" or "PDE4D4" refers to the splice variant 4 of the human phosphodiesterase PDE4D, i.e. the human phosphodiesterase PDE4D4 gene, for example the sequence defined by the NCBI reference sequence NM_001104631.1, in particular the nucleotide sequence shown in SEQ ID NO: 10, which corresponds to the sequence of the above-mentioned NCBI reference sequence of the PDE4D4 transcript, and also relates to the corresponding amino acid sequence, for example as shown in SEQ ID NO: 11, which corresponds to the protein sequence encoding the PDE4D4 polypeptide as defined by the NCBI protein accession reference sequence NP_001098101.1.

[0174] The term "phosphodiesterase 4D5" or "PDE4D5" refers to splice variant 5 of the human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D5 gene, for example, as defined by the NCBI reference sequence NM_001197218.1, in particular the nucleotide sequence shown in SEQ ID NO: 12, which corresponds to the sequence of the aforementioned NCBI reference sequence of the PDE4D5 transcript, and also to the corresponding amino acid sequence, for example, as shown in SEQ ID NO: 13, which corresponds to the protein sequence encoding the PDE4D5 polypeptide as defined by the NCBI protein accession reference sequence NP_001184147.1. The term "phosphodiesterase 4D5" or "PDE4D5" also refers to the amplicon that can be generated by the primer pair PDE4D5_forward (SEQ ID NO: 14) and PDE4D5_reverse (SEQ ID NO: 15) and detected by the probe SEQ ID NO: 16.

[0175] The term "phosphodiesterase 4D6" or "PDE4D6" refers to splice variant 6 of human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D6 gene, e.g., the sequence defined by NCBI reference sequence NM_001197223.1, in particular the nucleotide sequence shown in SEQ ID NO: 17, which corresponds to the sequence of the above-mentioned NCBI reference sequence of the PDE4D6 transcript, and also relates to the corresponding amino acid sequence, e.g., as shown in SEQ ID NO: 18, which corresponds to the protein sequence encoding the PDE4D6 polypeptide as defined by the NCBI protein accession reference sequence NP_001184152.1.

[0176] The term "phosphodiesterase 4D8" or "PDE4D8" relates to splice variant 8 of human phosphodiesterase PDE4D, i.e. the human phosphodiesterase PDE4D8 gene, e.g. the sequence defined by NCBI reference sequence NM_001197219.1, in particular the nucleotide sequence shown in SEQ ID NO: 27, which corresponds to the sequence of the above-mentioned NCBI reference sequence of the PDE4D8 transcript, and also to the corresponding amino acid sequence, e.g. as shown in SEQ ID NO: 28, which corresponds to the protein sequence encoding the PDE4D8 polypeptide as defined by the NCBI protein accession reference sequence NP_001184148.1.

[0177] The term "phosphodiesterase 4D9" or "PDE4D9" relates to splice variant 9 of the human phosphodiesterase PDE4D, i.e., the human phosphodiesterase PDE4D9 gene, for example, as defined by the NCBI reference sequence NM_001197220.1, in particular the nucleotide sequence shown in SEQ ID NO: 29, which corresponds to the sequence of the aforementioned NCBI reference sequence of the PDE4D9 transcript, and also to the corresponding amino acid sequence, for example, as shown in SEQ ID NO: 30, which corresponds to the protein sequence encoding the PDE4D9 polypeptide as defined by the NCBI protein accession reference sequence NP_001184149.1. The term "phosphodiesterase 4D9" or "PDE4D9" also relates to the amplicon that can be generated by the primer pair PDE4D9_forward (SEQ ID NO: 31) and PDE4D9_reverse (SEQ ID NO: 32) and that can be detected by the probe SEQ ID NO: 33.

[0178] The terms "PDE4D1", "PDE4D2", "PDE4D3", "PDE4D4", "PDE4D5", "PDE4D6", "PDE4D8" and "PDE4D9" also encompass nucleotide sequences that are highly homologous to PDE4D1, PDE4D2, PDE4D3, PDE4D4, PDE4D5, PDE4D6, PDE4D8 and PDE4D9, respectively, such as nucleic acid sequences that are at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequences set forth in SEQ ID NO: 1, 6, 8, 10, 12, 17, 27 or 29, respectively, or to SEQ ID NO: 2, 3 or 4, respectively. NO: 2, 7, 9, 11, 13, 18, 28 or 30, or an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 2, 7, 9, 11, 13, 18, 28 or 30, or a nucleic acid sequence that encodes an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: 2, 7, 9, 11, 13, 18, 28 or 30, or a nucleic acid sequence that encodes an amino acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of SEQ ID NO: An amino acid sequence encoded by a nucleic acid sequence that is at least 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence shown in NO: 1, 6, 8, 10, 12, 17, 27 or 29.

[0179] Incorporating information from PDE4D5 and PDE4D9 into preoperative prognostic risk scores

[0180] Like the PDE4D7 isoform, the PDE4D5 and PDE4D7 isoforms are long isoforms, each containing the UCR1 and UCR2 regulatory domains.Herein, we investigated the added value of including information from the PDE4D5 and PDE4D9 gene expression profiles in a combined CAPRA & PDE4D7 score model to predict longitudinal clinical outcomes.

[0181] Example

[0182] Patient cohorts and samples

[0183] Two patient cohorts were used: a radical prostatectomy (RP) cohort and a diagnostic biopsy (DB) cohort; demographic data are shown in Table 10. For the RP cohort, two small punch biopsies (approximately 1 mm × 2 mm) were collected from representative tumor areas (indicative of tumor lesions) of the prostate removed from 606 patients who underwent surgery consecutively at a large clinical center in Germany between 2000 and 2004. For the DB cohort, one punch biopsy sample (approximately 1 mm × 2 mm) was collected from each patient's highest Gleason grade–positive diagnostic biopsy. A total of 168 patients in this cohort were diagnosed with prostate cancer and underwent surgery at the University Klinik Münster, Germany, between 1995 and 2011. After quality control of the RNAseq and RT-qPCR data, 536 and 151 patient samples were found suitable for statistical analysis in the RP cohort and the DB cohort, respectively.

[0184] Table 10: Demographics of the Radical Prostatectomy (RP) and Diagnostic Biopsy (DB) Patient Cohorts

[0185]

[0186]

[0187] For patient age, preoperative PSA, biopsy tumor percentage, prostate volume, and PSA density, the minimum and maximum values ​​for each cohort are shown, with the median and IQR values ​​shown in parentheses. For CAPRA risk categories, the number of patients and the percentage of each risk group are shown. For preoperative pathology, the biopsy Gleason score and Gleason grade group, as well as the clinical stage (shown as number of patients and percentage) are indicated. Postoperative pathology is presented as pathological Gleason score and Gleason grade group, pathological stage, post-prostatectomy surgical margin status, and tumor invasion status of the seminal vesicles and pelvic lymph nodes (shown as number of patients and percentage). In this regard, it is important to note that extracapsular extension is not provided as a primary parameter but is derived from pathological stage pT3a. Follow-up shows the mean and median number of months of postoperative follow-up for all patients. The outcome categories describe the cumulative 5- and 10-year biochemical recurrence (BCR) and clinical recurrence (CR) to metastasis after first-line surgical treatment. Treatment categories list salvage radiation therapy (SRT) or salvage androgen deprivation therapy (SADT) initiated cumulatively 5 and 10 years after surgery. Mortality is shown as prostate cancer-specific survival (PCSS) and overall survival (OS). For all outcomes, the number of men experiencing the outcome at 5 or 10 years of follow-up is shown relative to the total number of men, with the percentage of events given in parentheses. (B) Demographic data for the diagnostic biopsy patient cohort. (N / A = not available).

[0188] Laboratory methods

[0189] To account for potential tumor heterogeneity, two tissue punch samples from the RP cohort were combined before nucleic acid extraction. Potential differences in tumor cellularity between tissue punch samples were addressed by normalizing RT-qPCR results for PDE4D transcripts to four reference genes: HPRT1, TUBA1B, PUM1, and TBP. All molecular laboratory methods used, including oligonucleotide primers and probes for RT-qPCR (quantitative real-time PCR), RNA extraction, and quality control, as well as procedures for including / excluding samples in statistical analyses, were previously described (see Alves de Inda M. et al., "Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes," European Urology Focus, 2017).

[0190] RNA sequencing

[0191] RNA sample processing : Using the Ribo-Zero Gold (human / mouse / rat) rRNA depletion kit (Illumina Inc.), 100 ng of total RNA was used as input to remove ribosomal RNA according to the manufacturer's instructions. For library construction, we used the fully depleted RNA input into the Scriptseq V2 RNA-Seq Library Preparation Kit (Epicentre / Illumina Inc.). The prepared RNAseq libraries were sequenced using the NextSeq 500 sequencing system (paired end; 2 x 75 bp read length; approximately 80 million total reads per sample).

[0192] RNAseq data processing : RNAseq raw data was preprocessed using Illumina's bcl2fastq software, which combines phred score filtering to reduce low-quality reads. Since FFPE can degenerate bases, the sequencing results have been filtered using a scoring algorithm to select reads representing high-quality parts. The score of a set of reads in the sample is calculated as follows: a set of reads is aligned with the reference genome. Each read counts the alignment results of each read (i.e., the number of bases correctly mapped to the reference genome). The total number of successfully mapped bases is the sum of all reads in the group. This sum is divided by the total number of bases in the group. The resulting relative number is called the score:

[0193] Score = sum of all reads in a sample (N_BASES_ALIGNED / reads) / N_BASES_SAMPLE 2)

[0194] Scoring filters are used to select a subset of reads that contribute to the EQ score by their good alignment results (all or most bases are correctly mapped to the genome). The obtained high-quality read subsets are selected for further processing. If the reads are mapped by fragmentation (required when aligning RNA), a measurement value is calculated based on the fragment alignment quality and fragments are selected accordingly.

[0195] Read quality filtering To retain only high-quality reads, the following filtering steps were applied. Reads were discarded when >50% of bases had a phred score <11. Reads were cut off at bases at the end of the read if the phred score was <11; reads <63 bases were discarded; reads with unknown (N) base calls were removed; and only paired reads were retained when each read passed the quality filter.

[0196] Gene expression calculationTo ensure comparability of expression values ​​between samples, all read counts were normalized by the transcripts per million method (TPM) implemented in the RSEM algorithm (see Li B. et al., “RNA-Seq gene expression estimation with read mapping uncertainty”, Bioinformatics, Vol. 26, No. 4, pages 493-500, 2010).

[0197] Data analysis and statistics

[0198] Normalized PDE4D transcript expression was generated by subtracting the RT-qPCR Cq of each PDE4D transcript from the mean RT-qPCR Cq of the reference gene. Normalized PDE4D5, PDE4D7, and PDE4D9 expression profiles were converted to PDE4D5, PDE4D7, and PDE4D9 scores as described above for PDE4D7. In correlation analyses of various available biological and treatment-related outcomes (see Table 10), PDE4D transcript scores were used as continuous or categorical variables, defined as: a) PDE4D5 / 7 / 9 score (1≤2); b) PDE4D5 / 7 / 9 score (>2 and ≤3); c) PDE4D5 / 7 / 9 score (>3 and ≤4); and d) PDE4D5 / 7 / 9 score (>4 and ≤5). CAPRA risk scores and corresponding low (1), intermediate (2), and high risk (3) categories were calculated as described by Cooperberg MR. Univariate and multivariate Cox regression and Kaplan Meier analysis were used to correlate biochemical recurrence (BCR) progression-free survival or second-line treatment (salvage radiotherapy and androgen deprivation)-free survival (STFS) with the PDE4D7 score in the RP cohort (n=536) and RP* cohort (from Taylor BS et al., "Integrative genomic profiling of human prostate cancer", Cancer Cell, Vol. 18, No. 1, pages 11-22, 2010 (130 of 178 patients were included in our study) and the DB cohort (n=151). To determine the TMPRSS2-ERG status of patient samples in the exon array cohort, we used relative ERG expression values ​​and applied Partitioning Around Medoids (PAM, R-package 'cluster', k=2) to assign patient samples into ERG-positive or -negative groups based on expression. As described in Vickers AJ et al., "Extension to decision curve analysis, a novel method for evaluating diagnostic Decision curve analysis was performed as described in "Tests, prediction models and molecular markers", BMC Medical Informatics and Decision Making, Vol. 8, pages 1-17, 2008. For statistical analysis, the software package MedCalc (MedCalc Software BVBA, Ostend, Belgium) was used.

[0199] result

[0200] Correlation of PDE4D transcript scores with longitudinal clinical outcomes depends on TMPRSS2-ERG fusion status

[0201] First, we performed Kaplan-Meier survival analyses of PDE4D7 score categories in TMPRSS2-ERG rearrangement-positive and fusion-negative patient samples. A total of 536 patient samples were included based on TMPRSS2-ERG status data, of which 280 (52.2%) were defined as fusion-positive and 256 (47.8%) were defined as lacking this prostate-specific fusion event. Biochemical recurrence (BCR) was selected as a surrogate endpoint for disease progression after surgery due to the high number of events for this outcome in the studied patient cohort (see Table 10).

[0202] In the presence of rearranged TMPRSS2-ERG gene fusions, a significant difference in BCR progression-free survival analysis was observed between fusion-positive and -negative tumors in the PDE4D7 category, with a significant high logrank p-value (<0.0001) (see Figure 12 In TMPRSS2-ERG fusion-positive cancers, the group of patients with the highest PDE4D7 expression levels (i.e., PDE4D7 scores 4-5) showed the lowest risk of disease progression after surgery. In contrast, in prostate tumors without ERG gene fusion events, the Kaplan-Meier survival analysis did not distinguish significantly between the four different PDE4D7 categories defined (logrank p value = 0.08; see Figure 13 Interestingly, when looking at the BCR-free progression survival analysis of the PDE4D5 score, we found the opposite of what was observed with the PDE4D7 score. Only in tumors without gene fusions did the PDE4D5 score category significantly (logrank p value < 0.0001) predict biochemical recurrence (see Figure 14 and 15 In the survival analysis of TMPRSS2-ERG-negative tumors, we observed similar results for the PDE4D5 score and PDE4D9 score categories, with logrank p-values ​​< 0.0001. However, in contrast to the PDE4D5 score analysis, the survival analysis of the PDE4D9 score categories in gene fusion-positive cancers also yielded a significant association with biochemical recurrence, although the p-values ​​were slightly weaker compared to those in TMPRSS2-ERG-negative tumors (logrank p-value = 0.005 vs logrank p < 0.0001, respectively, see Figure 16 and 17 ).

[0203] Next, we investigated the extent to which the scoring categories for the three different prostate cancer-expressed PDE4D transcripts were mutually exclusive within individual patient samples, or whether the same scoring category (e.g., [1-2] or [4-5]) was observed in the same samples for all three studied PDE4D splice variants. To this end, we created a heat map (not shown) that included all 536 patient samples, with an initial separation between TMPRSS2-ERG gene fusion-positive and fusion-negative samples. Samples within the TMPRSS2-ERG-negative group were sorted according to their PDE4D5 or PDE4D9 scoring category, while fusion-positive samples were sorted according to their PDE4D7 scoring category, from low to high. This heat map replicated the results of the Kaplan-Meier survival analysis, with more events in the lower PDE4D isoform scoring categories. However, the PDE4D transcript scoring categories did not overlap to some extent within the patient samples. When focusing on the lowest scoring category (i.e., all scores for PDE4D5 / PDE4D7 / PDE4D9 were between [1-2]), we identified 31 samples with a score category of [1-2] for at least one of the three PDE4D transcripts (see Figure 18 ). For three samples (marked in bold), we measured the lowest scoring category for all three PDE4D transcripts, while for two samples (marked in bold italics), at least two PDE4D transcripts fell into the lowest scoring category. For the other 26 samples, only one PDE4D splice variant was measured, and its expression was very low, while the other two isoforms showed higher expression levels in these samples. The risk of developing metastasis or dying from prostate cancer increased significantly with decreasing expression levels of multiple long prostate-expressed PDE4D isoforms (6 and 5 of 31 patients, respectively) (see Figure 18). Similarly, in those patients with at least two PDE4D transcripts scored as [1-2] and / or [2-3], the time scale from surgery to events such as BCR was generally shorter (<2 years). Vice versa, the higher the expression level of at least one of the three PDE4D splice variants, the less likely it was to experience a BCR after surgery. Alternatively, if this event occurred, it was usually over a longer time (2-5 years, in some cases >5 years after first-line treatment). In summary, these data suggest that, similar to PDE4D7, other long transcripts of PDE4D, namely PDE4D5 and PDE4D9, may also have important prognostic value in prostate cancer. Therefore, we hypothesized that adding the PDE4D5 and PDE4D9 scores to PDE4D7 would increase the ability to predict the risk of disease progression after surgery relative to clinical variables or relative to the above-mentioned PDE4D7-based model (see also Alves de Inda M. et al. and van Strijp D. et al., “The Prognostic PDE4D7 Score in a Diagnostic Biopsy Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes”, Prostate Cancer, 2018).

[0204] Logistic regression model of clinical variables and prostate cancer-expressed long PDE4D transcripts

[0205] To test this concept, we developed a prognostic model that incorporates the clinical CAPRA score (see Cooperberg MR) and gene expression profile scores for PDE4D5, PDE4D7, and PDE4D9. For model development, the RP (n = 536) and RP* cohorts (n = 130) were used. Logistic regression analysis was performed to predict postoperative biochemical recurrence in the RP and RP* cohorts to assess the weighting of the CAPRA score and PDE4D transcripts. Coefficients were calculated by logistic regression. Next, we adjusted the initial coefficients for the four model inputs in the RP* cohort by averaging the coefficients for the RP and RP* cohorts, thus accounting for heterogeneity across patient groups. The prognostic ability of the final CAPRA & PDE4D5 / 7 / 9 model (co1·PDE4D5 score+co2 PDE4D7 score+co3 PDE4D9 score+co4CAPRA score, where co1, co2, co3 and co4 are regression coefficients) was tested to predict BCR and the start of postoperative second-line treatment (i.e., radiotherapy or hormone deprivation) in an independent cohort of DB patients. For any other outcomes, such as metastasis or death, we used the RP and RP* cohorts (note: these clinical endpoints were not used during model development). An overview of the logistic regression modeling is provided in Table 11 below.

[0206] Table 11: A combined CAPRA & PDE4D5 / 7 / 9 score model was developed using logistic regression of CAPRA scores and standardized PD4D5, PDE4D7, and PDE4D9 expression values ​​in the RP patient cohort (n = 480, with complete 5-year postoperative follow-up) and the RP* cohort (n = 130; Taylor et al, 2010). The logistic regression coefficients for the two cohorts were averaged to generate mean coefficients for PD4D5, PDE4D7, and PDE4D9 with the CAPRA score based on data from two independent patient cohorts to account for variations across patient cohorts. These coefficients were used as weights in the final CAPRA & PDE4D5 / 7 / 9 regression model. Note: The CAPRA score was calculated based on Cooperberg MR; however, due to lack of information on the number of positive biopsy cores in the RP* cohort, only patient age, preoperative PSA, biopsy Gleason score, and clinical stage were used to calculate the CAPRA score for this cohort. As tested in the RP and DB cohorts, the impact of missing information on biopsy cores was very limited (data not shown).

[0207]

[0208] Coefficients and standard errors

[0209]

[0210]

[0211]

[0212] Coefficients and standard errors

[0213] variable coefficient Standard error Wald P PDE4D5 -0.91989 0.41366 4.9451 0.0262 constant 6.8611 3.68577 3.4652 0.0627 variable coefficient Standard error Wald P PDE4D7 -0.47163 0.23486 4.0326 0.0446 constant 2.4353 1.88706 1.6655 0.1969 variable coefficient Standard error Wald P PDE4D9 -0.77544 0.32339 5.7495 0.0165 constant 5.30545 2.77079 3.6664 0.0555 variable coefficient Standard error Wald P CAPRA score 0.48565 0.13132 13.6763 0.0002 constant -2.32506 0.37523 38.394 <0.0001

[0214] Average Model

[0215] coefficient

[0216] <![CDATA[co1]]> PDE4D5 -0,76 <![CDATA[co2]]> PDE4D7 -0,71 <![CDATA[co3]]> PDE4D9 -0,73 <![CDATA[co4]]> CAPRA score 0,65

[0217] aFor CAPRA analysis there were 459 samples

[0218] In a particularly preferred embodiment,

[0219] The coefficient co1 of PDE4D5 is in the range of -1.26 to -0.26, preferably in the range of -1.16 to -0.36, more preferably in the range of -1.06 to -0.46, more preferably in the range of -0.96 to -0.56, more preferably in the range of -0.86 to -0.66, most preferably -0.76, and / or

[0220] The coefficient co2 of PDE4D7 is in the range of -1.21 to -0.21, preferably in the range of -1.11 to -0.31, more preferably in the range of -1.01 to -0.41, more preferably in the range of -0.91 to -0.51, more preferably in the range of -0.81 to -0.61, most preferably -0.71, and / or

[0221] The coefficient co3 of PDE4D9 is in the range of -1.23 to -0.23, preferably in the range of -1.13 to -0.33, more preferably in the range of -1.03 to -0.43, more preferably in the range of -0.93 to -0.53, more preferably in the range of -0.83 to -0.63, most preferably -0.73, and / or

[0222] The coefficient co4 of the preoperative CAPRA score is in the range of 0.15 to 1.15, preferably in the range of 0.25 to 1.05, more preferably in the range of 0.35 to 0.95, more preferably in the range of 0.45 to 0.85, more preferably in the range of 0.55 to 0.75, and most preferably 0.65.

[0223] Kaplan-Meier survival analysis of the CAPRA & PDE4D5 / 7 / 9 model

[0224] In the Kaplan-Meier survival analysis, the CAPRA&PDE4D5 / 7 / 9 model stratified 29 men (19.2%) of the total DB cohort (n=151) within the lowest score category [1-2] into a group of patients with no risk of PSA recurrence during the 60-200 months follow-up period and no risk of initiating second-line therapy (see Figure 19 and 20 By slightly increasing the cutoff value for this model score category from [1-2] to [1-2.1], the number of men in this group who were at no risk of disease progression after surgery would increase from 29 to 36 (23.8%; data not shown). In contrast, patients in the highest CAPRA&PDE4D5 / 7 / 9 score categories of [3-4] and [4-5] had a risk of biochemical progression within 5 years after surgery of 63.9% and 83.3%, respectively. Similarly, for these patient groups, the risk of receiving second-line therapy within 5 years after surgery was estimated to be 44.1% and 75%, respectively, based on survival analysis (see Figure 19 and 20 ).

[0225] ROC curve analysis of the CAPRA&PDE4D5 / 7 / 9 model

[0226] For the DB cohort (described above), BCR and initiation of second-line therapy were measured as outcomes. The CAPRA&PDE4D5 / 7 / 9 model was compared with the CAPRA&PDE4D7 model described above (see also van Strijp D. et al.). For the clinical endpoints of these two tests, an increase in AUC (area under the curve) of 10% and 6%, respectively, compared to the CAPRA score alone and an increase of 5% and 4%, respectively, compared to the CAPRA&PDE4D7 model (see Figure 21 and 22 ).

[0227] To further explore this effect, other outcomes besides biochemical recurrence were tested. We developed a combined model of CAPRA and PDE4D transcript scores using BCR as an endpoint in two radical prostatectomy cohorts (RP and RP*), and we did not test the model on the endpoints in these cohorts. Instead, we used other outcome tests such as progression of metastasis after surgery or death from prostate cancer after first-line (i.e., RP) or second-line treatment (i.e., SRT-salvage radiotherapy; SADT-salvage androgen deprivation therapy) to study the potential added value of PDE4D5 and PDE4D9 for the previously described CAPRA and PDE4D7 models. Table 12 provides a summary of the AUC (area under the curve) increases of up to 5% and up to 12%, respectively, when using the additional prognostic value of PDE4D5 and PDE4D9 in addition to the CAPRA&PDE4D7 scoring model, compared to the CAPRA score or CAPRA&PDE4D7 scoring model. This data suggests that the use of additional prostate-related PDE4D transcripts may increase the prognostic power of our previously published combined model of CAPRA and PDE4D7 scores.

[0228] Table 12: Summary of AUCs of the CAPRA score, CAPRA&PDE4D7, and CAPRA&PDE4D5 / 7 / 9 regression models for predicting multiple endpoints in various patient cohorts.

[0229]

[0230]

[0231] Patient cohorts for the respective endpoints are shown, including the number of patients with the respective follow-up period. Measured clinical endpoints are given, including the number and percentage of corresponding measured events. Note: CAPRA scores were calculated based on Cooperberg MR; however, due to lack of information on the number of positive biopsy cores in the RP* cohort, CAPRA scores for this cohort were calculated using only patient age, preoperative PSA, biopsy Gleason score, and clinical stage. As tested in the RP and DB cohorts, the impact of missing information on biopsy cores was very limited.

[0232] Decision curve analysis of CAPRA&PDE4D5 / 7 / 9 model

[0233] A decision curve analysis is a net benefit analysis that compares the true positive rate to the weighted false positive rate across different risk thresholds that clinicians / patients may wish to accept (see Vickers AJ et al., “Net benefit approaches to the evaluation of prediction models, molecular markers, and diagnostic tests”, BMJ, Vol. 25, 2016). We explored the net benefit of avoiding first-line therapy based on the predicted risk of postoperative PSA recurrence according to the CAPRA score and the CAPRA & PDE4D7 score relative to the combined CAPRA & PDE4D5 / 7 / 9 model presented here. The analysis showed that all models showed a better net benefit than a “treat all” strategy, while the combined model of CAPRA and the three PDE4D transcripts showed the best net benefit across all modeled decision thresholds (see Figure 23 Similarly, analysis of net reductions in first-line treatment showed significant differences in treatment reduction between the CARPA score and the combined CARPA & PDE4D5 / 7 / 9 model across all decision thresholds (see Figure 24 Furthermore, the addition of PDE4D5 and PDE4D9 to the CAPRA & PDE4D7 model significantly improved the net benefit of the decision curve analysis and was more effective in reducing the number of interventions per 100 patients compared with the CAPRA combination model using PDE4D7 alone.

[0234] We demonstrate that the previously proposed CAPRA & PDE4D7 risk model can be further refined by incorporating long PDE4D transcripts into the model. The difference in predictive power between TMPRSS2-ERG-positive and gene fusion-negative patient tumors supports the prognostic benefit of incorporating PDE4D5 and PDE4D9. By supplementing PDE4D7 with two other prostate cancer-associated PDE4D transcripts, PDE4D5 and PDE4D9, we established a more comprehensive prognostic model to assess the risk of disease progression before first-line intervention.

[0235] discuss

[0236] A predictive model combining the clinical risk algorithm CAPRA with the prostate cancer biomarker PDE4D7 has been shown to provide value for prostate cancer risk stratification (see Alves de Inda M. et al. and van Strijp D. et al.). The experimental results presented indicate that PDE4D7 adds independent value to the clinical CAPRA model and significantly improves the prognostic ability to predict disease progression after surgery. To further increase the value of this CAPRA & PDE4D7 combination model, we identified differential expression of various long PDE4D isoforms in primary tumor material, which are distinct from prostate cancer-specific TMRPSS2-ERG gene rearrangements (see R. et al., "Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development ofdistant metastases", Oncotarget, Vol. 7, No. 43, pages 70669-70684, 2016).

[0237] The data presented here allowed us to analyze the impact of three distinct PDE4D transcripts, PDE4D5, PDE4D7, and PDE4D9, on the risk of disease progression after surgery, depending on the genomic context of the patient's tumor. Interestingly, in the context of TMRPSS2-ERG fusion-positive disease, PDE4D7 was found to be significantly associated with disease recurrence after treatment, whereas patients without this specific gene fusion event had a poorer prognosis. In contrast, PDE4D5 and PDE4D9 were highly prognostic in a non-fusion genomic context, whereas in the presence of the genomic fusion, PDE4D5 was not associated with disease progression, while PDE4D9 was significantly associated with less disease progression.

[0238] Active surveillance (AS) has become an acceptable treatment option and is recommended by national guidelines for men with low-risk and very low-risk prostate cancer (see Briganti A. et al., "Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018", European Urology, Vol. 74, No. 3, pages 357-368, 2018). The guiding principle of AS is to delay, rather than avoid, first-line treatment. When the treatment intention is still curative, AS should be switched to active intervention. Therefore, men with AS must adhere to a strict monitoring plan because they must be discontinued and switched to active treatment at the earliest signs of disease progression, such as elevated PSA, biopsy Gleason score, or clinical stage migration. However, given the low risk of death among men in the active surveillance arm of the ProtecT trial, it is uncertain to what extent these observed changes in clinical disease manifestations are associated with true biological disease progression (see Hamdy CF et al., “10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer”, The New England Journal of Medicine, Vol. 375, pages 1415-1424, 2016).

[0239] Currently, new technologies such as multiparametric MRI or genomics are being considered for stratifying men into active surveillance or monitoring men in AS (see Eineluoto JT, “Repeat multiparametric MRI in prostate cancer patients on active surveillance”, PLoS ONE, Vol. 12, No. 12, 2017, and Canfield S. et al., “Active Surveillance Use Among a Low-risk Prostate Cancer Population in a Large US Payer System: 17-Gene Genomic Prostate Score Versus Other Risk Stratification Methods”, Reviews in Urology, Vol. 19, No. 4, pages 203-212, 2017). It has been estimated that the longitudinal costs of AS are of the same order of magnitude as those of first-line intervention (see Keegan KA et al., “Active surveillance for prostate cancer compared with immediate treatment: an economic analysis”, Cancer, Vol. 118, No. 14, pages 3512-3518, 2012), particularly due to the costs of repeat biopsies (see Dall'Era MA, “The economics of active surveillance for prostate cancer”, Current Opinion in Urology, Vol. 23, No. 3, pages 278-282, 2013). Any newly implemented technological tool will only be cost-effective if its use leads to fewer men discontinuing AS to switch to definitive treatment and / or minimizing the surveillance program (or even avoiding it in some patients).

[0240] We believe that combining clinical measures such as the CAPRA score with the genomic biomarker presented here, namely, assessment of the long form of PDE4D (5 / 7 / 9) transcript, to predict the risk of patients experiencing future disease progression could provide future support for selecting patients for inclusion in active surveillance who require very limited (little or no) follow-up for a defined time after the initiation of (active) surveillance.

[0241] Any reference signs herein should not be construed as limiting the scope.

[0242] The present invention relates to a method for preoperative risk stratification of prostate cancer subjects, comprising determining a gene expression profile of phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining an expression-based risk score for the subject based on the gene expression profile, and determining a preoperative prognostic risk score for the subject based on the expression-based risk score and preoperative clinical variables of the subject. This can improve the stratification of subjects in the preoperative setting, resulting in better first-line treatment decisions. For example, for certain subpopulations of prostate cancer patients, a preoperative prognostic risk score can provide better advice on whether to choose active surveillance or active intervention, such as radical prostatectomy.

[0243] The accompanying sequence listing entitled 2017PF02734_Sequence Listing_ST25 is incorporated herein by reference in its entirety.

Claims

1. A non-transitory recording medium recording a computer program, wherein the computer program stores instructions that, when executed by a computer, perform a method for preoperative risk stratification of a prostate cancer subject, the method comprising: determining a gene expression profile of phosphodiesterase 4D variant 7 in a biological sample obtained from said prostate cancer subject, wherein phosphodiesterase 4D variant 7 is represented by PDE4D7, Determining an expression-based risk score for the prostate cancer subject based on the gene expression profile, wherein the expression-based risk score is determined by the following formula: EBRS=(((PDE4D7_norm+A)*B)+1), Wherein EBRS is an expression-based risk score, PDE4D7_norm is a normalized PDE4D7 gene expression profile value, A and B are variables, wherein A is 6-8 and B is 0.4-0.45, and wherein the normalized PDE4D7 gene expression profile value is a normalized Cq value of PDE4D7, which is generated by the following formula: N(CqPDE4D7)=Mean(Cqref_genes)–(CqPDE4D7), wherein N(CqPDE4D7) is the normalized Cq value of PDE4D7, Mean(Cqref_genes) is the arithmetic mean of the PCR Cq values ​​of one or more reference genes, and CqPDE4D7 is the PCR Cq value of PDE4D7, and determining a preoperative prognostic risk score for the prostate cancer subject based on the expression-based risk score and preoperative clinical variables of the prostate cancer subject by multivariate Cox regression analysis, wherein the preoperative clinical variables include: (i) age of the prostate cancer subject; (ii) prostate specific antigen level; (iii) primary and secondary biopsy Gleason score; (iv) clinical stage; and (v) percentage of tumor-positive biopsies, wherein the preoperative prognostic risk score is determined as a modified preoperative prostate cancer risk assessment score for the prostate cancer subject, wherein the primary and secondary biopsy Gleason scores are replaced with the expression-based risk score, wherein: the expression-based risk score is a value in the range of 1-5, and if the value is in the range of 1 to <2, 3 points are added to the modified preoperative prostate cancer risk assessment score; and if the value is in the range of 2 to <3, 2 points are added; if the value is in the range of 3 to <4, 1 point is added; and if the value is in the range of 4 to <5, no points are added.

2. The non-transitory recording medium according to claim 1, wherein the method further comprises: determining a preoperative prostate cancer risk assessment score for the prostate cancer subject, Wherein the preoperative prognostic risk score is determined by combining the expression-based risk score and the preoperative prostate cancer risk assessment score.

3. The non-transitory recording medium according to claim 1, wherein the method further comprises: recommending first-line treatment for the prostate cancer subject based on the preoperative prognostic risk score, wherein the first-line treatment is selected from: (i) at least partial prostatectomy; (ii) active treatment selected from radiation therapy, hormone therapy, chemotherapy and combinations thereof; and (iii) active surveillance.

4. The non-transitory recording medium according to claim 1, wherein: The one or more reference genes are selected from the group consisting of: human hypoxanthine phosphoribosyltransferase 1, tubulin-α-1b, human pumilio RNA binding family members and human TATA box binding protein. 5 . The non-transitory recording medium according to claim 4 , wherein the plurality of reference genes comprises at least two or at least three or all of human hypoxanthine phosphoribosyltransferase 1, tubulin-α-1b, human pumilio RNA binding family member, and human TATA box binding protein.

6. The non-transitory recording medium according to claim 1, wherein: Determination of the gene expression profile comprises performing RT-qPCR on RNA extracted from the biological sample, wherein a Cq value is determined for each of PDE4D7 and the one or more reference genes, and Determination of the expression-based risk score includes normalizing the Cq value of PDE4D7 using the Cq value of each of the one or more reference genes and calculating the expression-based risk score as a linear function of the normalized Cq values.

7. A diagnostic kit comprising: at least one primer and / or probe for determining the gene expression profile of phosphodiesterase 4D variant 7 in a biological sample obtained from a subject with prostate cancer, wherein phosphodiesterase 4D variant 7 is represented by PDE4D7; and Instructions for calculating a preoperative prognostic risk score based on the gene expression profile of PDE4D7 of the prostate cancer subject and preoperative clinical variables, the instructions being stored on a computer program product, which when executed by a computer performs a method comprising: Determining an expression-based risk score for the prostate cancer subject based on the gene expression profile of PDE4D7, wherein the expression-based risk score is determined by the following formula: EBRS=(((PDE4D7_norm+A)*B)+1), Wherein EBRS is an expression-based risk score, PDE4D7_norm is a normalized PDE4D7 gene expression profile value, A and B are variables, wherein A is 6-8 and B is 0.4-0.45, and wherein the normalized PDE4D7 gene expression profile value is a normalized Cq value of PDE4D7, which is generated by the following formula: N(CqPDE4D7)=Mean(Cqref_genes)–(CqPDE4D7), wherein N(CqPDE4D7) is the normalized Cq value of PDE4D7, Mean(Cqref_genes) is the arithmetic mean of the PCR Cq values ​​of one or more reference genes, and CqPDE4D7 is the PCR Cq value of PDE4D7, and determining the preoperative prognostic risk score for the prostate cancer subject based on the expression-based risk score and the preoperative clinical variables of the prostate cancer subject by multivariate Cox regression analysis, wherein the preoperative clinical variables include: (i) age of the prostate cancer subject; (ii) prostate specific antigen level; (iii) primary and secondary biopsy Gleason score; (iv) clinical stage; and (v) percentage of tumor-positive biopsies, wherein the preoperative prognostic risk score is determined as a modified preoperative prostate cancer risk assessment score for the prostate cancer subject, wherein the primary and secondary biopsy Gleason scores are replaced with the expression-based risk score, wherein: the expression-based risk score is a value in the range of 1-5, and if the value is in the range of 1 to <2, 3 points are added to the modified preoperative prostate cancer risk assessment score; and if the value is in the range of 2 to <3, 2 points are added; if the value is in the range of 3 to <4, 1 point is added; and if the value is in the range of 4 to <5, no points are added.

8. Use of the non-transitory recording medium of claim 1 in preparing a kit for preoperative risk stratification of prostate cancer subjects, wherein the kit further comprises At least one primer and / or probe for determining the gene expression profile of phosphodiesterase 4D variant 7 in a biological sample obtained from a subject with prostate cancer.

9. A computer program product comprising instructions, which, when executed by a computer, cause the computer to perform a method comprising: determining a gene expression profile of phosphodiesterase 4D variant 7 in a biological sample obtained from a subject with prostate cancer, wherein phosphodiesterase 4D variant 7 is represented by PDE4D7, Determining an expression-based risk score for the prostate cancer subject based on the gene expression profile, wherein the expression-based risk score is determined by the following formula: EBRS=(((PDE4D7_norm+A)*B)+1), Wherein EBRS is an expression-based risk score, PDE4D7_norm is a normalized PDE4D7 gene expression profile value, A and B are variables, wherein A is 6-8 and B is 0.4-0.45, and wherein the normalized PDE4D7 gene expression profile value is a normalized Cq value of PDE4D7, which is generated by the following formula: N(CqPDE4D7)=Mean(Cqref_genes)–(CqPDE4D7), wherein N(CqPDE4D7) is the normalized Cq value of PDE4D7, Mean(Cqref_genes) is the arithmetic mean of the PCR Cq values ​​of one or more reference genes, and CqPDE4D7 is the PCR Cq value of PDE4D7, and determining a preoperative prognostic risk score for the prostate cancer subject based on the expression-based risk score and preoperative clinical variables of the prostate cancer subject by multivariate Cox regression analysis, wherein the preoperative clinical variables include: (i) age of the prostate cancer subject; (ii) prostate specific antigen level; (iii) primary and secondary biopsy Gleason score; (iv) clinical stage; and (v) percentage of tumor-positive biopsies, wherein the preoperative prognostic risk score is determined as a modified preoperative prostate cancer risk assessment score for the prostate cancer subject, wherein the primary and secondary biopsy Gleason scores are replaced with the expression-based risk score, wherein: the expression-based risk score is a value in the range of 1-5, and if the value is in the range of 1 to <2, 3 points are added to the modified preoperative prostate cancer risk assessment score; and if the value is in the range of 2 to <3, 2 points are added; if the value is in the range of 3 to <4, 1 point is added; and if the value is in the range of 4 to <5, no points are added.

10. A computer program product comprising instructions, which, when executed by a computer, cause the computer to perform a method comprising: determining a gene expression profile of phosphodiesterase 4D variant 7 in a biological sample obtained from a subject with prostate cancer, wherein phosphodiesterase 4D variant 7 is represented by PDE4D7, Determining an expression-based risk score for the prostate cancer subject based on the gene expression profile, wherein the expression-based risk score is determined by the following formula: EBRS=(((PDE4D7_norm+A)*B)+1), Wherein EBRS is an expression-based risk score, PDE4D7_norm is a normalized PDE4D7 gene expression profile value, A and B are variables, wherein A is 6-8 and B is 0.4-0.45, and wherein the normalized PDE4D7 gene expression profile value is a normalized Cq value of PDE4D7, which is generated by the following formula: N(CqPDE4D7)=Mean(Cqref_genes)–(CqPDE4D7), wherein N(CqPDE4D7) is the normalized Cq value of PDE4D7, Mean(Cqref_genes) is the arithmetic mean of the PCR Cq values ​​of one or more reference genes, and CqPDE4D7 is the PCR Cq value of PDE4D7, and determining a preoperative prognostic risk score for the prostate cancer subject based on the expression-based risk score and preoperative clinical variables of the prostate cancer subject by multivariate Cox regression analysis, The method further comprises: determining a preoperative prostate cancer risk assessment score for the prostate cancer subject, wherein the preoperative prognostic risk score is determined by combining the expression-based risk score and the preoperative prostate cancer risk assessment score, wherein the preoperative clinical variables include: (i) age of the prostate cancer subject; (ii) prostate specific antigen level; (iii) primary and secondary biopsy Gleason score; (iv) clinical stage; and (v) percentage of tumor-positive biopsies, wherein the preoperative prognostic risk score is determined as a modified preoperative prostate cancer risk assessment score for the prostate cancer subject, wherein the primary and secondary biopsy Gleason scores are replaced with the expression-based risk score, wherein: the expression-based risk score is a value in the range of 1-5, and if the value is in the range of 1 to <2, 3 points are added to the modified preoperative prostate cancer risk assessment score; and if the value is in the range of 2 to <3, 2 points are added; if the value is in the range of 3 to <4, 1 point is added; and if the value is in the range of 4 to <5, no points are added.